: The AMEDEO Literature Guide

Home The Word Brain

My Amedeo

FAQ

Privacy

About

Amedeo C49

English + 你好 (nǐ hǎo) = limitless possibilities.
Start learning Mandarin Chinese today—for free, forever.

Amedeo C49 is completely free, for life. Next week: +49.

Vaccines

Free Subscription

Articles published in Vaccine
Retrieve available abstracts of 1298 articles:
HTML format

Single Articles

July 2025

MARANGOU J, Beaton A, Fulurija A, Carapetis J, et al
Cardiac monitoring safety assessment framework for early phase group a streptococcal vaccine trials.
Vaccine. 2025;60:127334.
PubMed Abstract available

NJOH AA, Dinga JN, Kongnyuy EJ, Ndoula TS, et al
Malaria vaccine acceptance and associated factors in cameroon: A nationwide cross-sectional survey.
Vaccine. 2025;60:127323.
PubMed Abstract available

STOUTEN V, Van Evercooren I, Vernemmen C, Braeye T, et al
Averted mortality by COVID-19 vaccination in Belgium between 2021 and 2023.
Vaccine. 2025;60:127290.
PubMed Abstract available

PIAL RH, Capeding MR, Song KR, Park EL, et al
Immune persistence after 5 years of vaccination by Vi-DT vaccine among children below 2 years: Result from long-term observational study.
Vaccine. 2025;60:127304.
PubMed Abstract available

LI H, Zhang J, Guo R, Li J, et al
Immunogenicity evaluation of a recombinant pseudorabies virus co-expressing PCV2 and PCV3 capsid proteins in mice and piglets.
Vaccine. 2025;60:127307.
PubMed Abstract available

June 2025

YI Z, Owusu-Edusei K, Elbasha EH
Economic evaluation of PCV21 in PCV-naive adults aged 50-64 years in the United States.
Vaccine. 2025;59:127264.
PubMed Abstract available

ESPARZA J
The illness of empress Maria Theresa as a trigger for the adoption of variolation in Austria (1768).
Vaccine. 2025;58:127253.
PubMed Abstract available

CHAIWONG W, Takheaw N, Laopajon W, Nisoong C, et al
Low-dose intradermal mRNA-1273 boosting vaccine following BBiBP-CorV vaccination during the omicron pandemics.
Vaccine. 2025;61:127330.
PubMed Abstract available

ROUX K, Roux F, Burns S, Guy R, et al
Effective strategies in human papillomavirus (HPV) vaccination interventions to increase uptake in rural, low socioeconomic, indigenous and migrant populations: A scoping review.
Vaccine. 2025;61:127359.
PubMed Abstract available

MOHAMMADI S, Sisay MM, Saraswati PW, Osman AK, et al
COVID-19 vaccine safety studies among special populations: A systematic review and meta-analysis of 120 observational studies and randomized clinical trials.
Vaccine. 2025;61:127342.
PubMed Abstract available

COSTELLO LM, Kerns EK, McCulloh RJ, Roberts JR, et al
Hesitancy and confidence in pediatric COVID-19 vaccination among diverse caregivers of unvaccinated children.
Vaccine. 2025;61:127245.
PubMed Abstract available

KIM C, Lee D, Oh YW, Jung SJ, et al
Association between parental and child influenza vaccination: A national health survey analysis.
Vaccine. 2025;61:127345.
PubMed Abstract available

KOBAYASHI K, Masuda K, Wu JT, Lin L, et al
Impact of digital communication message on HPV vaccine decision-making among Japanese mothers: A randomized controlled trial.
Vaccine. 2025;61:127327.
PubMed Abstract available

HALONEN A, Fan HSL, Masina S, Chooniedass R, et al
Understanding COVID-19 vaccine hesitancy during parenthood in British Columbia.
Vaccine. 2025;61:127305.
PubMed Abstract available

HU XX, Qin ZZ, Mo ZY, Wang R, et al
Timeliness and completeness of serial routine vaccinations among 8062 rural children in southwest China during the COVID-19 pandemic: A multi-stage stratified cluster sampling survey in 1094 villages.
Vaccine. 2025;61:127346.
PubMed Abstract available

ANASTASSOPOULOU C, Panagiotopoulos AP, Ferous S, Poland GA, et al
RSV vaccines and Guillain-Barre syndrome: Insights into an emerging concern.
Vaccine. 2025;61:127338.
PubMed Abstract available

AKTHER A, Laurie C, Elton-Marshall T, Ly V, et al
Healthcare workers' current practices, knowledge/awareness, barriers, and attitudes/perceptions related to pneumococcal vaccination of older adults: A mixed-methods systematic review.
Vaccine. 2025;61:127331.
PubMed Abstract available

JOLFAYI AG, Alipour S, Aminizadeh S, Yaghoubi SM, et al
Dendritic cell-based vaccines, a promising prospect for ending AIDS and eradication of HIV worldwide: A narrative review on the latest updates.
Vaccine. 2025;61:127340.
PubMed Abstract available

WAN JIA AARON H, Yuan R, Chan SCS
Socio-demographic and behavioral predictors of multiple-dose COVID-19 vaccine uptake among older adults in Hong Kong: A community-based cross-sectional study of the generations connect project.
Vaccine. 2025;61:127308.
PubMed Abstract available

May 2025

NG YF, Lockhart K, Dawar M, Vigor D, et al
Assessing measles immunity among healthcare workers, a systematic review of peer-reviewed literature (2013-2023). Where do we go from here?
Vaccine. 2025;57:127214.
PubMed Abstract available

STEPANEK L, Nakladalova M, Borikova A, Horakova D, et al
Measles-mumps-rubella booster and post-COVID-19 immunity: A retrospective cohort study.
Vaccine. 2025;57:127232.
PubMed Abstract available

SIDORENKO SV, Rennert W, Zhdanov KV, Lobzin YV, et al
Serotype dynamics of Streptococcus pneumoniae in some countries in Eastern Europe and Central Asia.
Vaccine. 2025;57:127213.
PubMed Abstract available

LIEN SB, Yang QW, Huang HW, Chiu KC, et al
A novel immunogen comprising a bc loop and mutant fusion loop epitopes generates potent neutralization and protective abilities against flaviviruses without risk of disease enhancement.
Vaccine. 2025;57:127219.
PubMed Abstract available

BREWER NT, Rockwell EM, Tomar A, Fisher EB, et al
Covid-19 vaccine incentives' effectiveness and differential impact on high-risk groups: A prospective cohort study.
Vaccine. 2025;61:127302.
PubMed Abstract available

SAYEM ASM, Musuka G, Atuhebwe PL, Dadari I, et al
Childhood vaccination catch-up and recovery plans for mitigating immunity gap post the COVID-19 pandemic: A case study of selected African countries.
Vaccine. 2025;61:127328.
PubMed Abstract available

HARTON PE, Chamberlain AT, Moore A, Fletcher G, et al
Estimating COVID-19 vaccine effectiveness among children and adolescents using data from a school-based weekly COVID-19 testing program.
Vaccine. 2025;61:127292.
PubMed Abstract available

COBELENS F, Pelzer PT, Churchyard GJ, Garcia-Basteiro A, et al
Sample size efficiency of restricting participation in tuberculosis vaccine trials to interferon-gamma release assay-positive participants.
Vaccine. 2025;61:127301.
PubMed Abstract available

DAVE E, Culhane JF, Lundsberg LS, Partridge C, et al
Trends in Tdap and influenza vaccination in pregnancy relative to the coronavirus disease-19 pandemic.
Vaccine. 2025;61:127329.
PubMed Abstract available

YADAV G, Dandu H, Malhotra HS, Jain A, et al
COVID-19 vaccination and utility of booster dose: A community-based cross-sectional study.
Vaccine. 2025;60:127325.
PubMed Abstract available

HUNG CT, Wang LM, Liu DC
National trends and disparities in herpes zoster vaccination coverage among U.S. older adults with cancer, 2008-2023.
Vaccine. 2025;60:127326.
PubMed Abstract available

NASREEN S, Jiang Y, Lu H, Lee A, et al
Risk of Guillain-Barre syndrome after COVID-19 vaccination or SARS-CoV-2 infection: A multinational self-controlled case series study.
Vaccine. 2025;60:127291.
PubMed Abstract available

ESCOBAR-ZIEDE P, Borras-Bermejo B, Pinos-Tella L, Vivet-Escale M, et al
Real-world effectiveness of MBA-VN vaccine against mpox, a test-negative case-control study.
Vaccine. 2025;59:127295.
PubMed Abstract available

ABE M, Shinmura Y, Tokieda Y, Mitsuhiro Y, et al
A phase I, randomized, placebo-controlled, double-blind, ascending-dose and single-center study to evaluate immunogenicity and safety of a live attenuated tetravalent dengue vaccine (KD-382) in Flavivirus antibody-naive healthy adults.
Vaccine. 2025;60:127313.
PubMed Abstract available

ABU-RAYA B, Giles ML, Kollmann T
Co-administration of vaccines in pregnancy: unique challenges and knowledge gaps.
Vaccine. 2025;60:127309.
PubMed Abstract available

SEILER P, Kaplan BS, Brice DC, Duan S, et al
Altered germinal center responses in mice vaccinated with highly pathogenic avian influenza A(H5N1) virus.
Vaccine. 2025;60:127311.
PubMed Abstract available

BHATIA D, Crowcroft N, Antoni S, Danovaro-Holliday MC, et al
Prediction of subnational-level vaccination coverage estimates using routine surveillance data and survey data.
Vaccine. 2025;60:127277.
PubMed Abstract available

SENPUKU K, Kunishima Y, Taniguchi K, Ito T, et al
Development and characterization of MRC-5 and Vero cell-adapted enterovirus D68 strains for vaccine production.
Vaccine. 2025;60:127314.
PubMed Abstract available

LEE N, Nguyen L, Nasreen S, Austin PC, et al
Limited durability of protection conferred by XBB.1.5 vaccines against omicron-associated severe outcomes among community-dwelling adults, Ontario, Canada.
Vaccine. 2025;60:127300.
PubMed Abstract available

KATSEFF AS, Toumanios C, Barahim E, McCormick AA, et al
PcrV in an intranasal adjuvanted tobacco mosaic virus conjugate vaccine mediates protection from Pseudomonas aeruginosa via an early Th1/Th17 skewed localized and systemic immune response.
Vaccine. 2025;60:127306.
PubMed Abstract available

DEVKOTA B, Lal BK, Gautam A, Poudel L, et al
Nationwide rollout of HPV vaccination in Nepal: Early key insights.
Vaccine. 2025;60:127312.
PubMed

KROEGER M, Fano E, Sponheim A, Schwartz KJ, et al
Assessment of homologous and heterologous PCV2 vaccine efficacy in a PCV2d/PRRSV co-challenge model.
Vaccine. 2025;60:127303.
PubMed Abstract available

MALANGE V, Mohaissen T, Conway KM, Rhoads A, et al
Influenza vaccination during early pregnancy and risk of major birth defects, US Birth Defects Study To Evaluate Pregnancy exposureS, 2014-2019.
Vaccine. 2025;59:127297.
PubMed Abstract available

ALSHURMAN BA, Majowicz SE, Grindrod K, Goh J, et al
Understanding the shift in COVID-19 vaccine hesitancy and its associated factors for primary and booster doses among university students: A cross-sectional study.
Vaccine. 2025;59:127296.
PubMed Abstract available

LI M, Cai W, Chandrasekhar A, Hu H, et al
Factors associated with primary care providers' recommendation of HPV vaccination for adolescent males in China: A mixed-methods study.
Vaccine. 2025;59:127299.
PubMed Abstract available

LAI SW, Liao KF
Breakthrough herpes zoster risk after recombinant zoster vaccination.
Vaccine. 2025 May 23:127294. doi: 10.1016/j.vaccine.2025.127294.
PubMed

BAKHT P, Hussain A, Pandey S, Pathania R, et al
Live attenuated hfq-deleted Acinetobacter baumannii vaccine provides protection against systemic infection.
Vaccine. 2025;59:127298.
PubMed Abstract available

MOHAMED Y, Luey E, Kata ', Tukia O, et al
"The only vaccine that we really question is the new vaccine": A qualitative exploration of the social and behavioural drivers of human papillomavirus (HPV) vaccination in Tonga.
Vaccine. 2025;59:127280.
PubMed Abstract available

RAHIMI HK, Jasim AA, Rezahosseini O, Harboe ZB, et al
Immunogenicity and adverse effects of pneumococcal vaccines co-administered with influenza or SARS-CoV-2 vaccines in adults: A systematic review and Meta-analysis.
Vaccine. 2025;59:127293.
PubMed Abstract available

SHAHI N, Singh B, Pande A, Chandra S, et al
Safe and efficacious inactivated immersion vaccine against KG+ phenotype of emerging bacterial pathogen Lactococcus garvieae for early developmental stage of rainbow trout (Oncorhynchus mykiss) in India.
Vaccine. 2025;59:127266.
PubMed Abstract available

KIBETI DM, Hoff NA, Merritt S, Lulebo AM, et al
Quality and usability of home-based record photos to assess vaccine coverage: A case study from the 2022 Democratic Republic of the Congo Vaccine Coverage Survey.
Vaccine. 2025;59:127248.
PubMed Abstract available

GANDHI K, Vijay Y, Page K, Dahari H, et al
Challenges in coverage of future hepatitis C vaccines: Review and potential solutions.
Vaccine. 2025;59:127256.
PubMed Abstract available

SURI RK, Maugeais D, Maithal K
COVID-19 pandemic: A multidimensional analysis and the strategic role played by developing countries vaccine manufacturers.
Vaccine. 2025;59:127271.
PubMed Abstract available

GIANNINI F, Hogan AB, Cameron E, Le H, et al
Estimating the impact of Western Australia's first respiratory syncytial virus immunisation program for all infants: A mathematical modelling study.
Vaccine. 2025;56:127155.
PubMed Abstract available

MANDVIWALA AS, Munje AK, Huckriede ALW, Arankalle VA, et al
Immunogenicity evaluation of respiratory syncytial virus prefusogenic-F based virus-like-particles consisting of G and M proteins in mice.
Vaccine. 2025;56:127203.
PubMed Abstract available

KISLAYA I, Caserta M, Faye SLB, Dia OK, et al
Evaluating the effects of a multisectoral dialogue-based COVID-19 awareness-raising intervention in a limited-resource setting: A quasi-experimental study in Senegal.
Vaccine. 2025;56:127168.
PubMed Abstract available

ISLAM MD, Islam MM, Inoue A, Yesmin S, et al
Neutralizing antibodies against the Japanese encephalitis virus are produced by a 12 kDa E. coli- expressed envelope protein domain III (EDIII) tagged with a solubility-controlling peptide.
Vaccine. 2025;56:127143.
PubMed Abstract available

XU P, Lu J, Chen L, Chen X, et al
Development of a chicken egg yolk antibody (IgY) could effectively prevent and treat goose astrovirus infection.
Vaccine. 2025;56:127167.
PubMed Abstract available

HASAN Z, Masood KI, Qaiser S, Kanji A, et al
Comparative study of humoral and cellular immunity against SARS-CoV-2 induced by different COVID-19 vaccine types: Insights into protection against wildtype, Delta and JN.1 omicron strains.
Vaccine. 2025;59:127270.
PubMed Abstract available

KEUTLER A, Lainka E, Hudert C, Bufler P, et al
Safety and immunogenicity of the measles-mumps-rubella vaccine in immunocompromised children with inflammatory bowel disease, or after liver transplantation: An observational study.
Vaccine. 2025;59:127288.
PubMed Abstract available

TIAN X, Zhou Y, Deng P, Xu N, et al
Effectiveness and safety of a novel intranasal influenza vaccine in Chinese children: A phase IV multi-Center, randomized, double-blind, placebo-controlled clinical trial.
Vaccine. 2025;59:127268.
PubMed Abstract available

QUENTIN E, Ahmed I, Duong CH, Tubert-Bitter P, et al
Covid-19 Vaccination During Pregnancy in France: a Descriptive Study of Uptake Using the National Healthcare data System.
Vaccine. 2025;58:127223.
PubMed Abstract available

FITZPATRICK T, Yamoah P, Summerby-Murray D, Cowan J, et al
Neurological adverse events following COVID-19 vaccination among Canadians referred to the special immunization clinic network.
Vaccine. 2025;59:127254.
PubMed Abstract available

BUSSINK-VOOREND D, Hulscher MEJL, Akkermans R, Krom A, et al
Vaccine hesitancy among Dutch parents of newborn children and its associated characteristics, values and uptake of vaccines.
Vaccine. 2025;59:127244.
PubMed Abstract available

NHAM E, Song JY, Sohn JW, Choi WS, et al
Real-world effectiveness of COVID-19 XBB.1.5 monovalent mRNA vaccine: Analysis over nine months.
Vaccine. 2025;59:127275.
PubMed Abstract available

SCHAFFER AL, Hulme WJ, Horne E, Parker EPK, et al
Effect of the 2022 COVID-19 booster vaccination campaign in people aged 50 years in England: Regression discontinuity analysis in OpenSAFELY-TPP.
Vaccine. 2025;59:127257.
PubMed Abstract available

MYBURGH L, van Loon K, Huijbers EJM, van Beijnum JR, et al
Guided design for the development of an evolution-proof influenza vaccine.
Vaccine. 2025;59:127281.
PubMed Abstract available

HATTORI F, Higashimoto Y, Miura H, Kawamura Y, et al
Epidemiology and clinical features of breakthrough varicella in the 9 years after universal vaccination began in Japan.
Vaccine. 2025;59:127274.
PubMed Abstract available

FURUSE Y, Tabuchi T
Impact of COVID-19 vaccination by implementation timing and coverage rate in relation to misinformation prevalence in Japan.
Vaccine. 2025;59:127273.
PubMed Abstract available

LIAW K, Konrath KM, Trachtman AR, Tursi NJ, et al
DNA co-delivery of seasonal H1 influenza hemagglutinin nanoparticle vaccines with chemokine adjuvant CTACK induces potent immunogenicity for heterologous protection in vivo.
Vaccine. 2025;59:127231.
PubMed Abstract available

MALTEZOU HC, Medic S, Cassimos DC, Effraimidou E, et al
Routine vaccination rates globally: A continuing and alarming situation.
Vaccine. 2025;59:127269.
PubMed

SOARES LMC, de Medonca AEO, de Souza DLB, Carvalho AV, et al
Factors associated with HPV vaccine hesitancy: A nationally representative cross-sectional study.
Vaccine. 2025;59:127278.
PubMed Abstract available

LUPTON D, Whitten T, Tay AK, Beek K, et al
Mental health and psychosocial factors predicting concerns about the COVID-19 vaccine among refugee background and Australian-born women.
Vaccine. 2025;58:127251.
PubMed Abstract available

NUNEZ IA, Ross TM
Corrigendum to "Human COBRA 2 vaccine contains two major epitopes that are responsible for eliciting neutralizing antibody responses against heterologous clades of viruses" [Vaccine 38 (4) (2020) 830-839].
Vaccine. 2025;58:127205.
PubMed

AVERIN A, Quinn E, Atwood M, Weycker D, et al
Cost-effectiveness of bivalent respiratory syncytial virus Prefusion F (RSVpreF) maternal vaccine among infants in the United States.
Vaccine. 2025;58:127191.
PubMed Abstract available

SASAKI E, Hamaguchi I, Hasegawa H, Takahashi Y, et al
Establishment of a novel adjuvant screening system for the development of intranasal vaccine adjuvants.
Vaccine. 2025;58:127267.
PubMed Abstract available

NIINIKOSKI V, Barkoff AM, Mertsola J, Holubova J, et al
Alterations in the expression of Bordetella pertussis antigens in relation to the use of acellular pertussis vaccine in Finland.
Vaccine. 2025;58:127279.
PubMed Abstract available

EINARSON TA, Musana E, Balonde J, Lorentzen KB, et al
Corrigendum to "Human papillomavirus awareness, vaccination rate, and sociodemographic covariates of vaccination status in a low-income country: A cross-sectional study in the rural Busoga region of Uganda" [Vaccine 53 (2025) 127089].
Vaccine. 2025;58:127204.
PubMed

HUNG SH, Torres JL, Chen F, Giang E, et al
Antigenic and EM characterization of the Chiron experimental hepatitis C virus vaccine.
Vaccine. 2025;58:127239.
PubMed Abstract available

BUHL E, Vedel JO, Nanque LM, Correia C, et al
Does timing of the Bacillus Calmette-Guerin vaccine affect weight in children under the age of 5 years? An observational study in Guinea-Bissau.
Vaccine. 2025;58:127246.
PubMed Abstract available

SOBLE A, Malhame M, Malvolti S, Mantel C, et al
Identification and sizing of the current use cases for seasonal influenza vaccines.
Vaccine. 2025 May 15:127233. doi: 10.1016/j.vaccine.2025.127233.
PubMed Abstract available

MOORE DCBC, Nehab MF, Reis AT, Junqueira-Marinho MF, et al
Childhood vaccine hesitancy: The power of metaphors.
Vaccine. 2025;58:127221.
PubMed Abstract available

PATTYN J, Hanning N, Valckx S, Claessens T, et al
Investigating the state of vaccine confidence among the general public and parents with children up to 13 years in Flanders (Belgium).
Vaccine. 2025;58:127250.
PubMed Abstract available

MERRITT A, Bansal S
Prison Vaccination in a pandemic: Geographic disparities and policy insights.
Vaccine. 2025;58:127218.
PubMed Abstract available

ELLIS JT, Kennedy PJ
Multi-criteria decision making and its application to in silico discovery of vaccine candidates for Toxoplasma gondii.
Vaccine. 2025;58:127242.
PubMed Abstract available

VARMA A, Bolotin S, De Serres G, Didierlaurent AM, et al
What is the current evidence base for measles vaccination earlier than 9 months of age?: Report from an informal technical consultation of the World Health Organization.
Vaccine. 2025;57:127187.
PubMed Abstract available

KUMARI M, Su SC, Lin HT, Ko SH, et al
Enhanced immunogenicity of an mRNA vaccine against dengue virus serotype 2 with modified key residue.
Vaccine. 2025;57:127216.
PubMed Abstract available

PEARCE A, Henery P, Dundas R, Katikireddi SV, et al
Socio-economic inequalities in uptake and timing of childhood vaccination: Taking a life course approach in an administrative cohort in Scotland.
Vaccine. 2025;57:127222.
PubMed Abstract available

MOU J, LaSalle G, Pflugeisen C, Sherls-Jones J, et al
Practice, beliefs and intent in influenza vaccination among Hispanic patients during the pandemic: An interventional study.
Vaccine. 2025;58:127207.
PubMed Abstract available

LE DOARE K, Benassi V, Cavaleri M, Enwere G, et al
Clinical and regulatory development strategies for GBS vaccines intended for maternal immunisation in low- and middle-income countries.
Vaccine. 2025;58:127131.
PubMed Abstract available

SPURGERS K, Wynn M, Charles L, Hamm S, et al
A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for the emergent vesicular stomatitis virus (VSV) viral vector vaccine for Lassa fever.
Vaccine. 2025;58:127137.
PubMed Abstract available

WANG-LU H, Valerio Mendoza OM, Chen S, Geldsetzer P, et al
Regional mobility and COVID-19 vaccine hesitancy: Evidence from China.
Vaccine. 2025;58:127179.
PubMed Abstract available

GELLERT FR, Gonzalez C, Mokdad AH
Bridging the gap: A mixed-methods analysis of Canadian and U.S. immunization programs for enhancing racial equity in childhood vaccinations.
Vaccine. 2025;57:127249.
PubMed Abstract available

ANYANGO RO, Nyawanda BO, Onyando BO, Haidara FC, et al
Factors associated with laboratory-confirmed SARS-Cov-2 infection among patients with severe respiratory illness (SRI): Findings from the COVID-19 vaccine effectiveness evaluation in Kenya and Mali, 2022-2023.
Vaccine. 2025 May 12:127234. doi: 10.1016/j.vaccine.2025.127234.
PubMed Abstract available

PATRICK E, Iuliano A, Bakare D, Salako J, et al
Non-specific effects of routine vaccinations on child survival between 12-59 months of age in Jigawa, Nigeria: A secondary analysis of the INSPIRING Jigawa trial.
Vaccine. 2025;57:127211.
PubMed Abstract available

NAVARRETE JAY, Rodriguez D, Kanno AI, de Cerqueira Leite LC, et al
Modulation of immune responses induced by recombinant BCG expressing LTAK63 adjuvant in an immunotherapeutic model vaccine.
Vaccine. 2025;57:127215.
PubMed Abstract available

NTAKIYISUMBA E, Tanveer M, Won G
A comprehensive analysis of the current strategy for developing live attenuated vaccines against African swine fever: A systematic review and meta-analysis.
Vaccine. 2025;57:127243.
PubMed Abstract available

CARTER DM, Bloom CE, Kirchenbaum GA, Tsvetnitsky V, et al
Corrigendum to "Cross-protection against H7N9 influenza strains using a live-attenuated H7N3 virus vaccine" [Vaccine (2015) 33(1) 108-16].
Vaccine. 2025;57:127174.
PubMed

SAXTON P, Hollingshead BM, Rich J, Saini S, et al
Mpox vaccine eligibility, uptake and coverage among gay, bisexual and other men who have sex with men in Aotearoa New Zealand.
Vaccine. 2025;57:127247.
PubMed Abstract available

HU J, Cao H, Luan N, Zhang X, et al
Herpes simplex virus 1 fusion glycoprotein B H516P prefusion mutation had no effect on vaccine immunogenicity.
Vaccine. 2025;57:127241.
PubMed Abstract available

ANGULO M, Ramos-Vega A, Angulo C
Trained immunity-based Adjuvated vaccines (TIbAV) approach: beta-glucans as example.
Vaccine. 2025;57:127240.
PubMed Abstract available

MACLENNAN CA, Cunningham AF, Dean JE, Pope S, et al
BactiVac, the Bacterial Vaccines Network.
Vaccine. 2025;57:127210.
PubMed Abstract available

XIONG Y, Wu C, Zhang Y, Guo D, et al
Can levels of HPV vaccine knowledge mitigate HPV vaccine hesitation among guardians of children aged 9-14 years? A moderated mediation model.
Vaccine. 2025;57:127208.
PubMed Abstract available

MEESTERS K, Sadarangani M, Clark SA, Borrow R, et al
Characterization of Canadian Neisseria meningitidis serogroup B isolates and factor-H binding protein expression, data from the Canadian Immunization Monitoring Program Active (IMPACT), 2013-2020.
Vaccine. 2025;55:127030.
PubMed Abstract available

GAGNON D, Gubany C, Ouakki M, Malo B, et al
Factors influencing acceptance of RSV immunization for newborns among pregnant individuals: A mixed-methods study.
Vaccine. 2025;55:127062.
PubMed Abstract available

SOTO-NOGUERON A, Carnalla-Barajas MN, Sanchez-Gonzalez G, Solorzano-Santos F, et al
Distribution of pneumococcal serotypes causing invasive and non-invasive diseases in children in Mexico after introduction of PCV13 (2012-2023). Results from the GIVEBPVac group.
Vaccine. 2025;55:127031.
PubMed Abstract available

XIE F, Du K, Li J, Zhong S, et al
Head-to-head immunogenicity comparison of one-dose Cecolin and Gardasil in Chinese girls aged 9-14 years: A randomized and open-label clinical trial.
Vaccine. 2025;55:127015.
PubMed Abstract available

PUTZ EJ, Andreasen CB, Stasko JA, Hamond C, et al
Circulating foamy macrophages and other features of bacillus Calmette-Guerin challenge in Golden Syrian hamsters.
Vaccine. 2025;55:127037.
PubMed Abstract available

HAO T, Ryan GE, Lydeamore MJ, Cromer D, et al
Predicting immune protection against outcomes of infectious disease from population-level effectiveness data with application to COVID-19.
Vaccine. 2025;55:126987.
PubMed Abstract available

KIM GL, Pyo SW, Kim SH, Song HJ, et al
Serological correlates of protection and long-term efficacy of a novel recombinant protective antigen-based anthrax vaccine in a rabbit model.
Vaccine. 2025;57:127212.
PubMed Abstract available

ADAME BJ, Corman SR, Von Feldt PA, Meneses CM, et al
Reactance as a cause of COVID-19 vaccination hesitancy.
Vaccine. 2025;57:127209.
PubMed Abstract available

ROULEAU I, Issa Kana KDN, Zafack JG, Viger YB, et al
New-onset anesthesia/paresthesia following the administration of COVID-19 vaccines in Quebec, Canada.
Vaccine. 2025;57:127217.
PubMed Abstract available

GEORGIADIS N, Katsimpris A, Tzanakaki G, Tsiodras S, et al
Cross-protection of meningococcal B vaccines against gonorrhea: A systematic review and Meta-analysis.
Vaccine. 2025;56:127180.
PubMed Abstract available

MASHAMBA M, Msibi T, Tshabalala G, Tsotetsi L, et al
Factors influencing influenza vaccine uptake among adults in Johannesburg, South Africa: A qualitative study.
Vaccine. 2025;57:127133.
PubMed Abstract available

RAHA JR, Kim KH, Le CTT, Bhatnagar N, et al
Intranasal vaccination with multi-neuraminidase and M2e virus-like particle vaccine results in greater mucosal immunity and protection against influenza than intramuscular injection.
Vaccine. 2025;57:127206.
PubMed Abstract available

GUMASING MJJ
Rebuilding Public Trust: Factors Influencing Dengue Vaccine Uptake in the Aftermath of the Dengvaxia Controversy in the Philippines: A Partial Least Structural Equation Modeling Approach.
Vaccine. 2025;57:127220.
PubMed Abstract available

VIETHS S, Waibler Z, Schumann GG
Opting for the appropriate methodology for quantification of residual DNA impurities in mRNA vaccines.
Vaccine. 2025;56:127186.
PubMed

SZONDY I, Lorincz K, Walter A, Mohammed AA, et al
Evaluating cross-protection: Meningococcal vaccines show effectiveness in gonorrhoea prevention - A systematic review and meta-analysis.
Vaccine. 2025;56:127188.
PubMed Abstract available

PADRON-REGALADO E, Escudero Gonzalez NA, Del Carmen Selvera HN
Morbidity of viral vaccine preventable diseases in the Mexican states bordering the U.S., 2014-2023.
Vaccine. 2025;56:127192.
PubMed Abstract available

ASHRAF U, Lee A, Gao Q, Gonzalez JC, et al
Impact of age and prior COVID-19 on the response to influenza a components in the 2020-2021 Fluzone vaccine.
Vaccine. 2025;56:127171.
PubMed Abstract available

BOUADDI O, Khalis M, Abdellatifi M, Seedat F, et al
Behavioural and social drivers of vaccination among child and adult migrants in Morocco: A qualitative interview study.
Vaccine. 2025;56:127166.
PubMed Abstract available

PITTER JG, Mihajlovic J, Nagy D, van der Schans J, et al
Underreported influenza mortality in Central and Eastern Europe hinders the extension of seasonal influenza vaccination programs in older adults.
Vaccine. 2025;56:127184.
PubMed Abstract available

ANNEQUIN M, Mora M, Fressard L, Cogordan C, et al
The relationship between men who have sex with men on PrEP and care providers is essential for HPV vaccination: A mixed-methods study in France.
Vaccine. 2025;56:127190.
PubMed Abstract available

ALGREN MH, Timmermann A, Valentiner-Branth P, Thygesen LC, et al
Comparing Risk Behaviour among 14,614 Human Papillomavirus Vaccinated and Unvaccinated Danish Young Women.
Vaccine. 2025;56:127202.
PubMed Abstract available

SEFAT KMSR, Kulkarni R, Trinh J, Leekha A, et al
Mucosal vaccines with STING-agonist liposomal formulations inhibit RSV (respiratory syncytial virus) replication in cotton rats.
Vaccine. 2025;56:127183.
PubMed Abstract available

ZHANG Z, Yildirim M, Keskinocak P, Dasthagirisaheb YBS, et al
Serotype specific pneumococcal vaccine effectiveness in children with sickle cell disease: A two-decade analysis.
Vaccine. 2025;56:127193.
PubMed Abstract available

WHELDRAKE K, Sisnowski J, AHoure M, Anagnostou N, et al
Surveillance of adverse events following immunisation with meningococcal B vaccine (4CMenB), South Australia, 2018-2022.
Vaccine. 2025;56:127158.
PubMed Abstract available

CHAN YT, Chair SY, Gao RT, Ng MH, et al
Effect of vaccine education intervention on vaccine uptake and vaccine knowledge among older adults: A systematic review with meta-analysis.
Vaccine. 2025;56:127182.
PubMed Abstract available

IBARZ-PAVON AB, Bielsky MC, Bose R, Cavaleri M, et al
Consultation report - considerations for a regulatory pathway for bivalent Salmonella Typhi/Paratyphi A vaccines for use in endemic countries.
Vaccine. 2025;56:127189.
PubMed Abstract available

AKMATOVA R, Otorbaeva D, Ebama MS
Impact of the COVID-19 pandemic on influenza knowledge, attitudes, and vaccination practices in at-risk groups in the Kyrgyz Republic: A comparative study.
Vaccine. 2025;56:127159.
PubMed Abstract available

OTORBAEVA D, Akmatova R, Cooley KM, Iwamoto C, et al
Corrigendum to "Post-introduction evaluation (PIE) of the seasonal influenza vaccination program in Kyrgyzstan in 2023" Vaccine 55 (2025) 127052.
Vaccine. 2025;56:127123.
PubMed

BADZI CD, Modey E, Apreku A, Guure C, et al
Factors influencing COVID-19 vaccine uptake among pregnant women in Greater Accra Region, Ghana.
Vaccine. 2025 May 1:127073. doi: 10.1016/j.vaccine.2025.127073.
PubMed Abstract available

KANESHITA S, Chambers CD, Johnson D, Kavanaugh A, et al
Short-term side effects following COVID-19 vaccination in pregnancies complicated by autoimmune inflammatory rheumatic diseases: A prospective cohort study.
Vaccine. 2025;56:127194.
PubMed Abstract available

April 2025

MOTTA M, Callaghan T, Ross JC, Gargano L, et al
Promoting RSV vaccine confidence through reversal narrative (RN) messaging.
Vaccine. 2025;56:127178.
PubMed Abstract available

PAUL MJ, Hudda MT, Pallett S, Groppelli E, et al
Mucosal immune responses to SARS-CoV-2 infection and COVID-19 vaccination.
Vaccine. 2025;56:127175.
PubMed Abstract available

WAN J, Wu M, Zhu Z, Liu X, et al
Vaccination of a CdrA fragment conferred protection against Pseudomonas aeruginosa in wound infection via inhibition of biofilm formation.
Vaccine. 2025;56:127185.
PubMed Abstract available

ZHENG F, Zhu M, Ran H, He J, et al
Assessment of recombinant Lactobacillus vector-based expressing IFITM3 protein anti-PRV infection in mice.
Vaccine. 2025;54:127093.
PubMed Abstract available

JAROVSKY D, Cereda RF, Figueiredo LM, Berezin EN, et al
Epidemiology and clinical burden of invasive pneumococcal disease in older adults in the city of Sao Paulo, Brazil.
Vaccine. 2025;54:126992.
PubMed Abstract available

BOLOTIN S, Wright J, McLachlan E, Severini A, et al
Investigating the measles susceptibility gap in Ontario infants.
Vaccine. 2025;54:126908.
PubMed Abstract available

WIBOWO DP, Chalid MT, Rasyak MR, El Khobar KE, et al
Characteristics of hepatitis B virus surface protein and occult hepatitis B infection in infants with immunoprophylaxis failure from Indonesia.
Vaccine. 2025;56:127130.
PubMed Abstract available

SHANKER A, Vlaev I
The social influence of the corrections of vaccine misinformation on social media.
Vaccine. 2025;56:127177.
PubMed Abstract available

OSEI I, Mendy E, van Zandvoort K, Sarwar G, et al
Effect of the 13-valent pneumococcal conjugate vaccine on pneumococcal carriage in rural Gambia 10 years after its introduction: A population-based cross-sectional study.
Vaccine. 2025;56:127181.
PubMed Abstract available

BAYSAC DJ, Guay M, Chen R, Dube E, et al
Did inequalities in COVID-19 vaccination resolve over time? Insights from the Canadian Community Health Survey.
Vaccine. 2025;56:127153.
PubMed Abstract available

LONG Q, Wang H, He Q, Liu W, et al
Effectiveness of rBS/WC cholera vaccine against bacterial infectious diarrhea: A test-negative study on children aged 2-6 years in Guangzhou China.
Vaccine. 2025;56:127139.
PubMed Abstract available

MELN I, Van Molle W, Velez MP, Abrahamsen G, et al
Advancing regulatory dialogue: In silico models for improved vaccine biomanufacturing - an expert meeting report.
Vaccine. 2025;56:127170.
PubMed Abstract available

HANSEN BT, Kristoffersen AB, Stecher M
Vaccination readiness among adults in Norway: A cross-sectional survey using the 7C model.
Vaccine. 2025;56:127169.
PubMed Abstract available

SINGLETON KL, Post DJ, Augustine AD, Ison MG, et al
Collaborative influenza vaccine innovation centers (CIVICs) program.
Vaccine. 2025;54:127118.
PubMed Abstract available

ESSINK BJ, Vermeulen W, Andrade C, de Rooij R, et al
Corrigendum to 'A randomised phase 2 immunogenicity and safety study of a MF59-adjuvanted quadrivalent subunit inactivated cell-derived influenza vaccine (aQIVc) in adults aged 50 years and older' Vaccine 51 (2025) 126791.
Vaccine. 2025;56:127127.
PubMed

FATIMAH MNN, Thian BYZ, Wong CL, Ong HK, et al
Chimeric virus-like particles of nodavirus displaying M2e of human and avian influenza A viruses as a potential dual-use vaccine: Inducing a broader immune response and protecting mice against viral infections.
Vaccine. 2025;56:127165.
PubMed Abstract available

OHNO M, Sekiya T, Obeng-Kyeremeh R, Handabile C, et al
Optimization of the preparation method of inactivated intact virus particle vaccine for COVID-19.
Vaccine. 2025;56:127173.
PubMed Abstract available

MELCHINGER H, Khemsara M, Ahmed N, Belgaumi SM, et al
Assessment of mpox awareness, attitudes, and vaccination intent among the United States public following an outbreak of mpox clade Ib in Africa.
Vaccine. 2025;56:127141.
PubMed Abstract available

JACOVETTY J, Wagner AL, Ichsan I, Yufika A, et al
Associations between parental vaccine hesitancy, religion-based vaccine hesitancy, and childhood full vaccination in a cross-sectional study in Aceh, Indonesia, 2023.
Vaccine. 2025;56:127154.
PubMed Abstract available

SUH TY, Park JH, Hwang SY, Park CR, et al
Safety and efficacy of a Vero-adapted live attenuated vaccine candidate for African swine fever.
Vaccine. 2025;56:127172.
PubMed Abstract available

LANATA CF, Ochoa TJ, Bancalari EM, Baylor NW, et al
Testing an experimental vaccine during a public health emergency: Lessons from a Peruvian case.
Vaccine. 2025;56:127176.
PubMed Abstract available

BUSTAMANTE Q, Sparkes D, Findlater L, Munro K, et al
Understanding occupational and attitudinal factors influencing UK healthcare worker decisions for COVID-19 and influenza vaccination: A cross-sectional survey within SIREN.
Vaccine. 2025;56:127160.
PubMed Abstract available

AGRUPIS KA, Crisostomo MV, Daag JV, Sarol J Jr, et al
Effectiveness of a single-dose mass dengue vaccination in Cebu, Philippines: Final results of a 5-year case-control study.
Vaccine. 2025;56:127142.
PubMed Abstract available

MCGRATH LJ, Khan FL, Lopez SMC, Brouillette MA, et al
2023-2024 COVID-19 vaccine uptake among immunocompromised individuals in two US states.
Vaccine. 2025;56:127120.
PubMed Abstract available

HONDA-OKUBO Y, Sakala IG, Li L, Bielefeldt-Ohmann H, et al
Advax(R)-adjuvanted inactivated influenza vaccine provides accelerated protection of mice via early induction of an influenza-specific IgM response.
Vaccine. 2025;56:127144.
PubMed Abstract available

ZHANG X, Shi H, Ross TM
Multivalent H3 COBRA-based influenza vaccine elicits enhanced immune response in a pre-immune elderly ferret model.
Vaccine. 2025;56:127156.
PubMed Abstract available

LUKA MM, Ferguson EA, Rees E, Hoffu H, et al
Optimising human rabies vaccine supply chains: A modelling study.
Vaccine. 2025 Apr 21:127108. doi: 10.1016/j.vaccine.2025.127108.
PubMed Abstract available

JURADO-MARTIN I, Tomas-Cortazar J, Rezk N, Hou Y, et al
The novel antigen, lipopolysaccharide export protein LptH, protects mice against Pseudomonas aeruginosa acute pneumonia in monovalent and multivalent vaccines.
Vaccine. 2025;56:127145.
PubMed Abstract available

KAHN R, Moiane B, Lessa FC, Massora S, et al
Corrigendum to "Nasopharyngeal carriage of Streptococcus pneumoniae among children and their household members in southern Mozambique five years after PCV10 introduction" Vaccine, Volume 47, 15 February 2025, 126,691.
Vaccine. 2025;56:127124.
PubMed

FINNEY J, Kuraoka M, Song S, Watanabe A, et al
Fluorescence-barcoded cell lines stably expressing membrane-anchored influenza neuraminidases.
Vaccine. 2025;56:127157.
PubMed Abstract available

XIA Y, Zhu W, Shi Z, Shen Y, et al
Herpes zoster vaccination coverage and factors associated among adults aged 40 and older in China: A population-based survey.
Vaccine. 2025;56:127122.
PubMed Abstract available

FERRERAS-COLINO E, de la Fuente J, Couto J, Golovchenko M, et al
Immunostimulant effect of heat-inactivated Mycobacterium bovis in mice challenged with vector-borne pathogens.
Vaccine. 2025;53:127076.
PubMed Abstract available

LUN J, Zheng P, Liang X, Hu Y, et al
Identification of a conserved cryptic epitope with cross-immunoreactivity in outer membrane protein K (OmpK) from Vibrio species.
Vaccine. 2025;53:126964.
PubMed Abstract available

TAKEUCHI N, Chang B, Ishiwada N, Cho Y, et al
Nationwide population-based surveillance of invasive pneumococcal disease in children in Japan (2014-2022): Impact of 13-valent pneumococcal conjugate vaccine and COVID-19 pandemic.
Vaccine. 2025;54:127138.
PubMed Abstract available

DE MELO ARAUJO AC, Oliveira TM, Souza JFA, da Fonseca Victer TN, et al
Incorporating vaccines into vaccination schedules around the world: A scoping review.
Vaccine. 2025;54:127132.
PubMed Abstract available

MANTLO EK, Huang YS
Knowledge-based mitigation of the environmental risk of Orthoflavivirus live-attenuated vaccines by targeting viral encoded determinants for the mosquito attenuated phenotype.
Vaccine. 2025;54:127114.
PubMed Abstract available

MO AX, McGugan G, Pesce JT
Meeting report: Expert consultation on late arresting replication competent (LARC) malaria sporozoite vaccine research & development.
Vaccine. 2025;54:127009.
PubMed Abstract available

ARSENAULT C, Ravishankar S, Lewis T, Armeni P, et al
The role of health systems in shaping vaccine decisions: Insights from Italy, Mexico, the United Kingdom, and the United States.
Vaccine. 2025;54:127134.
PubMed Abstract available

STONER MCD, Michaels J, Stocks JB, Mancuso N, et al
Evaluating concurrency and gaps between self-report and vaccine card data for COVID-19 vaccination.
Vaccine. 2025;54:127136.
PubMed Abstract available

WANG Z, Wang M, Wang F, Luo Y, et al
Corrigendum to "Dendritic cell targeting peptide plus Salmonella FliCd flagellin fused outer membrane protein H (OmpH) demonstrated increased efficacy against infections caused by different Pasteurella multocida serogroups in mouse models" [Vaccine 42
Vaccine. 2025;54:127126.
PubMed

URIU K, Kaku Y, Kihara M, Sato K, et al
Antiviral humoral immunity against SARS-CoV-2 omicron JN.1 subvariants induced by JN.1 recombinant protein vaccine.
Vaccine. 2025;54:127129.
PubMed

TONG F, Zhou T, Tang L, Wu X, et al
Evaluating the impact of influenza vaccine on preventing stroke hospitalization and death in Chinese elderly hypertensive patients: A retrospective cohort study.
Vaccine. 2025;54:127004.
PubMed Abstract available

WEETS CM, Wilson R, Swadley H, Katz R, et al
Strengthening health security through routine vaccination policy: A comprehensive analysis of childhood vaccination laws across 194 countries.
Vaccine. 2025;54:127121.
PubMed Abstract available

ENTRICAN G, Bredell H, Charlier J, Cunningham AF, et al
Opportunities and challenges for the adoption of novel platform technologies to develop veterinary bacterial vaccines.
Vaccine. 2025;54:127117.
PubMed Abstract available

YE Q, Li H, Xie Z, Gao X, et al
Corrigendum to "Antibody persistence in Chinese toddlers at 1 year and 2 years after two different 4-dose schedules of a novel 13-valent pneumococcal conjugate vaccine (PCV13-TT)" [Vaccine 49 (7) (2025) 126815].
Vaccine. 2025;54:127125.
PubMed

WANG F, Zheng J, Qiu F, Yang Y, et al
Long-term effectiveness of vaccination for prevention of hepatitis B virus mother-to-child transmission in Yunnan, China.
Vaccine. 2025;54:127128.
PubMed Abstract available

LEYNS C, McClenaghan E, Rodriguez P, Nguipdop-Djomo P, et al
Hybrid, vaccine-induced and natural immunity against SARS-CoV-2 in traditional food markets in Bolivia (2020-2022): A cross-sectional analysis of a serological survey.
Vaccine. 2025;54:127104.
PubMed Abstract available

SYROGIANNOPOULOS GA, Michoula AN, Moriondo M, Nieddu F, et al
Childhood invasive pneumococcal disease and acute otitis media in Central Greece during 2005-2024 - A report at the doorstep of the new multivalent PCV era.
Vaccine. 2025;52:126765.
PubMed Abstract available

OLIVEIRA LMA, Prasad N, Lynfield R, Ip M, et al
WHO defeating meningitis symposium, 3rd international symposium on Streptococcus agalactiae disease (ISSAD) in Rio de Janeiro, Brazil: State-of-the-art overview of S. agalactiae meningitis.
Vaccine. 2025;52:126895.
PubMed Abstract available

RESIK S, Lopez Cavestany R, Tejeda A, Diaz M, et al
Tropis needle-free injector for fractional-dose IPV administration: A pilot study for integration into routine immunization services in Cuba.
Vaccine. 2025;52:126903.
PubMed Abstract available

DEY A, Jackson J, Wang H, Lambert SB, et al
Australia's rotavirus immunisation program: Impact on acute gastroenteritis and intussusception hospitalisations over 13 years.
Vaccine. 2025;52:126789.
PubMed Abstract available

JOSHI R, Ayele HT, Johnson KD, Velentgas P, et al
Anticipated impact of novel adult-specific pneumococcal conjugate vaccine.
Vaccine. 2025;53:127080.
PubMed Abstract available

JOHN TJ, Dharmapalan D, Steinglass R, Hirschhorn N, et al
Lessons for polio eradication from the geographic variations of vaccine efficacy of oral polio.
Vaccine. 2025;53:127115.
PubMed

WALTENBURG MA, Kainulainen MH, Whitesell A, Nyakarahuka L, et al
Corrigendum to "Knowledge, attitudes, and practices and long-term immune response after rVSVDeltaG-ZEBOV-GP Ebola vaccination in healthcare workers in high-risk districts in Uganda" [Vaccine 24 (22) (2024) 126031].
Vaccine. 2025;54:127119.
PubMed

CHAN MXJ, Wouters OJ, Chan HY, Terblanche P, et al
Regional cooperation on pandemic preparedness and vaccine equity from an economic, regulatory and legal perspective.
Vaccine. 2025 Apr 10:127107. doi: 10.1016/j.vaccine.2025.127107.
PubMed Abstract available

BRUXVOORT KJ, Sy LS, Contreras R, Lewin B, et al
Development and validation of a clinical prediction tool for non-receipt of updated COVID-19 vaccines.
Vaccine. 2025;53:127074.
PubMed Abstract available

DYMOCK M, Marsh JA, Murray K, Snelling TL, et al
What is the quality of evidence informing vaccine clinical practice recommendations in Australia?
Vaccine. 2025;53:127105.
PubMed Abstract available

ZHANG L, Xia Y, Chu L, Sundaram ME, et al
Differences in seasonal influenza vaccine hesitancy profiles between clinicians practicing traditional Chinese medicine and modern Western medicine: A national cross-sectional survey.
Vaccine. 2025;53:127106.
PubMed Abstract available

JANI B, Hokororo A, Mchomvu J, Cortese MM, et al
Corrigendum to "Detection of rotavirus before and after monovalent rotavirus vaccine introduction and vaccine effectiveness among children in mainland tanzania" [Vaccine 36(47) (2018 Nov 12) 7149-7156].
Vaccine. 2025;53:127103.
PubMed

NA EJ, Chae SB, Oh B, Jeong CG, et al
A novel approach using IFNAR1 KO mice for assessing Akabane virus pathogenicity and vaccine efficacy.
Vaccine. 2025;53:127094.
PubMed Abstract available

EINARSON TA, Musana E, Balonde J, Lorentzen KB, et al
Human papillomavirus awareness, vaccination rate, and sociodemographic covariates of vaccination status in a low-income country: A cross-sectional study in the rural Busoga region of Uganda.
Vaccine. 2025;53:127089.
PubMed Abstract available

SHARIF E, Mobasheri T, Mohit E
Bioengineered ClearColi-derived outer membrane vesicles displaying CT26 neoepitopes as potent vaccine adjuvants against colon carcinoma in a preventive mouse model.
Vaccine. 2025;53:127088.
PubMed Abstract available

LA EM, Sweeney C, Davenport E, Bunniran S, et al
Pharmacy and healthcare provider offices as convenient adult vaccination settings in the US: Patient experiences from a survey of recently-vaccinated adults.
Vaccine. 2025;54:127057.
PubMed Abstract available

SASANKAN S, Gathers D, Bellerose A, Pankratz VS, et al
Behaviors, perceptions, and impact of the COVID-19 pandemic and vaccination on oncology patients in New Mexico with substantial representation of racial minorities and rural residents.
Vaccine. 2025;53:127091.
PubMed Abstract available

ZASZTOWT-STERNICKA M, Jagielska A, Rzad M, Szymusik I, et al
Immunogenicity of inactivated quadrivalent influenza vaccine in pregnant women, including the level of postvaccination antibodies in umbilical cord blood.
Vaccine. 2025;53:127047.
PubMed Abstract available

LLOYD PC, Acharya G, Zhao H, Shah N, et al
Safety monitoring of health outcomes following influenza vaccination during the 2023-2024 season among U.S. Medicare beneficiaries aged 65 years and older.
Vaccine. 2025;53:127069.
PubMed Abstract available

YUILL S, Hall MT, Caruana M, Lui G, et al
Erratum to "Predicted impact of HPV vaccination and primary HPV screening on precancer treatment rates and adverse pregnancy outcomes in Australia 2010-2070: Modelling in a high income, high vaccination coverage country with HPV-based cervical screeni
Vaccine. 2025;53:127079.
PubMed

ASSONI L, Valim V, Couto AJM, Trentini M, et al
In-silico and experimental analysis of Klebsiella pneumoniae fimbriae subunits for vaccine development.
Vaccine. 2025;53:127075.
PubMed Abstract available

PRALL S, Lopes A
"Better to die trying": Vaccine perceptions and COVID-19 experiences in rural Namibian pastoralists.
Vaccine. 2025;55:127061.
PubMed Abstract available

MOLLO A, Peri M, Lodi L, Gissi A, et al
Considering recombinant herpes zoster vaccine for fragile pediatric patients: A new opportunity.
Vaccine. 2025;53:127072.
PubMed Abstract available

FROSTH S, Reddick D, Righetti F, Bjerketorp J, et al
Sow vaccination with a novel recombinant protein vaccine protects piglets against Streptococcus suis infection.
Vaccine. 2025;53:127077.
PubMed Abstract available

DIEZ A, Arrieta-Aguirre I, Carrano G, Bregon-Villahoz M, et al
A synthetic peptide vaccine induces protective immune responses against Candida albicans infection in immunocompromised mice.
Vaccine. 2025;53:127102.
PubMed Abstract available

SHEARN C, Postavaru GI, Hylton L, Morris H, et al
COVID-19 vaccine decision-making and the role of institutions across the pandemic in UK Black African and Black Caribbean communities.
Vaccine. 2025;53:127071.
PubMed Abstract available

LI G, Cao S, Xu B, Hu J, et al
Safety, immunogenicity and immune persistence of a lyophilized purified human diploid cells rabies vaccine following rabies PEP regimen Essen and Zagreb: A randomized, blinded controlled phase 3 trial in healthy participants aged 10-60 years old.
Vaccine. 2025;53:127082.
PubMed Abstract available

LEADER AE, Burke-Garcia A, Afanaseva D, Cutroneo E, et al
Partnering with social media influencers to promote HPV vaccination in diverse communities.
Vaccine. 2025;53:127085.
PubMed Abstract available

SHALASH AO, Wang W, Xia Y, Hussein WM, et al
Evaluation of novel single-dose vaccine candidates against gonadotropin-releasing hormone (GnRH) in mice.
Vaccine. 2025;53:127092.
PubMed Abstract available

BERNARD C, Drouin J, Le Vu S, Botton J, et al
COVID-19 vaccination rates among pregnant women in France: A nationwide cohort study.
Vaccine. 2025;53:127070.
PubMed Abstract available

FISHER KA, Goldthwait L, Desrochers O, Zemel M, et al
Reasons for COVID-19 vaccination late in the pandemic: A qualitative study.
Vaccine. 2025;53:127084.
PubMed Abstract available

FLYNN PM, Stull C, Jain VM, Evans MD, et al
A national cross-sectional study of dentists' vaccine hesitancy and intention to provide HPV vaccines following emergency COVID-19 vaccination authorization.
Vaccine. 2025;53:127035.
PubMed Abstract available

CHEN PL, Richardson RA, Rovito S, Yang G, et al
Live-attenuated pandemic H1N1 influenza vaccines expressing computationally optimized broadly reactive antigens (COBRAs) are immunogenic and protective in mice and ferrets.
Vaccine. 2025;53:127090.
PubMed Abstract available

PAYNE AB, Novosad S, Sung HM, Zhang Y, et al
Effectiveness of 2023-2024 COVID-19 vaccines against COVID-19-associated hospitalizations among adults aged >/=18 years with end stage kidney disease - United States, September 2023-April 2024.
Vaccine. 2025;55:127010.
PubMed Abstract available

EIDEN AL, Mackie DS, Modi K, Drakeley S, et al
Corrigendum to the article titled, "Attitudes and beliefs about vaccination among adults in the United States: A real-world, cross-sectional, web-based survey study" [Vaccine 50 (2025) 126807].
Vaccine. 2025;53:127053.
PubMed

FELIX P, Melo AA, Costa JP, Colaco M, et al
Exploring TLR agonists as adjuvants for COVID-19 oral vaccines.
Vaccine. 2025;53:127078.
PubMed Abstract available

MCCOSKER LK, Dyer B, Sudarmana T, Seale H, et al
COVID-19 vaccination uptake in people experiencing homelessness during the first three years of the global COVID-19 vaccination effort: A systematic review and meta-analysis.
Vaccine. 2025;53:127050.
PubMed Abstract available

ANTILLON M, Verjans A, El Sheikh F, Scarna T, et al
Microarray patch vaccines for typhoid conjugate vaccines: A global cost-effectiveness analysis.
Vaccine. 2025;53:127055.
PubMed Abstract available

DAVIDSON N, Fisher J
"If I know about it of course I would give my son and daughter", barriers to and enablers of accessing human papillomavirus vaccination among women from refugee and asylum-seeking backgrounds resettling in Melbourne, Australia - A qualitative study.
Vaccine. 2025;53:127064.
PubMed Abstract available

EIDEN AL, Drakeley S, Modi K, Mackie DS, et al
Corrigendum to, "Attitudes and beliefs of healthcare providers toward vaccination in the United States: A cross-sectional online survey" [Vaccine (2024) Dec 2 42(26) 126437].
Vaccine. 2025;53:127054.
PubMed

MCKECHNIE JL, Kepl E, Louth J, Sun CJ, et al
Nanoparticles displaying fHbp elicit an enhanced antibody response against meningococcal B isolates compared to low valency fHbp antigens.
Vaccine. 2025;51:126885.
PubMed Abstract available

CARNALLA M, Gaspar-Castillo C, Dimas-Gonzalez J, Aparicio-Antonio R, et al
A population-based measles serosurvey in Mexico: Implications for re-emergence.
Vaccine. 2025;51:126886.
PubMed Abstract available

MONCHAUSSE T, Launay T, Rossignol L, Ait El Belghiti F, et al
Clinical characteristics of cases during the 2024 pertussis epidemic in France, January 2024 to December 2024.
Vaccine. 2025;51:126862.
PubMed Abstract available

OLIVIERI G, Amodio D, Manno EC, Santilli V, et al
Shielding the immunocompromised: COVID-19 prevention strategies for patients with primary and secondary immunodeficiencies.
Vaccine. 2025;51:126853.
PubMed Abstract available

JOHNSTONE SL, Shapiro D, Chiwandire N, Matoti L, et al
Effectiveness of BNT162b2 and Ad26.COV2.S vaccines against COVID-19-related hospitalisation amongst adult members of a private health insurance plan in South Africa during the Delta and Omicron periods: A test-negative case-control study.
Vaccine. 2025 Apr 2:127068. doi: 10.1016/j.vaccine.2025.127068.
PubMed Abstract available

PEREZ MARC G, Coria LM, Ceballos A, Rodriguez JM, et al
Immunogenicity and safety of monovalent and bivalent SARS-CoV-2 variant adapted RBD-based protein booster vaccines in adults previously immunized with different vaccine platforms: A phase II/III, randomized clinical trial.
Vaccine. 2025;54:127045.
PubMed Abstract available

HE X, Pu Y, Li Z, Huan S, et al
The global regulatory landscape for combined vaccines: A comparative case study of registration strategies for diphtheria-tetanus-pertussis-containing vaccines.
Vaccine. 2025;54:127017.
PubMed Abstract available

PATRICK R, Mahale P, Ackerson BK, Hong V, et al
Respiratory syncytial virus vaccine uptake among adults aged >/=60 years in a large, integrated healthcare system in Southern California 2023-2024.
Vaccine. 2025;53:127033.
PubMed Abstract available

FORAN AM, Jetten J, Muldoon OT
Religious group membership and conspiracy beliefs influence vaccine uptake: Insights from 20 European countries.
Vaccine. 2025;53:127086.
PubMed Abstract available

ALVES K, Kouassi A, Plested JS, Kalkeri R, et al
Immunogenicity and safety of a monovalent Omicron XBB.1.5 SARS-CoV-2 recombinant spike protein vaccine in previously unvaccinated, SARS-CoV-2 seropositive participants: Primary day-28 analysis of a phase 2/3 open-label study.
Vaccine. 2025;55:127046.
PubMed Abstract available

STRONG C, Joson P, Chu IY, Chuang TT, et al
Prioritization and barriers of mpox vaccination uptake among gay, bisexual and other men who have sex with men in Taiwan: 2023 HEART survey.
Vaccine. 2025;53:127059.
PubMed Abstract available

VADREVU KM, Chavan A, Chawla A, Chakravarthy BS, et al
A double-blind, randomised phase III clinical trial to evaluate safety, immunogenicity, non-inferiority & lot to lot consistency of single component oral cholera vaccine BBV131 (Hillchol(R)) in comparison to Shanchol.
Vaccine. 2025;55:126998.
PubMed Abstract available

OTORBAEVA D, Akmatova R, Cooley KM, Iwamoto C, et al
Post-introduction evaluation (PIE) of the seasonal influenza vaccination program in Kyrgyzstan in 2023.
Vaccine. 2025;55:127052.
PubMed Abstract available

March 2025

KARAN S, Opdensteinen P, Ma Y, De Oliveira JFA, et al
A replicon-based COVID-19 vaccine candidate delivered by tobacco mosaic virus-like particles.
Vaccine. 2025;53:127063.
PubMed Abstract available

DA SILVA TMR, de Sa ACMGN, Prates EJS, Veloso GA, et al
Trends and spatial distribution of the burden of vaccine-preventable diseases in children under five in Brazil from 2000 to 2019.
Vaccine. 2025;55:127060.
PubMed Abstract available

JIANG J, Lam KF, Lau EHY, Yin G, et al
Estimation of trajectory of COVID-19 vaccines effectiveness against infection.
Vaccine. 2025;55:127067.
PubMed Abstract available

NEWBERN EC, Shoaibi A, Haynes K, Blacketer C, et al
A rapid cycle analytics framework for vaccine safety surveillance within a real-world data network: Experience with enhanced surveillance of the Janssen COVID-19 vaccine.
Vaccine. 2025;55:127044.
PubMed Abstract available

LEE JW, Lee DY, Baek S, Jeong JY, et al
Sensitive detection of pertussis toxin in acellular pertussis vaccines using HRH1-mediated calcium signaling.
Vaccine. 2025;54:127056.
PubMed Abstract available

CENAT JM, Moshirian Farahi SMM, Dalexis RD, Xu Y, et al
Vaccine hesitancy among racially diverse parents in Canada: The important role of health literacy, conspiracy beliefs and racial discrimination.
Vaccine. 2025;55:127049.
PubMed Abstract available

TIRUNEH YM, Choi J, Cuccaro PM, Martinez J, et al
Sociodemographic and health-related predictors of COVID-19 booster uptake among fully vaccinated adults.
Vaccine. 2025;54:127048.
PubMed Abstract available

OKOLI GN, Grossman Moon A, Soos AE, Neilson CJ, et al
Hepatitis B vaccination initiation and vaccination series completion: An in-depth systematic evidence review, with meta-analysis of associations with individual socioeconomic and health-related factors.
Vaccine. 2025;55:127051.
PubMed Abstract available

STRAVORAVDI AS, Ladas AI, Frantzidis CA, Papazisis G, et al
HAVI: A novel tool to explore vaccine hesitancy among adults in Greece.
Vaccine. 2025;55:127042.
PubMed Abstract available

VYSOTSKAYA V, Gassowski M, Kasper A, Gasich E, et al
Hepatitis B serosurvey to validate the achievement of regional hepatitis B control targets in Belarus.
Vaccine. 2025;55:127058.
PubMed Abstract available

MOUCHERAUD C, Ochieng E, Kweka A, Wang P, et al
Parent-daughter agreement about HPV vaccination status in Kenya and Malawi.
Vaccine. 2025;55:127025.
PubMed Abstract available

KANG M, Marks KM, Cox AL, Sherman KE, et al
An efficient vaccine clinical trial: ACTG A5379 hepatitis B vaccine trial in persons with HIV.
Vaccine. 2025;55:127028.
PubMed Abstract available

FUNK T, Norgaard SK, Hallundbaek L, Grau J, et al
Effect of a proactive childhood vaccination reminder system on vaccination coverage and uptake in Denmark: A register-based cohort study.
Vaccine. 2025;54:126934.
PubMed Abstract available

ZHANG Y, Sullivan N, Abraham M, Haley HD, et al
Evaluation of HPV-loaded PLGA microparticles as single-dose HPV vaccine: Insights for sustained-release vaccine development.
Vaccine. 2025;55:127024.
PubMed Abstract available

VEDEL JO, Furtado O, Almeida LL, Martins JSD, et al
Refresher training in administering intradermal BCG-vaccine increased BCG-scarring rates in rural Guinea-Bissau.
Vaccine. 2025;55:127039.
PubMed Abstract available

EMARY K, Bentsi-Enchill AD, Giersing BK, Gordon M, et al
Landscape analysis of invasive non-typhoidal salmonella (iNTS) disease and iNTS vaccine use case and demand: Report of a WHO expert consultation.
Vaccine. 2025;55:127008.
PubMed Abstract available

BAKARE AA, Gobbo E, Akinsola KO, King C, et al
"It's easier to deal with the vaccines you know than the ones you don't know": A qualitative study on healthcare workers' vaccine confidence in Nigeria.
Vaccine. 2025;55:127020.
PubMed

FRIVOLD C, Giersing B, Amorij JP, Mvundura M, et al
Identification of potential vaccines for use with microarray patches in low- and middle-income countries: An assessment from the Vaccine Innovation Prioritisation Strategy Alliance.
Vaccine. 2025;55:126996.
PubMed Abstract available

BLACKWELL CK, Bekelman T, Bakre S, Jacobson LP, et al
Sociodemographic differences in parental hesitancy to the COVID-19 vaccine.
Vaccine. 2025;55:127041.
PubMed Abstract available

GOEDERS N, Vanneste K, Roosens NHC, Bogaerts B, et al
Molecular and WGS-based characterization of invasive Neisseria meningitidis isolates collected in Belgium (2016-2022) and MenB-FHbp vaccine coverage estimation of serogroup B.
Vaccine. 2025;55:127026.
PubMed Abstract available

MELOT L, Thyfault E, Hester K, Prausnitz MR, et al
Perceptions of non-needle-based vaccination devices in the state of Georgia.
Vaccine. 2025;55:127038.
PubMed Abstract available

HARALAMBIEVA IH, Ratishvili T, Goergen KM, Grill DE, et al
Effect of lymphocyte miRNA expression on influenza vaccine-induced immunity.
Vaccine. 2025;55:127023.
PubMed Abstract available

FRANCIS MJ
A rapid human vaccine process development map outlining lessons learnt from ChAdOx1 nCoV-19 vaccine during the COVID-19 pandemic.
Vaccine. 2025;55:127040.
PubMed Abstract available

AHMAD I, Burton R, Arshad R, Younis BB, et al
Humoral immune response to 10-valent pneumococcal conjugate vaccine (PCV10) in individuals with type 2 diabetes mellitus.
Vaccine. 2025;55:127029.
PubMed Abstract available

YAN K, Xu S, Fang H, Yang H, et al
Next-generation immunotherapeutic strategy and clinical advances of vaccines against nicotine addiction.
Vaccine. 2025;55:127036.
PubMed Abstract available

GOLDMAN RD, Hart RJ, Bone JN, Seiler M, et al
Adverse events among early caregivers' COVID-19 vaccination correlated inversely with intention to vaccinate their children.
Vaccine. 2025;55:127001.
PubMed Abstract available

SALLOUM M, Lariviere Y, Bikioli Bolombo F, Zola Matuvanga T, et al
The exclusion of pregnant women from an Ebola vaccine trial in Boende, western DRC: Perceptions of female participants who became pregnant and community members.
Vaccine. 2025;55:127000.
PubMed Abstract available

VACHON A, Keeshan A, Galipeau Y, Crawley AM, et al
Alcohol consumption does not influence SARS-CoV-2 vaccine immunogenicity: A stop the spread Ottawa cohort analysis.
Vaccine. 2025;55:127034.
PubMed Abstract available

KAISER S, Kaiser S, Reis J, Marschalek R, et al
Quantification of objective concentrations of DNA impurities in mRNA vaccines.
Vaccine. 2025;55:127022.
PubMed Abstract available

CRAWLEY AW, Murphy K, Plumb ID, Ocansey GA, et al
Challenges and enablers to establishing COVID-19 vaccine effectiveness studies in the World Health Organization Africa region: A mixed-methods evaluation of the African region monitoring vaccine effectiveness (AFRO-MoVE) network.
Vaccine. 2025 Mar 20:126823. doi: 10.1016/j.vaccine.2025.126823.
PubMed Abstract available

HAMID S, Simeone RM, Newhams MM, Halasa N, et al
Concordance between parent-reported and documented COVID-19 vaccination status among hospitalized children and adolescents: Implications for vaccine effectiveness estimates, May 2021-October 2023.
Vaccine. 2025;54:126891.
PubMed Abstract available

SHINO MY, Ibarrondo FJ, Yang OO
SARS-CoV-2 spike antibody levels in lung transplantation recipients versus the spectrum in non-immunocompromised persons.
Vaccine. 2025;50:126851.
PubMed Abstract available

HAGEDORN B, Frey K, Scarna T, El Sheikh F, et al
Microarray patches likely to reduce the operational costs of immunization: A Monte Carlo simulation study.
Vaccine. 2025;50:126840.
PubMed Abstract available

ILIYASU Z, Danzomo AA, Jeyaseelan V, Gofama MM, et al
Impact of novel Oral Poliovirus Type 2 vaccination campaigns: A seroprevalence survey in Nigeria, 2022.
Vaccine. 2025;54:126978.
PubMed

THORS V, Vias RD, Bjornsdottir K, Palsdottir EB, et al
Influenza vaccine effectiveness in Iceland 2014-2022: A test-negative design.
Vaccine. 2025;55:126981.
PubMed Abstract available

RASKIN N, Hiligsmann M, Luyten J, Tubeuf S, et al
Socio-demographic differences in citizen' preferences for distributing a scarce, lifesaving resource: A case study using COVID-19 vaccine distribution in Belgium.
Vaccine. 2025;55:126997.
PubMed Abstract available

NAZIAT H, Rahman MH, Das RC, Islam M, et al
Impact of 10-valent pneumococcal conjugate vaccine on the epidemiology of otitis media with otorrhea among Bangladeshi children.
Vaccine. 2025;55:126995.
PubMed Abstract available

CHOI J, Feelemyer J, Choe K, Lynch K, et al
Anti-vaccine attitudes and COVID-19 vaccine status at the end of the U.S. public health emergency.
Vaccine. 2025;55:127003.
PubMed Abstract available

BALDOLLI A, Fournier A, Roger H, Piednoir E, et al
Implementation of school-based vaccination in French middle schools: Efficient or not?
Vaccine. 2025;55:127007.
PubMed Abstract available

MPABALWANI EM, Sakala C, Kamiji E, Simwaka J, et al
Challenges and lessons learned during the switching of rotavirus vaccine from Rotarix to Rotavac in Zambia.
Vaccine. 2025;55:127012.
PubMed Abstract available

HEGMANN TE, Walter EB, Smith MJ, Campbell J, et al
A phase I study of the safety, reactogenicity and immunogenicity of two quadrivalent seasonal influenza vaccines (Fluzone(R) or Flublok(R)) with or without one of two adjuvants (AF03 or Advax-CpG55.2) in healthy adults 18-45 years of age.
Vaccine. 2025;54:126991.
PubMed Abstract available

GHARPURE R, Vegvari C, Abdissa A, Alimi Y, et al
Meeting report: CEPI workshop on Rift Valley fever epidemiology and modeling to inform human vaccine development, Nairobi, 4-5 June 2024.
Vaccine. 2025;54:126860.
PubMed Abstract available

MACGIBBON J, Storer D, Bavinton BR, Cornelisse VJ, et al
Mpox vaccination coverage among Australian gay and bisexual men and non-binary people: Results of behavioural surveillance in early 2024.
Vaccine. 2025;55:127014.
PubMed Abstract available

YANAI T, Yoshida S, Kawakami K
Gastroenteritis hospitalizations over 19 years before and after introduction of rotavirus vaccine in Japan: A nationwide claims database.
Vaccine. 2025;55:127027.
PubMed Abstract available

YUILL S, Hall MT, Caruana M, Lui G, et al
Predicted impact of HPV vaccination and primary HPV screening on precancer treatment rates and adverse pregnancy outcomes in Australia 2010-2070: Modelling in a high income, high vaccination coverage country with HPV-based cervical screening.
Vaccine. 2025;54:126986.
PubMed Abstract available

ZHANG X, Zhao T, Cai X, Zhang W, et al
Are health education effective to improve herpes zoster vaccine willingness in vulnerable elderly.
Vaccine. 2025;54:126975.
PubMed Abstract available

XU J, Davoudpour S, Phillips G 2nd
Applying the health belief model (HBM) to understand COVID-19 vaccine uptake among youth and young adults: Findings from a 6-month follow-up study in the United States.
Vaccine. 2025;54:127002.
PubMed Abstract available

PATTHAMMAVONG C, Wodniak N, Phounphenghack K, Tengbriacheu C, et al
Factors associated with influenza and COVID-19 vaccination among health workers in Lao PDR, 2023.
Vaccine. 2025;54:127006.
PubMed Abstract available

RICCI L, Fery C, Tubach F, Agrinier N, et al
Health care institutions and their physicians are the greatest promoters of COVID-19 vaccine acceptance among health care workers.
Vaccine. 2025;54:127005.
PubMed Abstract available

MYBURGH L, Karsjens H, Blanas A, de Ligt A, et al
Targeting the early life stages of SARS-CoV-2 using a multi-peptide conjugate vaccine.
Vaccine. 2025;54:126989.
PubMed Abstract available

LU H
Generative AI for vaccine misbelief correction: Insights from targeting extraversion and pseudoscientific beliefs.
Vaccine. 2025;54:127018.
PubMed Abstract available

FIRTH C, Emary K, Stuart A, Browne R, et al
Acceptability of the gonorrhoea human challenge model to accelerate vaccine development in UK men.
Vaccine. 2025;54:127013.
PubMed Abstract available

SKOCZYNSKA A, Golebiewska A, Wrobel-Pawelczyk I, Ronkiewicz P, et al
The direct impact of mandatory PCV10 vaccination on invasive pneumococcal disease in Polish children.
Vaccine. 2025;54:126999.
PubMed Abstract available

TAMIR TT, Tekeba B, Techane MA, Alemu TG, et al
Coverage of complete basic childhood vaccination and its variation by basic characteristics among children aged 12-23 months in 41 low- and middle-income countries: A Meta-analysis of demographic and health survey reports between 2015 and 2025.
Vaccine. 2025;54:127019.
PubMed Abstract available

VEDEL JO, Furtado O, Almeida LL, Nehal KR, et al
Childhood vaccination coverages in rural Guinea-Bissau before and during the early COVID-19 pandemic, a cohort study.
Vaccine. 2025;54:127011.
PubMed Abstract available

MARTINON-TORRES F, Martinez SN, Kline MJ, Drozd J, et al
A phase 3 study of 20-valent pneumococcal conjugate vaccine in healthy toddlers previously vaccinated in infancy with 13-valent pneumococcal conjugate vaccine.
Vaccine. 2025;53:126931.
PubMed Abstract available

DAVIS P, Montroy J, Warshawsky B, Abrams EM, et al
Immunogenicity of pre-exposure rabies vaccination comparing number of doses and routes of administration: A systematic review and meta-analyses.
Vaccine. 2025;53:126878.
PubMed Abstract available

SIKUVI K, Nghitukwa N, Kakehongo N, Katjitae I, et al
Effectiveness of COVID-19 vaccines against laboratory-confirmed SARS-CoV-2 infection amongst health workers, Windhoek, Namibia.
Vaccine. 2025 Mar 11:126977. doi: 10.1016/j.vaccine.2025.126977.
PubMed Abstract available

BOLU O, Alo OD, Iwara E, Longley AT, et al
Feasibility of cohort event monitoring and assessment of reactogenicity and adverse events among a cohort of AstraZeneca and Moderna COVID-19 vaccine recipients in Nigeria, 2021.
Vaccine. 2025;52:126907.
PubMed Abstract available

DI CHIARA C, Karimi-Shahrbabak E, Peresin J, Farrar DS, et al
A review of Canadian online resources providing information on COVID-19 vaccination for caregivers of children aged 5-11 years.
Vaccine. 2025;54:126990.
PubMed Abstract available

MEERAUS W, Postema A, Gray CM, Lee A, et al
Second booster doses of adenoviral- and mRNA-based COVID-19 vaccines increase protection against COVID-19 hospitalization: Final analysis from the REFORCO-Brazil real-world effectiveness study during Omicron.
Vaccine. 2025;53:126955.
PubMed Abstract available

KRAMMER F
Next-generation seasonal influenza virus vaccines need a neuraminidase component.
Vaccine. 2025;54:126994.
PubMed

OTIENO NA, Kalani R, Ayugi J, Nyawanda BO, et al
Seasonal influenza vaccination in Kenya: What determines healthcare Workers' willingness to accept and recommend vaccination?
Vaccine. 2025;54:126963.
PubMed Abstract available

DE SOUZA RA, Barreto FR, de Jesus Lima CCO, da Natividade MS, et al
Efficacy of BCG vaccination on incidence, severity and clinical progression of COVID-19: A BCG-REVAC population analysis.
Vaccine. 2025;54:126911.
PubMed Abstract available

JI C, Senthinathan A, Apajee J, Dubey V, et al
Impact of the COVID-19 pandemic on routine immunization coverage of children and teenagers in Ontario, Canada.
Vaccine. 2025;49:126811.
PubMed Abstract available

FORZY T, Tesfaye L, Getnet F, Misganew A, et al
Assessing the geographic and socioeconomic determinants of vaccine coverage in Ethiopia: A spatial and multistage analysis at the district level.
Vaccine. 2025;53:126834.
PubMed Abstract available

DESILVA MB, Vazquez-Benitez G, Seburg EM, Henderson MSG, et al
Pregnant persons perceptions and uptake of prenatal RSV vaccine - Minnesota, 2023-2024.
Vaccine. 2025;54:126958.
PubMed Abstract available

DOWGIER G, Hobbs A, Greenwood D, Shawe-Taylor M, et al
Accurate evaluation of live-virus microneutralisation for SARS-CoV-2 variant JN.1 in the assessment of vaccination and therapeutics.
Vaccine. 2025;54:126960.
PubMed Abstract available

NAVAEISEDDIGHI Z, Schmit T, Wang Z, Ahamed N, et al
The vaccine dosing effect overcomes the reduced immunogenic potential and in vivo efficacy of 33F pneumococcal serotype.
Vaccine. 2025;54:126983.
PubMed Abstract available

LEE DW, Nasir A, Elbashir S, Jani H, et al
mRNA-1273 vaccines adapted to JN.1 or KP.2 elicit cross-neutralizing responses against the JN.1 sublineages of SARS-CoV-2 in mice.
Vaccine. 2025;54:126961.
PubMed Abstract available

ABAASA AM, Kusemererwa S, Ankunda V, Ongaria TA, et al
Effectiveness of COVID-19 vaccine against SARS-CoV-2 infection among symptomatic COVID-19 patients in Uganda.
Vaccine. 2025 Mar 6:126976. doi: 10.1016/j.vaccine.2025.126976.
PubMed Abstract available

KUSEMERERWA S, Ankunda V, Ongaria TA, Abaasa A, et al
COVID-19 vaccination status and associated factors among patients presenting with COVID-19-like symptoms in Uganda.
Vaccine. 2025 Mar 6:126984. doi: 10.1016/j.vaccine.2025.126984.
PubMed Abstract available

CARTER JJ, Smith RA, Scherer EM, Skibinski DAG, et al
Corrigendum to "Long-Term immune memory responses to human papillomavirus (HPV) vaccination following 2 versus 3 doses of HPV vaccine" [Vaccine, Volume 50, 19 March 2025, 126,817].
Vaccine. 2025;54:126974.
PubMed

TILLYA R, Abdallah G, Msuya H, Bajaria S, et al
Associated factors for dropout of first versus third doses of pentavalent vaccination in Tanzania.
Vaccine. 2025;54:126962.
PubMed Abstract available

XIMENES R, Simmons AE, Gebretekle GB, Nam A, et al
Cost-effectiveness analysis of 21-valent pneumococcal conjugated vaccine among adults in Canada.
Vaccine. 2025;54:126985.
PubMed Abstract available

MINUTTI AF, Sasse JP, Dos Santos Silva AC, Martins TA, et al
Evaluation of a DNA vector plasmid encoding a partial rop18 gene from toxoplasma gondii in domestic cats as a vaccine candidate.
Vaccine. 2025;54:126965.
PubMed Abstract available

GORDON JL, Boespflug EL, Coleman A, Taylor K, et al
Development of broadly protective coronavirus vaccines: A joint NIAID-CEPI workshop report.
Vaccine. 2025;54:126909.
PubMed

CARROLL M, Fox HB, Tran A, Chellappan G, et al
SARS-CoV-2 conjugate vaccine elicits robust immune responses that can protect against evolving variants.
Vaccine. 2025;54:126988.
PubMed Abstract available

PROCTOR RA, Jackson AM, Fowler VG
The lack of a biorepository during vaccine trials: A lost opportunity to understand staphylococcal immunity.
Vaccine. 2025;53:126896.
PubMed Abstract available

GATES CJ, Brazel EB, Kennedy EV, Brown JS, et al
A gamma-irradiated pneumococcal vaccine elicits superior immunogenicity in comparison to heat or chemically inactivated whole-cell vaccines.
Vaccine. 2025;54:126982.
PubMed Abstract available

MOORE M, Anderson L, Schiffer JT, Matrajt L, et al
Durability of COVID-19 vaccine and infection induced immunity: A systematic review and meta-regression analysis.
Vaccine. 2025;54:126966.
PubMed Abstract available

CHISNALL G, Letley L, Mounier-Jack S, Bedford H, et al
Parents' experiences of accessing childhood vaccination services in England: A qualitative longitudinal cohort study.
Vaccine. 2025;52:126921.
PubMed Abstract available

RAMIREZ-BENCOMO F, Thistlethwaite A, Viviani V, Bartolini E, et al
Identification of immunogenic outer membrane vesicle vaccine antigen components using a meningococcal protein microarray.
Vaccine. 2025;53:126953.
PubMed Abstract available

PEIXOTO DE MIRANDA EJF, Calado RT, Boulos FC, de Sousa Moreira JA, et al
Safety and immunogenicity of an inactivated recombinant Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Results of a randomized vaccine-controlled phase I ADAPTCOV trial in Brazil.
Vaccine. 2025;52:126680.
PubMed Abstract available

CHU CF, Chang TH, Ho JJ
Comparative analysis of fourteen COVID-19 vaccine injury compensation systems and claim approval rates.
Vaccine. 2025;52:126830.
PubMed Abstract available

HAMIDI A, Willemsen M, Robert T, Drugmand JC, et al
Sabin inactivated polio vaccine upstream process development using fixed-bed bioreactor technology.
Vaccine. 2025;53:126950.
PubMed Abstract available

ZHAO T, Xu Q, Cai X, Wang M, et al
Global spatio-temporal distribution of coronavirus disease 2019 vaccine hesitancy between 2020 and 2022: A meta-analysis.
Vaccine. 2025;53:126933.
PubMed Abstract available

MAFUTA EM, Lulebo AM, Kasonga JN, Mvuama NM, et al
Designing a National Rapid Vaccine Coverage Survey in low-resource settings: Experiences from the Democratic Republic of the Congo 2018-2023.
Vaccine. 2025;53:126956.
PubMed Abstract available

FRANCA AP, Domingues CMAS, Domingues RAS, Barata RB, et al
Vaccine hesitancy in the vaccination of children in Brazil.
Vaccine. 2025;53:126905.
PubMed Abstract available

COTTER LM, Hopkins-Sheets M, Yang S, Passmore SR, et al
Increasing confidence for pediatric COVID-19 and influenza vaccines using messages affirming parental autonomy: A randomized online experiment.
Vaccine. 2025;53:126947.
PubMed Abstract available

AYAD C, Porter D, Lambert E, Libeau P, et al
An LNP-mRNA vaccine protects fish against rhabdovirus infection.
Vaccine. 2025;53:126957.
PubMed Abstract available

TENGATTINI S, Bavaro T, Rinaldi F, Temporini C, et al
Novel tuberculosis vaccines based on TB10.4 and Ag85B: State-of-art and advocacy for good practices.
Vaccine. 2025;53:126932.
PubMed Abstract available

ONYANDO BO, Nyawanda BO, Onguru D, Haidara FC, et al
Factors associated with mortality among patients aged 12 years and above requiring hospitalization for severe respiratory illness (SRI): Findings from the COVID-19 vaccine effectiveness evaluation in Kenya and Mali, 2022-2023.
Vaccine. 2025 Mar 1:126910. doi: 10.1016/j.vaccine.2025.126910.
PubMed Abstract available

DAVIES A, Schreiber D, Carey C, Tucker SB, et al
Community pharmacists' pneumococcal vaccine knowledge and perceived barriers to vaccination.
Vaccine. 2025;53:126930.
PubMed Abstract available

KEELING MJ, Hill EM, Petrou S, Tran PB, et al
Cost-effectiveness of routine COVID-19 adult vaccination programmes in England.
Vaccine. 2025;53:126948.
PubMed Abstract available

NIU Y, Yan Y, Hu Y, Yang X, et al
A novel tetravalent influenza vaccine based on one chimpanzee adenoviral vector.
Vaccine. 2025;53:126959.
PubMed Abstract available

February 2025

SHAO Q
Corrigendum to The origin of vaccine nationalism [Vaccine 51 (2025) 126897].
Vaccine. 2025;53:126935.
PubMed

RIGAMONTI V, Torri V, Morris SK, Ieva F, et al
Real-world effectiveness of influenza vaccination in preventing influenza and influenza-like illness in children.
Vaccine. 2025;53:126946.
PubMed Abstract available

WANG B, Lassi Z, Andraweera P, Chen G, et al
Pregnant women's choices for preventing respiratory syncytial virus (RSV).
Vaccine. 2025;48:126790.
PubMed Abstract available

ZHOU S, Wang J, Lv M, Lan W, et al
Long-term antibody trajectories after PPSV23 in elderly: Results from a 4-year follow-up study.
Vaccine. 2025;48:126737.
PubMed Abstract available

ADU P, Popoola T, Iqbal N, Roemer A, et al
A cross-country network analysis of disease infodemics: Looking through the lens of the COVID-19 pandemic.
Vaccine. 2025;48:126733.
PubMed Abstract available

AN SJ, Yang JS, Chae MH, Woo JS, et al
Development of invasive non-typhoidal Salmonella conjugate vaccines and their evaluation in a trivalent formulation with typhoid conjugate vaccine.
Vaccine. 2025;52:126913.
PubMed Abstract available

GUTTIERES D, Van Riet C, Vandaele N, Decouttere C, et al
Dynamics of global emergency vaccine stockpiles: A systems analysis and application to cholera.
Vaccine. 2025;52:126889.
PubMed Abstract available

KIM HJ, Lee SH, Park YS, Seo DW, et al
Utility of edible plant-derived exosome-like nanovesicles as a novel delivery platform for vaccine antigen delivery.
Vaccine. 2025;52:126902.
PubMed Abstract available

SHEERAH HA, Al-Jedai AH, Al-Jerian NA, Al-Otaiby MA, et al
COVID-19 and influenza hospitalizations and the role of COVID-19 vaccination in the post-pandemic period: A cross-sectional study from Saudi Arabia.
Vaccine. 2025;52:126937.
PubMed Abstract available

SINGER D, Salem A, Stempniewicz N, Ma S, et al
Corrigendum to "The potential impact of increased recombinant zoster vaccine coverage on the burden of herpes zoster among adults aged 50-59 years" [Vaccine 41 (37) (23 August 2023) 5360-5367].
Vaccine. 2025;52:126805.
PubMed

MATHUR I, Ruisch A, Conlin M, Oyatoye I, et al
COVID-19 vaccination integration, innovations and key populations: Results from a global survey.
Vaccine. 2025;52:126863.
PubMed Abstract available

ARABIAN S, Sadr M, Ayati MH, Ince F, et al
The earliest report of smallpox oral vaccination by Baha' al-Dawlah Razi in the 16th century.
Vaccine. 2025;52:126949.
PubMed Abstract available

PEREZ-PEREZ A, Vallejo JR
Francisco Oller y Ferrer (1758-1831). The surgeon who performed the first smallpox vaccination in a Hispanic American territory.
Vaccine. 2025;51:126875.
PubMed Abstract available

GRIFFIN LB, Polnaszek BE, Shin J, Clark MA, et al
Parental status and gender are associated with differences in Tdap vaccination rates among United States adults.
Vaccine. 2025;52:126901.
PubMed Abstract available

BENDERA A, Nakamura K, Tran XMT, Kapologwe NA, et al
Persistent socioeconomic disparities in childhood vaccination coverage in Tanzania: Insights from multiple rounds of demographic and health surveys.
Vaccine. 2025;52:126904.
PubMed Abstract available

DHINGRA MS, Peterson J, Hedrick J, Pan J, et al
Corrigendum to "Immunogenicity, safety and inter-lot consistency of a meningococcal conjugate vaccine (MenACYW-TT) in adolescents and adults: A Phase III randomized study" [Vaccine (38) (2020) 5194-5201].
Vaccine. 2025;52:126912.
PubMed

DIYA O, Gayed J, Lowry FS, Ma H, et al
A phase 2/3 trial to investigate the safety and immunogenicity of monovalent Omicron JN.1-adapted BNT162b2 COVID-19 vaccine in adults >/=18 years old.
Vaccine. 2025;52:126869.
PubMed Abstract available

LEBLANG D, Smith MD, Wesselbaum D
Global perspectives on COVID-19 vaccination: Impacts on well-being and inequality.
Vaccine. 2025;52:126906.
PubMed Abstract available

ANDERSEN KM, Allen KE, Nepal RM, Mateus JS, et al
Effectiveness of BNT162b2 XBB.1.5 vaccine in immunocompetent adults using tokenization in two U.S. states.
Vaccine. 2025;52:126881.
PubMed Abstract available

DUDLEY MZ, Zapf AJ, Delamater P, Proveaux TM, et al
Attitudes of California school personnel on potential COVID-19 vaccine mandates and state law SB277 to remove nonmedical vaccine exemptions.
Vaccine. 2025;52:126888.
PubMed Abstract available

GARLING A, Goursat C, Seguy C, Martin P, et al
Development of intimin-enriched outer membrane vesicles (OMVs) as a vaccine to control intestinal carriage of Enterohemorrhagic Escherichia coli.
Vaccine. 2025;52:126899.
PubMed Abstract available

FARAH Z, Bazant ES, Basha I, Saleh N, et al
Determinants of seasonal influenza vaccination uptake, intention and recommendations among Lebanese physicians.
Vaccine. 2025;52:126890.
PubMed Abstract available

CHIBA S, Halfmann PJ, Iida S, Hirata Y, et al
Correction to "Recombinant Spike protein vaccines coupled with adjuvants that have different modes of action induce protective immunity against SARS-CoV-2" [Vaccine 2023 Sep 22 41(41) 6025-6035. Doi: 10.1016/j.vaccine.2023.08.054].
Vaccine. 2025;52:126880.
PubMed Abstract available

YE Q, Xiao Z, Bai C, Yao H, et al
Unveiling the multi-characteristic potential of hyper-productive suspension MDCK cells for advanced influenza A virus propagation.
Vaccine. 2025;52:126900.
PubMed Abstract available

MACKENZIE LJ, Bousie JA, Newman P, Cunningham J, et al
What three years of COVID-19 vaccine administration reveals about the incidence of shoulder injury related to vaccine administration (SIRVA).
Vaccine. 2025;51:126892.
PubMed Abstract available

VAN BEEK LF, van der Gaast-de Jongh C, Platenburg PP, Hilgers L, et al
Improving the immunogenicity of the pneumococcal conjugate vaccine using a synthetic carbohydrate fatty acid monosulphate squalane-in-water adjuvant.
Vaccine. 2025;51:126893.
PubMed Abstract available

ATTI A, England A, Sung J, Foulkes S, et al
Estimating neutralising antibody responses against emerging SARS-CoV-2 variants utilising convalescent sera before the roll-out of XBB-lineage vaccines.
Vaccine. 2025;51:126898.
PubMed Abstract available

MEYERS E, De Rop L, Deschepper E, Duysburgh E, et al
SARS-CoV-2 seroreversion and all-cause mortality in nursing home residents and staff post-primary course vaccination in Belgium between February and December 2021.
Vaccine. 2025;51:126865.
PubMed Abstract available

BERGSTROM F, Gunther F, Britton T
A counterfactual analysis quantifying the COVID-19 vaccination impact in Sweden.
Vaccine. 2025;52:126870.
PubMed Abstract available

DERBISE A, Guillas C, Echenique-Rivera H, Carniel E, et al
Contribution of the type 3 secretion system to adaptive and innate immunity induced by a live Yersinia pseudotuberculosis plague vaccine.
Vaccine. 2025;51:126887.
PubMed Abstract available

SHAO Q
The origin of vaccine nationalism.
Vaccine. 2025;51:126897.
PubMed

HALL C, Lanning J, Romano CJ, Bukowinski AT, et al
COVID-19 vaccine initiation in pregnancy and risk for adverse neonatal outcomes among United States military service members, January-December 2021.
Vaccine. 2025;51:126894.
PubMed Abstract available

ZHAO T, Liu X, Huang X, Wang L, et al
Development and evaluation of mosaic VLPs vaccine for enhanced broad-Spectrum immunity against influenza B virus lineages in mice.
Vaccine. 2025;51:126882.
PubMed Abstract available

TAAFFE J, Goldin S, Lambach P, Sparrow E, et al
Global production capacity of seasonal and pandemic influenza vaccines in 2023.
Vaccine. 2025;51:126839.
PubMed Abstract available

DARWAR R, Huang X, Abayeneh A, Alemayehu Beshah S, et al
Costing approaches for vaccine-preventable disease surveillance: Lessons from Ethiopia and Nepal.
Vaccine. 2025;50:126776.
PubMed Abstract available

SIERRA MS, Carvajal LJ, Dull P, Herrero R, et al
Human papillomavirus type 16 and 18 viral clearance and progression to precancer among women aged 18-25 years enrolled in the Costa Rica HPV prophylactic vaccine trial (CVT).
Vaccine. 2025;50:126841.
PubMed Abstract available

APPEL AM, Janbek J, Laursen TM, Gasse C, et al
Dementia and influenza vaccination: Time trends and predictors of vaccine uptake among older adults.
Vaccine. 2025;51:126864.
PubMed Abstract available

MONTROY J, Yan C, Khan F, Forbes N, et al
Post-exposure prophylaxis for the prevention of measles: A systematic review.
Vaccine. 2025;47:126706.
PubMed Abstract available

KAHN R, Moiane B, Lessa FC, Massora S, et al
Nasopharyngeal carriage of Streptococcus pneumoniae among children and their household members in southern Mozambique five years after PCV10 introduction.
Vaccine. 2025;47:126691.
PubMed Abstract available

YILDIRIM M, Keskinocak P, Hinderstein S, Tran K, et al
A comprehensive analysis of serotype-specific invasive capacity, clinical presentations, and mortality trends of invasive pneumococcal disease.
Vaccine. 2025;47:126692.
PubMed Abstract available

KEMP M, Capriola A, Schauer S
RSV immunization uptake among infants and pregnant persons - Wisconsin, October 1, 2023-March 31, 2024.
Vaccine. 2025;47:126674.
PubMed Abstract available

YE Q, Li H, Xie Z, Gao X, et al
Antibody persistence in Chinese toddlers at 1 year and 2 years after two different 4-dose schedules of a novel 13-valent pneumococcal conjugate vaccine (PCV13-TT).
Vaccine. 2025 Feb 15:126815. doi: 10.1016/j.vaccine.2025.126815.
PubMed Abstract available

CHANG C, Patel H, Ferrari A, Scalzo T, et al
sa-mRNA influenza vaccine raises a higher and more durable immune response than mRNA vaccine in preclinical models.
Vaccine. 2025;51:126883.
PubMed Abstract available

BENN CS
Non-specific effects of vaccines: The status and the future.
Vaccine. 2025;51:126884.
PubMed

THOMPSON EL, Akpan IN, Alkhatib S, Grace J, et al
Implementation of mid-adult HPV vaccination guidelines into clinical practice.
Vaccine. 2025;51:126867.
PubMed Abstract available

SMITH DS, Postma M, Fisman D, Mould-Quevedo J, et al
Cost-effectiveness models assessing COVID-19 booster vaccines across eight countries: A review of methods and data inputs.
Vaccine. 2025;51:126879.
PubMed Abstract available

DEANE A, White C, Morrissey Y, Jessop L, et al
The impact of HPV vaccine disinformation and misinformation in disadvantaged educational settings in Ireland: A multi-year analysis of a school immunisation system.
Vaccine. 2025;51:126868.
PubMed Abstract available

BERRYMAN S, Asfor A, Benham E, Howe N, et al
Foot-and-mouth disease vaccine quality: A universal test for intact viral capsids based on detection of VP4.
Vaccine. 2025;51:126845.
PubMed Abstract available

VAN DIEMEN PM, Lean FZX, Ramsay A, Mollett BC, et al
Evaluation of a nanoparticle influenza vaccine in the pig model.
Vaccine. 2025;49:126844.
PubMed Abstract available

KIM SY, Song M, Kwon SL
Impact of caregiver vaccination status on child influenza vaccination hesitancy: A time-to-vaccination analysis for 2023-2024 season in the Republic of Korea.
Vaccine. 2025;49:126852.
PubMed Abstract available

COTUGNO N, Sanna M, Amodio D, Morrocchi E, et al
Pre-vaccination immune markers predict response to BNT162b2 mRNA vaccine in vulnerable groups - The CONVERS project, report from a pediatric tertiary hospital.
Vaccine. 2025;49:126778.
PubMed Abstract available

SHERMAN ME, Michalski J, Das S, Yang H, et al
BECC-engineered live-attenuated Shigella vaccine candidates display reduced endotoxicity with robust immunogenicity in mice.
Vaccine. 2025;50:126779.
PubMed Abstract available

ADAMS L, Karachaliou Prasinou A, Trotter C
Modelling the impact and cost effectiveness of universal varicella vaccination in England.
Vaccine. 2025;50:126831.
PubMed Abstract available

ESSINK BJ, Vermeulen W, Andrade C, de Rooij R, et al
A randomised phase 2 immunogenicity and safety study of a MF59-adjuvanted quadrivalent subunit inactivated cell-derived influenza vaccine (aQIVc) in adults aged 50 years and older.
Vaccine. 2025;51:126791.
PubMed Abstract available

WILLIAMS JTB, Johnson D, Weinshenker D, O'Leary ST, et al
Co-creation of pediatric influenza digital stories via rapid community translation.
Vaccine. 2025;51:126866.
PubMed Abstract available

O'KENNEDY MM, Reedy SE, Abolnik C, Khan A, et al
Protective efficacy of a bivalent equine influenza H3N8 virus-like particle vaccine in horses.
Vaccine. 2025;50:126861.
PubMed Abstract available

CAPAO A, Araujo MF, Tort LFL, Toledo TS, et al
Impact in the humoral and cellular immune response to SARS-CoV-2 variants after primary vaccination with AZD1222/COVISHIELD protocol in healthy adults.
Vaccine. 2025;50:126785.
PubMed Abstract available

HOULE SKD, Constantinescu C, Dube E
Navigating the 'sea of Cs' in vaccine hesitancy: Where does collaboration fit?
Vaccine. 2025;51:126876.
PubMed

SHARMA A, Kerkhoff AD, Haambokoma M, Shamoya B, et al
Intention to receive new vaccines post-COVID-19 pandemic among adults and health workers in Lusaka, Zambia.
Vaccine. 2025;50:126846.
PubMed Abstract available

GEIGER M, Betsch C, Bohm R
Mind the jingle: A call to consider construct validity of the 7C of vaccination readiness.
Vaccine. 2025 Feb 8:126843. doi: 10.1016/j.vaccine.2025.126843.
PubMed

FAUSTINI SE, Backhouse C, Duggal NA, Toellner KM, et al
Time of day of vaccination does not influence antibody responses to pneumococcal and annual influenza vaccination in a cohort of healthy older adults.
Vaccine. 2025;49:126770.
PubMed Abstract available

NAFICY A, Chugh Y, Tariq M, Hawksworth H, et al
Immune response and safety of the adjuvanted recombinant zoster vaccine in adults 50 years of age and older in India: A randomized phase 3 trial.
Vaccine. 2025;50:126819.
PubMed Abstract available

SCALSKY R, Dwivedi A, Stabler TC, Mbambo G, et al
Whole-genome sieve analysis: Identification of protective malaria antigens by leveraging allele-specific vaccine efficacy.
Vaccine. 2025;50:126783.
PubMed Abstract available

FU Y, Xu Z, Wang Q, Zhang J, et al
Effectiveness and coverage of COVID-19 vaccination among the infection-naive population: A community-based retrospective cohort study in China.
Vaccine. 2025;50:126836.
PubMed Abstract available

FRITSCHI N, Heininger U
Pertussis vaccination campaign among health care workers and validity of recall of previous adverse events following immunization.
Vaccine. 2025;50:126850.
PubMed Abstract available

ABBAD A, Yueh J, Yellin T, Singh G, et al
Co-administration of seasonal quadrivalent influenza and COVID-19 vaccines leads to enhanced immune responses to influenza virus and reduced immune responses to SARS-CoV-2 in naive mice.
Vaccine. 2025;50:126825.
PubMed Abstract available

KRAJCAR N, Trkulja V, Butic I, Tesovic G, et al
Impact of the 10-valent pneumococcal conjugate vaccine (PCV10) on pneumococcal carriage in healthy children and children with acute otitis media and pneumonia: emergence of serotypes 3, 6C and 19A in Croatia.
Vaccine. 2025;50:126848.
PubMed Abstract available

GEBREAL A, Ashmawy R, Ahmed MJ, Khattab M, et al
A systematic review and meta-analysis on parental uptake and willingness to vaccinate children against human papillomavirus in the Eastern Mediterranean Region.
Vaccine. 2025 Feb 6:126832. doi: 10.1016/j.vaccine.2025.126832.
PubMed Abstract available

NAKAYAMA T, Hamada S, Kawamura A, Sogawa Y, et al
Non-inferiority and vaccine titer-confirmation studies of MMR vaccine (JVC-001; measles AIK-C, mumps RIT4385, and rubella Takahashi strains) in healthy 1-year-old Japanese children.
Vaccine. 2025 Feb 6:126698. doi: 10.1016/j.vaccine.2024.126698.
PubMed Abstract available

VAHORA MS, Leao O, da Silveira MF, Domingues MR, et al
Impacts of vaccination, school attendance, and nutrition on SARS-CoV-2 antibody titer in a prospective birth cohort in Brazil.
Vaccine. 2025;49:126838.
PubMed Abstract available

MCCLYMONT E, Wong JMH, Forward L, Blitz S, et al
Acceptance and preference between respiratory syncytial virus vaccination during pregnancy and infant monoclonal antibody among pregnant and postpartum persons in Canada.
Vaccine. 2025;50:126818.
PubMed Abstract available

KANG HS, Kim SY, De Gagne JC, Chae SM, et al
Pregnant women's experiences of and attitudes toward COVID-19 vaccination: A qualitative descriptive study.
Vaccine. 2025;50:126835.
PubMed Abstract available

SOENS M, Ananworanich J, Hicks B, Lucas KJ, et al
A phase 3 randomized safety and immunogenicity trial of mRNA-1010 seasonal influenza vaccine in adults.
Vaccine. 2025;50:126847.
PubMed Abstract available

JENNINGS MC, Nabia S, Morgan C, Nduka CC, et al
Realist review of low- to upper-middle-income country experiences on integration of HPV vaccination with other adolescent health services.
Vaccine. 2025;50:126833.
PubMed Abstract available

HONDA-OKUBO Y, Sajkov D, Wauchope B, Turner JV, et al
Immunogenicity and safety study of a single dose of SpikoGen(R) vaccine as a heterologous or homologous intramuscular booster following a primary course of mRNA, adenoviral vector or recombinant protein COVID-19 vaccine in ambulatory adults.
Vaccine. 2025;49:126744.
PubMed Abstract available

PORTER RM, Bednarczyk RA
Better, worse, or holding the course? Analysis of HPV vaccination patterns in the US, 2008-2020.
Vaccine. 2025;50:126824.
PubMed Abstract available

DOUA J, Ndembi N, Auerbach J, Kaseya J, et al
Advancing local manufacturing capacities for vaccines within Africa - Opportunities, priorities and challenges.
Vaccine. 2025;50:126829.
PubMed Abstract available

CARTER JJ, Smith RA, Scherer EM, Skibinski DAG, et al
Term immune memory responses to human papillomavirus (HPV) vaccination following 2 versus 3 doses of HPV vaccine.
Vaccine. 2025;50:126817.
PubMed Abstract available

WALKER RI
Conserved antigens for enteric vaccines.
Vaccine. 2025;50:126828.
PubMed Abstract available

SORENSEN JK, Jensen A, Zimakoff AC, Vittrup DM, et al
Genetic associations with measles PRNT and IgG antibody response to MMR vaccination in 6- and 15-month-old children.
Vaccine. 2025;50:126788.
PubMed Abstract available

GAO MZ, Awonusi OO, Ramkumar SP, Myint JA, et al
The Affordable Care Act and change in human papillomavirus (HPV) vaccine uptake in the United States.
Vaccine. 2025;50:126842.
PubMed Abstract available

KAN AKC, Mak HWF, Chiang V, Yim JSH, et al
Leveraging COVID-19 vaccine allergy evaluations with coincident drug allergy delabelling: Effectiveness and impact on quality of life.
Vaccine. 2025;50:126849.
PubMed Abstract available

URSELLI F, Gomez A, Gray MD, Cameron CE, et al
Identification of antibodies induced by immunization with the syphilis vaccine candidate Tp0751.
Vaccine. 2025;50:126804.
PubMed Abstract available

POWELL A, Jones A, Van Hout MC, Montgomery C, et al
Influenza vaccine uptake in socially deprived areas: A multilevel retrospective population-based cross-sectional study using electronic health records in Liverpool, United Kingdom.
Vaccine. 2025;50:126837.
PubMed Abstract available

VAN ENTER BJD, de Zeeuw J, Bakar O, Bakhlakh S, et al
Health system barriers to HPV-vaccination in adolescent females with a Moroccan or Turkish migration background in the Netherlands: A qualitative study.
Vaccine. 2025;50:126827.
PubMed Abstract available

GE Y, Handel A, Giabbanelli PJ, Lemacks J, et al
Exploring bias due to below-limit-of-detection values in influenza vaccine antibody modeling: A case study and instructional guide for the CIVIC study.
Vaccine. 2025;49:126802.
PubMed Abstract available

PIGHI L, Salvagno GL, Lippi G
Correlation between basal humoral immunogenicity and side effects after receiving the bivalent formulation of a mRNA-based vaccine.
Vaccine. 2025 Feb 1:126803. doi: 10.1016/j.vaccine.2025.126803.
PubMed

CHUNG H, Krishnasamy M, Joyce T, Dryden T, et al
"It's a risk-benefit analysis": Qualitative perspectives on barriers and enablers to post-treatment vaccination from adults affected by a haematological malignancy in Australia.
Vaccine. 2025;50:126826.
PubMed Abstract available

EIDEN AL, Mackie DS, Modi K, Drakeley S, et al
Attitudes and beliefs about vaccination among adults in the United States: A real-world, cross-sectional, web-based survey study.
Vaccine. 2025;50:126807.
PubMed Abstract available

January 2025

MCGOLDRICK M, Truong TBQ, Campa C, Ali M, et al
How to accelerate the supply of vaccines to all populations worldwide? Part III: Reflections after the pandemic.
Vaccine. 2025;49:126782.
PubMed Abstract available

GSCHWEND MH, Marchese AM, Poelaert D, Warren B, et al
Efficacy, immunogenicity, and safety of the Novavax COVID-19 vaccine in immunocompromised patients: A targeted literature review.
Vaccine. 2025;49:126777.
PubMed Abstract available

GRAILEY K, Crespo RF, Woldmann L, Chisambi M, et al
Implementing behavioural science-informed letter interventions to increase COVID-19 vaccination uptake in London residents. A difference-in-difference study in London, United Kingdom.
Vaccine. 2025;49:126781.
PubMed Abstract available

FETENSA G, Tolossa T, Besho M, Yadesa G, et al
Willingness to take Mpox vaccine and associated factors among health professionals in Ethiopia: A cross-sectional study.
Vaccine. 2025;49:126822.
PubMed Abstract available

BARAL R, Amponsa-Achiano K, Barros I, Cofie P, et al
What will introducing and delivering new maternal vaccines cost in Ghana and Mozambique? A prospective analysis.
Vaccine. 2025;49:126769.
PubMed Abstract available

DALE KD, Denholm JT
Optimising the M72/AS01E tuberculosis vaccine candidate phase 3 trial based on the phase 2b trial results.
Vaccine. 2025;49:126816.
PubMed

ONO S, Nakajima M, Yamana H, Michihata N, et al
Tetanus toxoid vaccination uptake by trauma patients in Japan: A retrospective cohort study using large administrative claims data.
Vaccine. 2025;49:126812.
PubMed Abstract available

YILMAZ IC, Ipekoglu EM, Golcuklu BS, Bildik T, et al
A phase I/II study of CpG/alum-adjuvanted mammalian-derived quadruple antigen carrying virus-like particle COVID-19 vaccine.
Vaccine. 2025;49:126787.
PubMed Abstract available

MWENDA JM, Mandomando I, Worwui AK, Gacic-Dobo M, et al
A decade of rotavirus vaccination in the World Health Organization African Region: An in-depth analysis of vaccine coverage from 2012 to 2023.
Vaccine. 2025 Jan 30:126768. doi: 10.1016/j.vaccine.2025.126768.
PubMed Abstract available

JIANG Y, Luo Y, Xiao X, Li X, et al
Global, regional, and national burdens of vaccine-preventable infectious diseases with high incidence among middle-aged and older adults aged 55-89 years from 1990 to 2021: Results from the global burden of disease study 2021.
Vaccine. 2025;49:126786.
PubMed Abstract available

HASHIMOTO M, Tsujii K, Nakajima-Yoshida H, Akiyama N, et al
A-910823, a squalene-based emulsion adjuvant, enhances robust and broad immune responses of quadrivalent influenza vaccine in ferrets.
Vaccine. 2025;49:126780.
PubMed Abstract available

VIGEZZI GP, Vecchio R, Barbati C, Bonazza G, et al
Historical analysis of the first smallpox vaccination campaigns in early 19-century northern Italy: organisation and communication insights for contemporary epidemics' prevention and control.
Vaccine. 2025;49:126764.
PubMed Abstract available

WIEGAND RE, Devine O, Wallace M, Ortega-Sanchez IR, et al
Estimating COVID-19 associated hospitalizations, ICU admissions, and in-hospital deaths averted in the United States by 2023-2024 COVID-19 vaccination: A conditional probability, causal inference, and multiplier-based approach.
Vaccine. 2025;49:126808.
PubMed Abstract available

KHAN A, Zhu Y, Babcock HM, Busse LW, et al
COVID-19 and influenza vaccine Hesitancy among adults hospitalized in the United States, 2019-2022.
Vaccine. 2025 Jan 29:126806. doi: 10.1016/j.vaccine.2025.126806.
PubMed Abstract available

STRECKENBACH B, Baldt J, Heidler F, Frahm N, et al
Corrigendum to "General vaccination willingness and current vaccination status in relation to clinical and psychological variables in patients with multiple sclerosis" [Vaccine 40 (23) (2022 May 20) 3236-3243].
Vaccine. 2025;48:126741.
PubMed

FLECK-VIDAL C, Doubell A, Gerke C, Lamichhane U, et al
Vaccines and AMR: An analysis of the funding landscape for human bacterial vaccines in low-and middle-income countries.
Vaccine. 2025;49:126771.
PubMed Abstract available

ITO S, Tsuchida N, Kusunoki S, Kaneko Y, et al
Safety comparison between Pfizer BNT162b2, Moderna mRNA-1273, and AstraZeneca AZD1222 in a Nationwide prospective cohort survey at the beginning of the severe acute respiratory syndrome coronavirus 2 vaccination in Japan.
Vaccine. 2025;49:126754.
PubMed Abstract available

LAO G, Feng J, Wu L, Su W, et al
Development of a genetically modified full-length human respiratory syncytial virus preF protein vaccine.
Vaccine. 2025;49:126799.
PubMed Abstract available

ROPER LE, Link-Gelles R, Surie D, DeCuir J, et al
A framework for monitoring RSV prevention product effectiveness in the United States.
Vaccine. 2025;45:126633.
PubMed Abstract available

EURICH DT, Weaver O, McDermott C, Soprovich A, et al
Describing COVID-19 immunizations for First Nations people on-reserve in Alberta using real-time integration of point of care and provincial data.
Vaccine. 2025;45:126614.
PubMed Abstract available

CONLIN K, Jenkin D, de Whalley P, Weckx LY, et al
Predictors of severity of SARS-CoV-2 infections in Brazil: Post hoc analyses of a randomised controlled trial.
Vaccine. 2025;45:126582.
PubMed Abstract available

WEI Y, Wang J, Wang L, Liu B, et al
Comparative study on the inactivation and immunogenicity of Mycoplasma hyopneumoniae and Mycoplasma hyorhinis vaccines prepared using different inactivants.
Vaccine. 2025 Jan 24:126766. doi: 10.1016/j.vaccine.2025.126766.
PubMed Abstract available

KHETSURIANI N, Tursunova D, Kasimova R, Sharapov S, et al
Prevalence of chronic hepatitis B virus infection among children in Uzbekistan: Impact of vaccination.
Vaccine. 2025;48:126743.
PubMed Abstract available

GLOANEC N, Guyard-Nicodeme M, Chemaly M, Dory D, et al
Reverse vaccinology: A strategy also used for identifying potential vaccine antigens in poultry.
Vaccine. 2025;48:126756.
PubMed Abstract available

OKA E, Ueda Y, Yagi A, Machida M, et al
Challenges to promoting maternal respiratory syncytial virus vaccination in Japan.
Vaccine. 2025;48:126767.
PubMed Abstract available

FARNSWORTH MG, Khanipov K, Botnar K, Weaver SC, et al
Real-world evidence of yellow Fever vaccination data-driven study.
Vaccine. 2025;48:126758.
PubMed Abstract available

SATO R
Closing the gap on vaccine uptake in developing countries: Is there a role for cash incentives?
Vaccine. 2025;48:126763.
PubMed Abstract available

BJERKHAUG AU, Ramalingham S, Mboizi R, Le Doare K, et al
Corrigendum to "The immunogenicity and safety of Group B Streptococcal maternal vaccines: A systematic review" [Vaccine 42 (2024) 84-98].
Vaccine. 2025;48:126732.
PubMed

PROSSER LA, Perroud J, Chung GS, Gebremariam A, et al
The cost-effectiveness of vaccination against COVID-19 illness during the initial year of vaccination.
Vaccine. 2025;48:126725.
PubMed Abstract available

NGOCHO JS, de Jongh CEVG, Sebba J, Mtei M, et al
Emerging of non-vaccine Streptococcus pneumoniae serotypes colonizing the nasopharynx of children under the age of five years in the 13-vallent pneumococcal conjugate vaccine era in Moshi district, Tanzania. A short communication.
Vaccine. 2025;48:126724.
PubMed Abstract available

HINMAN AR, Banerjee E, Brewer NT, Hayes ES, et al
Corrigendum to "Sustainability of measles, rubella, and congenital rubella syndrome (CRS) elimination in the United States, January 2022 - June 2024" [Vaccine 46C (2025) 126681].
Vaccine. 2025;48:126739.
PubMed

GIOVANETTI M, Cella E, Sampaio SC, Elias MC, et al
Dengue vaccination and outbreaks: Bridging clinical diagnosis with genomic surveillance.
Vaccine. 2025 Jan 20:126755. doi: 10.1016/j.vaccine.2025.126755.
PubMed

CLAESSENS T, Eagan RL, Hendrickx G, Van Damme P, et al
Navigating vaccine confidence: A mixed methods study investigating healthcare providers' perspectives across four non-EU European regions.
Vaccine. 2025;47:126694.
PubMed Abstract available

MARTINON-TORRES F, Wysocki J, Szenborn L, Carmona-Martinez A, et al
Corrigendum to "A Phase III, multicenter, randomized, double-blind, active comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of V114 compared with PCV13 in healthy infants (PNEU-PED-EU-1)" [Vaccine 41 (2023) 3387-339
Vaccine. 2025;48:126628.
PubMed

LIAO Z, Deng L, Luo J, Shi M, et al
Association between adults' vaccine literacy and their intention to recommend older family members for influenza vaccine.
Vaccine. 2025;48:126757.
PubMed Abstract available

RAINERI D, Mazzucca CB, Moia R, Bruna R, et al
Impairment of the T cell memory response in chronic lymphocytic leukemia patients after SARS-CoV-2 vaccination.
Vaccine. 2025;48:126723.
PubMed Abstract available

BANU S, Kishor PV, Krishnappa S, Ramasamy Periyasamy TS, et al
Effect of vaccination against foot-and-mouth disease during mid-pregnancy on the neutralizing antibody response in the cow.
Vaccine. 2025;48:126738.
PubMed Abstract available

MADESH S, McGill J, Jaworski DC, Ferm J, et al
Prolonged immune response to tick-borne Ehrlichia chaffeensis infection using a genetically modified live vaccine.
Vaccine. 2025;48:126730.
PubMed Abstract available

SILVA-FERNANDES AT, Moreira SB, Gaspar LP, Cajaraville ACDRA, et al
Safety and immunogenicity of different 17DD yellow fever vaccines in golden-headed tamarins (Leontopithecus chrysomelas): Inhibition of viremia and RNAemia after homologous live-attenuated vaccination.
Vaccine. 2025;48:126721.
PubMed Abstract available

TRANTER I, Judd D, Stickley M, Vasant B, et al
Promoting aged care COVID-19 and influenza vaccination through education of Australian residential aged care staff: A mixed methods project evaluation.
Vaccine. 2025;48:126742.
PubMed Abstract available

SHAH RM, Parzen-Johnson S, Sun S, Patel SJ, et al
Childhood opportunity index and vaccine uptake in pediatric COVID-19 hospitalizations.
Vaccine. 2025;48:126734.
PubMed Abstract available

DOS SANTOS CVB, Coelho LE, de Noronha TG, Goedert GT, et al
The impact of vaccination on the length of stay of hospitalized COVID-19 patients in Brazil.
Vaccine. 2025;48:126735.
PubMed Abstract available

POURAKBARI B, Mahmoudi S, Sajedi Moghaddam S, Jafari E, et al
Evaluation of anti-Pertussis antibody levels in Iranian infants and children: Is it time to include booster acellular Pertussis Vaccines in the immunization schedule?
Vaccine. 2025;48:126736.
PubMed Abstract available

KUMAR S, Hazlett K, Bai G
Mucosal immunity elicited by a human-Fcgamma receptor-I targeted intranasal vaccine platform enhances resistance against nasopharyngeal colonization of Streptococcus pneumoniae and induces broadly protective immunity against respiratory pathogens.
Vaccine. 2025;48:126729.
PubMed Abstract available

SONG H, Jin S, Yang GJ, Lim NWH, et al
Modelling the impact and cost-effectiveness of upcoming Zika virus vaccines on congenital Zika syndrome.
Vaccine. 2025;48:126728.
PubMed Abstract available

SANTANA AP, Soborg B, Jacobsen SU, Zettler I, et al
Danish parents' vaccination readiness is associated with their children's officially registered vaccination history.
Vaccine. 2025;47:126693.
PubMed Abstract available

ISLAM EA, Fegan JE, Zeppa JJ, Ahn SK, et al
Adjuvant-dependent impacts on vaccine-induced humoral responses and protection in preclinical models of nasal and genital colonization by pathogenic Neisseria.
Vaccine. 2025;48:126709.
PubMed Abstract available

AANYU HT, Nalunkuma C, Kaudha E, Nalumansi E, et al
Effectiveness of monovalent rotavirus vaccine against hospital-attended rotavirus gastroenteritis among children in Uganda.
Vaccine. 2025;48:126726.
PubMed Abstract available

DE OLIVEIRA PMN, Hartmann K, Bhamare C, Lucchesi MBB, et al
Active vaccine safety surveillance in low- and middle-income countries: Challenges for vaccine manufacturers from emerging countries.
Vaccine. 2025;48:126727.
PubMed Abstract available

ZHANG Y, Li X, Yang Y, Yin Y, et al
Impact of SARS-CoV-2 inactivated vaccine on symptoms following omicron variant breakthrough infection.
Vaccine. 2025;48:126722.
PubMed Abstract available

COROMINAS J, Garriga C, Prenafeta A, Moros A, et al
Humoral and cellular immune responses after 6 months of a heterologous SARS-CoV-2 booster with the protein-based PHH-1V vaccine in a phase IIb trial.
Vaccine. 2025;47:126685.
PubMed Abstract available

XIE W, Luo D, Soni V, Wang Z, et al
Functional characterization of MMAR_1296 in Mycobacterium marinum and its potential as a vaccine candidate.
Vaccine. 2025;48:126720.
PubMed Abstract available

GONG X, Huang Z, Zheng Y, Xiao W, et al
Rotavirus vaccine effectiveness and coverage among children younger than 5 years old in Shanghai, China: A test-negative case control study.
Vaccine. 2025;48:126731.
PubMed Abstract available

ROSENTHAL M, Stoecker C, Leidner AJ, Cho BH, et al
Cost-effectiveness of 15-valent or 20-valent pneumococcal conjugate vaccine for U.S. adults aged 65 years and older and adults 19 years and older with underlying conditions.
Vaccine. 2025;44:126567.
PubMed Abstract available

ESCABI-WOJNA E, Alvelo-Fernandez PM, Suarez E, Colon-Lopez V, et al
Sex differences in parental reasons for lack of intent to initiate HPV vaccination among adolescents ages 13-17 years: National Immunization Survey - Teen 2019-2021.
Vaccine. 2025;44:126584.
PubMed Abstract available

MARCHESE AM, Beyhaghi H, Rousculp MD, Huang V, et al
Local and systemic reactogenicity after mRNA and protein-based COVID-19 vaccines compared to meningococcal vaccine (MenACWY) in a UK blinded, randomized phase 2 trial (COV-BOOST).
Vaccine. 2025;44:126569.
PubMed Abstract available

FILIMONOVIC J, Stosic M, Gazibara T, Dotlic J, et al
The trend in national childhood immunization program coverage throughout Serbian communities in Kosovo and Metohija from 2003 to 2022: pre-COVID-19 period vs. COVID-19 pandemic.
Vaccine. 2025;44:126576.
PubMed Abstract available

CARNEIRO GB, Yerneni SS, Chinaia K, Araujo AP, et al
Protection induced by Streptococcus pneumoniae extracellular vesicles against nasal colonization and invasive infection in mice and the role of PspA.
Vaccine. 2025;44:126566.
PubMed Abstract available

OLIVERO-DEIBE N, Frigini EN, Ramos N, Carrion F, et al
The stability of PCV2 virus-like particles from mammalian cells and challenges for biotechnological applications.
Vaccine. 2025;44:126549.
PubMed Abstract available

HARTEVELD LM, van Leeuwen LM, Euser SM, Smit LJ, et al
Respiratory syncytial virus (RSV) prevention: Perception and willingness of expectant parents in the Netherlands.
Vaccine. 2025;44:126541.
PubMed Abstract available

LI Y, Chen L, Xiao J, Feng K, et al
Immunoprotective efficacy of Escherichia coli-derived outer membrane vesicles displaying PlpE protein of Pasteurella multocida.
Vaccine. 2025;44:126532.
PubMed Abstract available

DE LIMA EDS, Antunes MOB, de Souza JS, Jones MH, et al
Effectiveness of BNT162b2 and CoronaVac against COVID-19-related severe outcomes among children and adolescents: A Brazilian nationwide cohort study.
Vaccine. 2025;44:126550.
PubMed Abstract available

SILVA HM
Return of poliomyelitis: A real risk in a country afflicted by scientific denialism.
Vaccine. 2025;44:126449.
PubMed Abstract available

DAVIES C, Baker B, Berger MN, Knox SL, et al
Vaccine microarray patch self-administration: A preliminary study in adults 50 years of age and over.
Vaccine. 2025 Jan 12:126699. doi: 10.1016/j.vaccine.2024.126699.
PubMed Abstract available

VITTRUP DM, Charabi S, Jensen A, Stensballe LG, et al
A systematic review and meta-analysis of adverse events following measles-containing vaccines in infants less than 12 months of age.
Vaccine. 2025;47:126687.
PubMed Abstract available

RITCHIE AJ, Meeyai A, Trotter C, Douglas AD, et al
Routine childhood rabies pre-exposure prophylaxis can be cost effective in low- and middle-income countries.
Vaccine. 2025;47:126703.
PubMed Abstract available

OSEI I, Schmidt-Chanasit J, Licciardi PV, Secka O, et al
Immunogenicity of yellow fever vaccine co-administered with 13-valent pneumococcal conjugate vaccine in rural Gambia: A cluster-randomised trial.
Vaccine. 2025;47:126712.
PubMed Abstract available

FREY SE, Brady R, Jackson L, Goepfert P, et al
Safety and immunogenicity of ascending doses of influenza A(H7N9) inactivated vaccine with or without MF59(R).
Vaccine. 2025;47:126702.
PubMed Abstract available

HONDA-OKUBO Y, Vaghasiya U, Petrovsky N
Immunogenicity in mice and non-human primates of an Advax-CpG55.2-adjuvanted recombinant hemagglutinin seasonal quadrivalent influenza vaccine.
Vaccine. 2025;47:126707.
PubMed Abstract available

GENDLER Y, Ofri L, Videl H
Understanding factors contributing to vaccination underutilization among Jewish ultra-orthodox communities in Israel: A cross-sectional study.
Vaccine. 2025;47:126711.
PubMed Abstract available

SHIELDS T, King KD, Cripps S, Edwards SA, et al
Perspectives on vaccination among unvaccinated members of a Canadian indigenous population.
Vaccine. 2025;47:126665.
PubMed Abstract available

CHIU CY, Sampathkumar P, Brumble LM, Vikram HR, et al
Optimizing hepatitis B virus seroprotection in thoracic organ transplantation: The role of HepB-CpG (Heplisav-B) vaccination schedule.
Vaccine. 2025;47:126705.
PubMed Abstract available

NAVARRO-TORNE A, Anderson A, Panwar K, Ghys E, et al
Corrigendum to How has post-implementation surveillance of high-coverage vaccination with HPV16/18-AS04 vaccine in England added to evidence about its cross-protective effects? Vaccine. 2024 Oct 24;42(24):126215. doi: 10.1016/j.vaccine.2024.126215. Ep
Vaccine. 2025;47:126701.
PubMed

CASPERSEN IH, Skodvin SN, Blix K, Robertson AH, et al
Post-COVID symptoms after SARS-CoV-2 omicron infection and the effect of booster vaccination: A population-based cohort study.
Vaccine. 2025;47:126664.
PubMed Abstract available

CAO Y, da Silva Araujo M, Lorang CG, Dos Santos NAC, et al
Distinct immunogenicity outcomes of DNA vaccines encoding malaria transmission-blocking vaccine target antigens Pfs230D1M and Pvs230D1.
Vaccine. 2025;47:126696.
PubMed Abstract available

LE N, McMann TJ, Wenzel C, Li Z, et al
COVID-19 pediatric vaccine Hesitancy: Themes and interactions with verified twitter accounts.
Vaccine. 2025;47:126688.
PubMed Abstract available

SEO H, Kim BJ, Oh J, Jung S, et al
Protection against tuberculosis by vaccination of secreted chorismate mutase (Rv1885c) combined with a hepatitis B virus (HBV)-derived peptide, Poly6, and alum adjuvants.
Vaccine. 2025;47:126710.
PubMed Abstract available

SU Q, Qiu F, Gao Z, Zhao Y, et al
Long-term efficacy and anamnestic response of hepatitis B vaccine derived from Chinese hamster ovary cell after 18-20 years.
Vaccine. 2025;47:126655.
PubMed Abstract available

ZHANG S, Liu G, Wang C, Guo A, et al
Enhanced immunogenicity of a BoHV-1 gG-/tk- vaccine.
Vaccine. 2025;47:126704.
PubMed Abstract available

LI W, Li YA, Wang S, Shi H, et al
A universal live vaccine platform against multiple serotypes Streptococcus suis based on polyvalent antigen protein.
Vaccine. 2025;47:126700.
PubMed Abstract available

DE LA FUENTE J, Gortazar C, Contreras M, Kabi F, et al
Anti-tick vaccine in Uganda - from bench to field.
Vaccine. 2025 Jan 6:126695. doi: 10.1016/j.vaccine.2024.126695.
PubMed

EL SAHLY HM, Anderson EJ, Jackson LA, Neuzil KM, et al
Anti-neuraminidase and anti-hemagglutinin stalk responses to different influenza a(H7N9) vaccine regimens.
Vaccine. 2025;47:126689.
PubMed Abstract available

NAKANO T, Tanaka T
Looking back at the 27th Academic Conference of the Japanese Society for Vaccinology.
Vaccine. 2025;47:126697.
PubMed

DUAN Y, Suo L, Li X, Bai C, et al
Association between underlying conditions, multimorbidity, and COVID-19 vaccination status of adults aged >/=80 years old in Beijing, China.
Vaccine. 2025;47:126677.
PubMed Abstract available

ALVARADO-FACUNDO E, Herrup R, Wang W, Colombo RE, et al
Comparison of neuraminidase inhibiting antibody responses elicited by egg- and cell-derived influenza vaccines.
Vaccine. 2025;46:126669.
PubMed Abstract available

ANSELEM O, Charlier C, Viaud M, Lelong N, et al
Barriers to influenza vaccination during pregnancy in France: A national population-based study.
Vaccine. 2025;47:126671.
PubMed Abstract available

KAUL R, Leidner AJ, Chesson HW
Trends in costs of routinely recommended vaccines in the United States, 2001-2023.
Vaccine. 2025;47:126667.
PubMed Abstract available

POLAND GA, de la Fuente J
Quantum vaccinology: A new science and epistemological abstraction framework for developing new vaccines and understanding the generation of the immune response.
Vaccine. 2025;46:126641.
PubMed

GALETTI SC, Gadoth A, Halbrook M, Tobin NH, et al
Historic smallpox vaccination and Mpox cross-reactive immunity: Evidence from healthcare workers with childhood and adulthood exposures.
Vaccine. 2025;46:126661.
PubMed Abstract available

GIERSING B, Mo AX, Hwang A, Baqar S, et al
Meeting summary: Global vaccine and immunization research forum, 2023.
Vaccine. 2025;46:126686.
PubMed Abstract available

POSTON TB, Girardi J, Kim M, Zwarycz P, et al
Intranasal immunization with CPAF combined with ADU-S100 induces an effector CD4 T cell response and reduces bacterial burden following intravaginal infection with Chlamydia muridarum.
Vaccine. 2025;43.
PubMed Abstract available

LANG BALIJA M, Jagusic M, Forcic D, Ivancic-Jelecki J, et al
Mumps virus neurovirulence assessment-impact of viral doses, animal sex and age on results dispersion.
Vaccine. 2025;43.
PubMed Abstract available

CHAUDHARY M, Cutland CL, Bonet M, Gentile A, et al
Burden of Lassa fever disease in pregnant women and children and options for prevention.
Vaccine. 2025;43.
PubMed Abstract available

DERMENCHYAN A, Choi KR, Bokhoor PR, Cho DJ, et al
Receipt of respiratory vaccines among patients with heart failure in a multicenter health system registry.
Vaccine. 2025;46:126682.
PubMed Abstract available

FLORES-VALDEZ MA
Intravenous vaccination with BCG against tuberculosis: Strengths and questions deserving further research.
Vaccine. 2025 Jan 1:126666. doi: 10.1016/j.vaccine.2024.126666.
PubMed

December 2024

GURRY CE, Mwenda JM, Nardone A, Cohuet S, et al
Establishing the African region monitoring vaccine effectiveness (AFRO-MoVE) network for respiratory pathogens.
Vaccine. 2024 Dec 31:126616. doi: 10.1016/j.vaccine.2024.126616.
PubMed Abstract available

FERNANDEZ A, Askenazy F, Thummler S
Letter to the editor: SARS-CoV-2 vaccination in children and adolescents with neurodevelopmental or psychiatric disorders.
Vaccine. 2024 Dec 30:126679. doi: 10.1016/j.vaccine.2024.126679.
PubMed

HUSSEIN I, Valiverronen E, Nohynek H, Lamsa R, et al
What makes an expert in childhood vaccinations? Perceptions of parents in Finland.
Vaccine. 2024;46:126645.
PubMed Abstract available

PILAPITIYA D, Lee WS, Vu MN, Kelly A, et al
Mucosal vaccination against SARS-CoV-2 using recombinant influenza viruses delivering self-assembling nanoparticles.
Vaccine. 2024;46:126668.
PubMed Abstract available

CHOI YJ, Jung J, Kang M, Choi MJ, et al
Corrigendum to The risk of pregnancy-related adverse outcomes after COVID-19 vaccination: propensity score-matched analysis with influenza vaccination.
Vaccine. 2024;46:126676.
PubMed

ERBS G, Jakobsen JT, Schmidt ST, Christensen D, et al
Retinoic acid-adjuvanted vaccine induces antigen-specific secretory IgA in the gut of newborn piglets.
Vaccine. 2024;46:126672.
PubMed Abstract available

TANG E, Ray I, Arnold BF, Acharya NR, et al
Recombinant zoster vaccine and the risk of dementia.
Vaccine. 2024;46:126673.
PubMed Abstract available

NAZARENO AL, Wood JG, Muscatello DJ, Homaira N, et al
Estimating the cost-effectiveness of maternal respiratory syncytial virus (RSV) vaccination in Australia: A dynamic and economic modelling analysis.
Vaccine. 2024;46:126651.
PubMed Abstract available

MALTEZOU HC, Poland GA, de Lejarazu RO
Influenza vaccination for children in Europe: The health of every child matters.
Vaccine. 2024 Dec 27:126675. doi: 10.1016/j.vaccine.2024.126675.
PubMed

SAHA R, Lo M, De P, Deb AK, et al
Epidemiology of viral gastroenteritis in children and genetic diversity of rotavirus strains in Kolkata, West Bengal after introduction of rotavirus vaccine.
Vaccine. 2024;45:126637.
PubMed Abstract available

ZHANG J, Zhang L, Li J, Ma J, et al
Moderate effectiveness of influenza vaccine in outpatient settings: A test-negative study in Beijing, China, 2023/24 season.
Vaccine. 2024;46:126662.
PubMed Abstract available

MA Y, Dong C, Kim JK, Zhu W, et al
Impact of influenza immune imprinting on immune responses to subsequent vaccinations in mice.
Vaccine. 2024;46:126670.
PubMed Abstract available

CHO JY, Lee H, Wannaadisai W, Vietri J, et al
Systematic literature review of cost-effectiveness analyses of adult 15- and 20-valent pneumococcal vaccines.
Vaccine. 2024;46:126656.
PubMed Abstract available

AI L, Gao Z, Lv H, Zhang J, et al
Immunogenicity and safety of live attenuated influenza vaccine in children aged 3-17 years in China.
Vaccine. 2024;46:126653.
PubMed Abstract available

BEERENS D
Navigating the future of vaccination strategies: Insights from the 17(th) annual vaccine congress.
Vaccine. 2024;46:126634.
PubMed

ZHANG Y, Zhao K, Liu Y, Xu J, et al
An oral probiotic vaccine loaded by Lactobacillus casei effectively increases defense against GCRV infection in grass carp.
Vaccine. 2024;45:126660.
PubMed Abstract available

GRIMES DR
Tortured confessions? Potentially erroneous statistical inferences may underpin misleading claims of harms in reanalyses of COVID-19 and HPV vaccines.
Vaccine. 2024 Dec 25:126657. doi: 10.1016/j.vaccine.2024.126657.
PubMed Abstract available

SAVULESCU C, Prats-Uribe A, Brolin K, Uuskula A, et al
Relative effectiveness of the second booster COVID-19 vaccines against laboratory confirmed SARS-CoV-2 infection in healthcare workers: VEBIS HCW VE cohort study (1 October 2022-2 May 2023).
Vaccine. 2024;45:126615.
PubMed Abstract available

KILANY WH, Zain El-Abideen MA, Hisham I, Van Gaver D, et al
Laboratory safety and immunogenicity evaluation of live attenuated avian infectious bronchitis GI-23 virus vaccine.
Vaccine. 2024;45:126659.
PubMed Abstract available

PEREZ-SAUCEDO D, Castro-Perea NV, Ruiz-Cruz A, Bustos-Jaimes I, et al
Design and evaluation of a multi-epitope HIV-1 vaccine based on human parvovirus virus-like particles.
Vaccine. 2024;45:126663.
PubMed Abstract available

SHELDENKAR A, Ling TP, Schulz PJ, Chen MI, et al
Trust in government vaccine recommendations during the Covid-19 pandemic in Singapore: A longitudinal survey study.
Vaccine. 2024;45:126643.
PubMed Abstract available

BARAL R, Fleming JA, Barros I, Cofie P, et al
What will it take? Perspectives from five low- and middle-income countries on opportunities and challenges of introducing new maternal vaccines.
Vaccine. 2024;45:126654.
PubMed Abstract available

CAMPANELLA S, Volpe T, Safar Y, Lunsky Y, et al
"They need to speak a language everyone can understand": Accessibility of COVID-19 vaccine information for Canadian adults with intellectual and developmental disabilities.
Vaccine. 2024;45:126618.
PubMed Abstract available

WERTHNER Q, Faehrmann L, Och K, Bragazzi NL, et al
Client satisfaction, safety, and insights from a three-season survey on influenza vaccinations delivered at community pharmacies in Germany.
Vaccine. 2024;45:126650.
PubMed Abstract available

GOMEZ JA, Pannunzio ME, Karwala P, Nocita F, et al
Impact on meningococcal disease of different vaccination strategies with 4CMenB and MenACWY-CRM197 in infants and adolescents in Argentina.
Vaccine. 2024;45:126589.
PubMed Abstract available

TANAKA H, Takahashi Y, Matsumoto S, Matsuyama M, et al
Shorter incubation period in symptomatic measles patients who had no history of measles vaccination.
Vaccine. 2024;45:126652.
PubMed Abstract available

LIEBERMANN E, Kornides M, Matsunaga M, Lim E, et al
Corrigendum to "Use of social media and its influence on HPV vaccine hesitancy: US National Online Survey of mothers of adolescents, 2023".
Vaccine. 2024;45:126640.
PubMed

SERPA GONCALVES M, de Oliveira MM, Andrade RS, de Oliveira LF, et al
Systematic review on the effectiveness of Brucella abortus S19 and RB51 vaccine strains in field studies.
Vaccine. 2024;45:126649.
PubMed Abstract available

FRAIHA ALS, da Silva Santos BSA, Aguilar NR, Gallinari GC, et al
Immunization and challenge trials in a murine model using different inactivated recombinant vaccines against H1N1 swine influenza virus circulating in Brazil.
Vaccine. 2024;45:126638.
PubMed Abstract available

WANG J, Tonnies T, Brinks R
Seasonal influenza vaccination coverage and the social determinants of influenza vaccination among people over 50 with diabetes in Europe: Analyzing population-based SHARE data for the 2019-2020 and 2021-2022 influenza seasons.
Vaccine. 2024;45:126646.
PubMed Abstract available

KASSAM P, El-Zein M, Tota JE, Tellier PP, et al
HPV vaccination and anal HPV infection in gay, bisexual, and other men who have sex with men.
Vaccine. 2024;45:126644.
PubMed Abstract available

DE OLIVEIRA LA, de Morais IRB, Marchioro SB, de Almeida GB, et al
Corrigendum to Assessment of the Bnt162b2 covid-19 vaccine immune response in Brazilian indigenous adolescents. Vaccine Volume 43, Part 1, 1 January 2025, 126494.
Vaccine. 2024;45:126630.
PubMed

YANG J, Yao YL, Lv XY, Geng LH, et al
The Safety and Efficacy of inactivated COVID-19 vaccination in couples undergoing assisted reproductive technology: A prospective cohort study.
Vaccine. 2024;45:126635.
PubMed Abstract available

NUZHATH T, Yang Y, Couture MC, Gu NY, et al
Structural equation modeling to evaluate the adult vaccine hesitancy scale for vaccines recommended during pregnancy.
Vaccine. 2024;45:126568.
PubMed Abstract available

BIAN S, Cai Q, Wang S, Xie Y, et al
Evaluation of the toxoplasma Urm1 gene deletion mutant (PruDeltaUrm1) as a promising vaccine candidate against toxoplasmosis in mice.
Vaccine. 2024;45:126632.
PubMed Abstract available

SINGER R, Hubotter I, Holzner F, Genedl C, et al
School vaccination programmes to increase HPV vaccination coverage - Experiences from Bremen, Germany.
Vaccine. 2024;45:126636.
PubMed Abstract available

SUN JW, Dodge LE, Kim EJ, Zhou L, et al
Risk of adverse events after Omicron XBB-adapted BNT162b2 COVID-19 vaccination in the United States.
Vaccine. 2024;45:126629.
PubMed Abstract available

PERRIER Q, Noble J, Bonadona A, Augier C, et al
Timing of rejection events preceded by Covid-19 mRNA vaccination in recipients of solid organ transplants.
Vaccine. 2024;45:126617.
PubMed Abstract available

MOGHTADERI A, Callaghan T, Luo Q, Motta M, et al
Evidence on trends in uptake of childhood vaccines and association with COVID-19 vaccination rates.
Vaccine. 2024;45:126631.
PubMed Abstract available

WILLIAMS JTB, Ritger C, Holliman BD, Huebschmann AG, et al
Staff and caregivers' perceptions of digital storytelling to increase influenza vaccine confidence in an urban safety-net healthcare system.
Vaccine. 2024;45:126572.
PubMed Abstract available

LIMA JLC, da Silva AB, Cabral AS, de Miranda FM, et al
Changes in population genetic structure of serotype 19A Streptococcus pneumoniae after universal childhood use of the 10-valent pneumococcal conjugate vaccine in Brazil.
Vaccine. 2024;45:126588.
PubMed Abstract available

BAINBRIDGE S, Mappi T, Cleaveland S, Chubwa C, et al
Field vaccination of locally-owned cattle against malignant catarrhal fever under environmentally challenging conditions in Tanzania.
Vaccine. 2024;45:126587.
PubMed Abstract available

KARACHALIOU M, Espinosa A, Farre X, Blay N, et al
Mental illness and antibody responses after COVID-19 vaccination in a prospective population-based study in Catalonia.
Vaccine. 2024;45:126591.
PubMed Abstract available

SLAMANIG S, Lemus N, Lai TY, Singh G, et al
A single immunization with intranasal Newcastle disease virus (NDV)-based XBB.1.5 variant vaccine reduces disease and transmission in animals against matched-variant challenge.
Vaccine. 2024;45:126586.
PubMed Abstract available

ENDER E, Joshi A, Snyder M, Kumar S, et al
Seroconversion following PPSV23 vaccination in children with type 1 diabetes mellitus.
Vaccine. 2024;45:126592.
PubMed Abstract available

MASSEY PM, Murray RM, Kostizak K, Lo WJ, et al
Exploring the ethics of using fictional stories for health education on social media to share information and emotions about the HPV vaccine: A cross-sectional study with interdisciplinary health experts.
Vaccine. 2024 Dec 10:126575. doi: 10.1016/j.vaccine.2024.126575.
PubMed Abstract available

HOMSI MR, Davey-Rothwell MA, Alonge O, Caniza MA, et al
Knowledge, attitudes, and practices of healthcare providers regarding vaccinating children with cancer in Latin America and the Caribbean.
Vaccine. 2024;45:126578.
PubMed Abstract available

MASEMOLA NM, Burnett RJ, Makamba-Mutevedzi PC, Schonfeldt M, et al
Vaccine stock-outs: A preventable health facility obstacle contributing to missed vaccinations in South African children.
Vaccine. 2024;45:126583.
PubMed Abstract available

ESKENAZI B, Rauch S, Elsiwi B, Bornman R, et al
Undernutrition and antibody response to measles, tetanus and Haemophilus Influenzae type b (Hib) vaccination in pre-school south African children: The VHEMBE birth cohort study.
Vaccine. 2024 Dec 7:126564. doi: 10.1016/j.vaccine.2024.126564.
PubMed Abstract available

BODY A, Lal L, Srihari S, MacIntyre CR, et al
Comprehensive humoral and cellular immune responses to COVID-19 vaccination in adults with cancer.
Vaccine. 2024 Dec 7:126547. doi: 10.1016/j.vaccine.2024.126547.
PubMed Abstract available

CUNNINGHAM-ERVES J, Sanderson M, Jin SW, Davis J, et al
Predictors of HPV vaccination coverage among adolescents in Tennessee during the COVID-19 pandemic: A cross-sectional study.
Vaccine. 2024 Dec 7:126581. doi: 10.1016/j.vaccine.2024.126581.
PubMed Abstract available

XIA M, Huang P, Vago FS, Jiang W, et al
Pseudovirus nanoparticles targeting the receptor binding HA1 domains of influenza viruses elicited high HA1-specific antibody responses and protected mice against mortality caused by influenza virus challenges.
Vaccine. 2024 Dec 7:126585. doi: 10.1016/j.vaccine.2024.126585.
PubMed Abstract available

SANKAR C, Meyer JC, Schonfeldt M, Gunter H, et al
Vaccine safety surveillance in South Africa through COVID-19: A journey to systems strengthening.
Vaccine. 2024 Dec 6:126535. doi: 10.1016/j.vaccine.2024.126535.
PubMed Abstract available

KAPLAN BS, Souza CK, Kimble JB, Brand MW, et al
A neuraminidase-based inactivated influenza virus vaccine significantly reduced virus replication and pathology following homologous challenge in swine.
Vaccine. 2024 Dec 6:126574. doi: 10.1016/j.vaccine.2024.126574.
PubMed Abstract available

LIEBERMANN E, Kornides M, Matsunaga M, Lim E, et al
Use of social media and its influence on HPV vaccine hesitancy: US National Online Survey of mothers of adolescents, 2023.
Vaccine. 2024 Dec 5:126571. doi: 10.1016/j.vaccine.2024.126571.
PubMed Abstract available

HODGSON D, Sanchez-Ovando S, Carolan L, Liu Y, et al
Quantifying the impact of pre-vaccination titre and vaccination history on influenza vaccine immunogenicity.
Vaccine. 2024 Dec 4:126579. doi: 10.1016/j.vaccine.2024.126579.
PubMed Abstract available

HSIAO A, Lewis N, Hansen J, Timbol J, et al
Effectiveness of 13-valent pneumococcal conjugate vaccine against vaccine-type invasive pneumococcal disease in older adults.
Vaccine. 2024;44:126543.
PubMed Abstract available

MATTHEWS RL, Khan N, Beckman B, Sharma S, et al
Immune profile diversity is achieved with synthetic TLR4 agonists combined with the RG1-VLP vaccine in mice.
Vaccine. 2024 Dec 3:126577. doi: 10.1016/j.vaccine.2024.126577.
PubMed Abstract available

MOUSTAFA DA, Lou E, Schafer-Kestenman ME, Mateu-Borras M, et al
Pseudomonas aeruginosa elongation factor-Tu (EF-Tu) is an immunogenic protective protein antigen.
Vaccine. 2024;42:126476.
PubMed Abstract available

TANG A, Zhu M, Zhu J, Zhang D, et al
The recombinant feline herpesvirus 1 expressing feline Calicivirus VP1 protein is safe and effective in cats.
Vaccine. 2024;42:126468.
PubMed Abstract available

TONG K, Hernandez EM, Basore K, Fremont DH, et al
Chikungunya virus E2 B domain nanoparticle immunogen elicits homotypic neutralizing antibody in mice.
Vaccine. 2024;42:126405.
PubMed Abstract available

WU R, Chen Z, Yang X, Chen Y, et al
Investigating the characteristics of mumps outbreaks in Fujian Province, China.
Vaccine. 2024;42:126415.
PubMed Abstract available

FOTAKIS EA, Picasso E, Sacco C, Petrone D, et al
Impact of the 2023/24 autumn-winter COVID-19 seasonal booster campaign in preventing severe COVID-19 cases in Italy (October 2023-March 2024).
Vaccine. 2024;42:126375.
PubMed Abstract available

PRY JM, McCullough K, Lai KW, Lim E, et al
Defining long COVID using a population-based SARS-CoV-2 survey in California.
Vaccine. 2024;42:126358.
PubMed Abstract available

CHUN J, Yoon D, Nowakowska A, Lee HD, et al
Delivery of SARS-CoV-2 spike and membrane genes in a single Baculoviral vector enhance the immune breadth against SARS-CoV-2 variants of concern.
Vaccine. 2024;42:126355.
PubMed Abstract available

CANETTI M, Barda N, Lustig Y, Weiss-Ottolenghi Y, et al
Risk factors and correlates of protection against XBB SARS-CoV-2 infection among health care workers.
Vaccine. 2024;42:126308.
PubMed Abstract available

November 2024

PICHE-RENAUD PP, Drover SSM, Austin PC, Morris SK, et al
COVID-19 vaccine effectiveness against severe omicron-related outcomes in children aged 5 to 11 years in Ontario: A Canadian immunization research network (CIRN) study.
Vaccine. 2024 Nov 30:126539. doi: 10.1016/j.vaccine.2024.126539.
PubMed Abstract available

GONG S, Beukema M, De Vries-Idema J, Huckriede A, et al
Assessing human B cell responses to influenza virus vaccines and adjuvants in a PBMC-derived in vitro culture system.
Vaccine. 2024;44:126563.
PubMed Abstract available

ANABE D, Terasjarvi JT, Barkoff AM, Knuutila A, et al
Association of baseline cytokines with antibody concentrations after diphtheria-tetanus-acellular pertussis booster vaccination in Finnish children.
Vaccine. 2024 Nov 30:126573. doi: 10.1016/j.vaccine.2024.126573.
PubMed Abstract available

GRIGAS J, Spancerniene U, Simanavicius M, Pautienius A, et al
Adaptive immune response to a wild boar-derived recombinant hepatitis e virus capsid protein challenge in pigs.
Vaccine. 2024 Nov 30:126561. doi: 10.1016/j.vaccine.2024.126561.
PubMed Abstract available

COSMA C, Radi A, Cattano R, Zanobini P, et al
Exploring Chatbot contributions to enhancing vaccine literacy and uptake: A scoping review of the literature.
Vaccine. 2024;44:126559.
PubMed Abstract available

NYIKA P, Yankey D, Elam-Evans LD, Meyer S, et al
Human papillomavirus vaccination coverage among adolescent boys and girls in the United States: A birth year cohort analysis of the National Immunization Survey-Teen, 2016-2022.
Vaccine. 2024;44:126560.
PubMed Abstract available

FLORES D, Luna EM
The effectiveness of vaccines against COVID-19 in Mexico: A time series approach.
Vaccine. 2024;44:126565.
PubMed Abstract available

BHAT N, Vodicka E, Clifford A, Ananth KB, et al
The evidence base for rotavirus vaccination in India: Current status, future needs.
Vaccine. 2024;44:126551.
PubMed Abstract available

THIEM VD, Anh DD, Ha VH, Van Thom N, et al
Safety and immunogenicity of an inactivated recombinant Newcastle disease virus vaccine expressing SARS-CoV-2 spike: A randomised, comparator-controlled, phase 2 trial.
Vaccine. 2024;44:126542.
PubMed Abstract available

WANG Q, Yang L, Li L, Xiu S, et al
Investigating parental perceptions of respiratory syncytial virus (RSV) and attitudes to RSV vaccine in Jiangsu, China: Insights from a cross-section study.
Vaccine. 2024;44:126570.
PubMed Abstract available

EDELSTEIN M, Shibli H, Bornstein J
Differences in knowledge, attitudes and intentions towards HPV vaccination among young adults from diverse socio-cultural groups in Israel: A cross-sectional study.
Vaccine. 2024;44:126548.
PubMed Abstract available

BORYS D, Smulders R, Haranaka M, Nakano T, et al
Safety, reactogenicity, and immunogenicity of a novel 24-valent pneumococcal vaccine candidate in healthy, pneumococcal vaccine-naive Japanese adults: A phase 1 randomized dose-escalation trial.
Vaccine. 2024;44:126545.
PubMed Abstract available

LINK EK, Tscherne A, Sutter G, Smith ER, et al
A Brighton collaboration standardized template with key considerations for a benefit/risk assessment for a viral vector vaccine based on a non-replicating modified vaccinia virus Ankara viral vector.
Vaccine. 2024;43.
PubMed Abstract available

PITTS PJ, Poland GA
Addressing vaccine misinformation: The critical need for complete product information disclosure.
Vaccine. 2024;44:126558.
PubMed

KASAIJA PD, Kabi F, Semakula J, Kyakuwa I, et al
One-year follow-up evaluation of approved Subolesin anti-tick vaccine in Uganda.
Vaccine. 2024;44:126562.
PubMed Abstract available

GEMANDER N, Kemlin D, Depickere S, Kelkar NS, et al
COVID-19 vaccine responses are influenced by distinct risk factors in naive and SARS-CoV-2 experienced hemodialysis recipients.
Vaccine. 2024;44:126544.
PubMed Abstract available

BLUKACZ A, Obach A, Vasquez P, Campana C, et al
Determinants of COVID-19 and non-COVID-19 vaccine confidence in low- and middle-income countries: A systematic review of qualitative evidence and thematic synthesis.
Vaccine. 2024;44:126546.
PubMed Abstract available

AMODIO D, Angelidou A, Cotugno N, Sherman AC, et al
Biomarkers of vaccine safety and efficacy in vulnerable populations: Lessons from the fourth international precision vaccines conference.
Vaccine. 2024;43.
PubMed Abstract available

CHOI YJ, Jung J, Kang M, Choi MJ, et al
The risk of pregnancy-related adverse outcomes after COVID-19 vaccination: Propensity score-matched analysis with influenza vaccination.
Vaccine. 2024;44:126506.
PubMed Abstract available

DEAN NE, Halloran ME, Zarnitsyna VI
Poor vaccine responders mask the true trend in vaccine effectiveness against progression to severe disease.
Vaccine. 2024;43.
PubMed Abstract available

CASTILLO-ZUNINO F, Hester KA, Keskinocak P, Nazzal D, et al
Associations between family planning, healthcare access, and female education and vaccination among under-immunized children.
Vaccine. 2024;44:126540.
PubMed Abstract available

GLESER D, Cohen M, Kenigswald G, Kedmi M, et al
Optimizing protocols for the 919 strain-based bovine ephemeral fever virus vaccine (Ultravac(R), Zoetis): Evaluation of dose-dependent effectiveness and long-term immunity.
Vaccine. 2024;43.
PubMed Abstract available

REED NS, Brewer CC, Akintunde G, Blackie FF, et al
Report of a SPEAC webinar 22 september 2023: Sensorineural hearing loss, lassa virus disease and vaccines.
Vaccine. 2024;43.
PubMed Abstract available

TSAI Y, Leung J, Anderson TC, Zhou F, et al
Herpes zoster vaccination among Medicare beneficiaries with and without prescription drug coverage.
Vaccine. 2024;43.
PubMed Abstract available

LEE M, Qin C, Lee Y, Deng J, et al
COVID-19 vaccine acceptance and 5C psychological antecedents amid the omicron surge in South Korea and China.
Vaccine. 2024;43.
PubMed Abstract available

WANTUCH PL, Knoot CJ, Marino EC, Harding CM, et al
Klebsiella pneumoniae bioconjugate vaccine functional durability in mice.
Vaccine. 2024;43.
PubMed Abstract available

DE OLIVEIRA LA, de Morais IRB, Marchioro SB, de Almeida GB, et al
Assessment of the BNT162B2 COVID-19 vaccine immune response in Brazilian indigenous adolescents.
Vaccine. 2024;43.
PubMed Abstract available

COULTER FJ, Messer WB
Breakthroughs and insights: A comprehensive review of yellow fever vaccine breakthrough infection across 8 decades.
Vaccine. 2024;43.
PubMed Abstract available

SUFFEL AM, Carreira H, Walker J, Grint D, et al
The association of maternal mental health with vaccination coverage and timeliness in early childhood - A historical cohort study in England using electronic health records.
Vaccine. 2024;43.
PubMed Abstract available

HUNG CT, Wang LM, Hung YC
Trends and characteristics of herpes zoster vaccination among older adults with asthma in the United States, 2008-2023: Findings from self-reported national surveys.
Vaccine. 2024;43.
PubMed Abstract available

MEELDIJK A, Vandeberg L, Akkermans R, Hautvast J, et al
How text message reminders increase COVID-19 booster vaccine uptake: Two randomized controlled trials.
Vaccine. 2024;43.
PubMed Abstract available

MAO J, Kang HJ, Eom GD, Yoon KW, et al
Vaccine efficacy induced by 2020-2021 seasonal influenza-derived H3N1 virus-like particles co-expressing M2e5x or N2.
Vaccine. 2024;43.
PubMed Abstract available

MARSZALEK M, Hawking MKD, Gutierrez A, Firman N, et al
Improving the timeliness and equity of preschool childhood vaccinations: Mixed methods evaluation of a quality improvement programme in primary care.
Vaccine. 2024;43.
PubMed Abstract available

VASQUEZ WF, Trudeau JM
Americans' willingness to give to global immunization programs: Political heterogeneity in preferences for program management and response to priming communications.
Vaccine. 2024;42:126126.
PubMed Abstract available

KIRK B, Bush C, Toyip A, Mues KE, et al
Real-world comparative effectiveness of a third dose of mRNA-1273 versus BNT162b2 among adults aged >/= 65 years in the United States.
Vaccine. 2024;42:126113.
PubMed Abstract available

BONNIN FA, Talarico LB, Ferolla FM, Acosta PL, et al
Antibody levels against respiratory syncytial virus fusion protein conformations and lack of association with life-threatening infection in previously healthy infants.
Vaccine. 2024;42:126119.
PubMed Abstract available

TOMATIS C, Ferrer MF, Aquila S, Thomas PD, et al
Baculovirus surface display of a chimeric E-NS1 protein of YFV protects against YFV infection.
Vaccine. 2024;42:126045.
PubMed Abstract available

LEE YS, Cheong MS, Lee J, Bang EK, et al
Immunogenicity and protection of a triple repeat domain III mRNA vaccine against Zika virus.
Vaccine. 2024;43.
PubMed Abstract available

PARK JY, Senevirathne A, Lee JH
Development of a candidate vaccine against severe fever with thrombocytopenia syndrome virus using Gn/Gc glycoprotein via multiple expression vectors delivered by attenuated Salmonella confers effective protection in hDC-SIGN transduced mice.
Vaccine. 2024;43.
PubMed Abstract available

FURUICHI M, Ohnishi T, Yaginuma M, Yamada Y, et al
Live-attenuated vaccine failure after liver transplantation: A 20-year cohort study.
Vaccine. 2024;43.
PubMed Abstract available

KIM SS, Garcia Quesada M, Prasad PV, Nelson KN, et al
Challenges of using the test-negative design to measure vaccine effectiveness of multi-pathogen combination vaccines targeting one syndrome.
Vaccine. 2024 Nov 12:126520. doi: 10.1016/j.vaccine.2024.126520.
PubMed

BERTHOUD TK, Ahmed T, Nadia W, Petrov I, et al
A three antigen hepatitis B vaccine induces T cells to Pres1 and Pres2 which correlate with anti HBs antibody titers: An investigation into the immunological mechanisms contributing to high anti-HBs titers.
Vaccine. 2024;43.
PubMed Abstract available

LAMBACH P, Silal S, Sbarra AN, Koh M, et al
Report from the World Health Organization's immunization and vaccines-related implementation research advisory committee (IVIR-AC) meeting, virtual gathering, 10-13 September 2024.
Vaccine. 2024;43.
PubMed Abstract available

LOCKMAN A, Callaghan T, Blackburn CC, Colwell B, et al
Vaccine spillover effects in Africa: A cross-national study of vaccine spillover and confidence in Kenya, Nigeria, and South Africa.
Vaccine. 2024;43.
PubMed Abstract available

JASTORFF A, Gymnopoulou E, Salas J, Merrall E, et al
Safety and immunogenicity of the Ad26/protein preF RSV vaccine in adults aged 18 to 59 years with and without at-risk comorbidities for severe respiratory syncytial virus disease: A phase 3, randomized, controlled, immunobridging trial.
Vaccine. 2024;43.
PubMed Abstract available

WIJDICKS EFM
Fatal ascending paralysis after typhoid vaccine: Guillain and Barre's description of the very first case.
Vaccine. 2024;42:126443.
PubMed Abstract available

CHOE S, Park GN, Kim KS, Shin J, et al
Immunogenicity of a classical swine fever bait vaccine (Flc-LOM- BE(rns)) in hybrid-wild boars.
Vaccine. 2024;43.
PubMed Abstract available

REGAN AK, Couture MC, Callaghan T, Agnew B, et al
Modification and validation of a vaccine hesitancy scale for adolescent COVID-19 vaccination.
Vaccine. 2024;43.
PubMed Abstract available

LOPEZ-MACIAS C, Torres M, Armenta-Copca B, Wacher NH, et al
Phase II study on the safety and immunogenicity of single-dose intramuscular or intranasal administration of the AVX/COVID-12 "Patria" recombinant Newcastle disease virus vaccine as a heterologous booster against COVID-19 in Mexico.
Vaccine. 2024;43.
PubMed Abstract available

PERALTA ALVAREZ MP, Downward K, White A, Harris SA, et al
Intravenous BCG vaccination in non-human primates induces superior serum antibody titers with enhanced avidity and opsonizing capacity compared to the intradermal route.
Vaccine. 2024;42:126444.
PubMed Abstract available

GWAK E, Choe SA, Bolormaa E, Choe YJ, et al
Relative effectiveness of homologous NVX-CoV2373 and BNT162b2 COVID-19 vaccinations in South Korea.
Vaccine. 2024;43.
PubMed Abstract available

GOKTUNA PT, Cokcaliskan C
Concurrent use of the foot-and-mouth disease and other vaccines in livestock.
Vaccine. 2024;43.
PubMed Abstract available

DE LUCA C, Hess M
Vaccination strategies to protect chickens from fowl adenovirus (FAdV)-induced diseases: A comprehensive review.
Vaccine. 2024;43.
PubMed Abstract available

DILANGE L, El Belghiti FA, Demiguel V, Anselem O, et al
Pertussis vaccination coverage in women at two months postpartum and associated factors in France, National Perinatal Survey 2021.
Vaccine. 2024;43.
PubMed Abstract available

PETERSON J, Drazan D, Moughan B, Maguire JD, et al
Randomized trial showing persistence of hSBA titers elicited by a pentavalent meningococcal MenABCWY vaccine for up to 4 years following a primary series and safety and immunogenicity of a booster dose.
Vaccine. 2024;43.
PubMed Abstract available

MATTES F, Dratva J, Schmelzer S, Wagner A, et al
The association between service experience in vaccination centers and expectation confirmation as a driver of future vaccination intentions: Results from a survey among users of a Swiss mass COVID-19 vaccination center.
Vaccine. 2024;43.
PubMed Abstract available

AGUIRRE-CAMACHO A, Hidalgo B, Rash JA
Exposure to objective/sensationalist information moderates associations between psychological factors and COVID-19 anti-vaccination attitudes: An experimental study.
Vaccine. 2024;43.
PubMed Abstract available

ANGULO M, Angulo C
Trained immunity-based vaccines: A vision from the one health initiative.
Vaccine. 2024;43.
PubMed Abstract available

WILLIAMS E, Echeverri Tribin F, Carreno JM, Krammer F, et al
Proteomic signatures of vaccine-induced and breakthrough infection-induced host responses to SARS-CoV-2.
Vaccine. 2024;43.
PubMed Abstract available

LEWIS NM, Harker EJ, Leis A, Zhu Y, et al
Assessment and mitigation of bias in influenza and COVID-19 vaccine effectiveness analyses - IVY Network, September 1, 2022-March 30, 2023.
Vaccine. 2024;43.
PubMed Abstract available

DENG Y, Hayes KN, Zhao Y, Chachlani P, et al
Variation in the time to complete the primary COVID-19 vaccine series by race, ethnicity, and geography among older US adults.
Vaccine. 2024;43.
PubMed Abstract available

STEFFENS MS, Bolsewicz KT, King C, Bullivant B, et al
Australian parents' experiences with adolescent age-based vaccinations during the COVID-19 pandemic.
Vaccine. 2024;43.
PubMed Abstract available

LE MARCHAND C, Singson JRC, Clark A, Shah D, et al
Multisystem inflammatory syndrome in children (MIS-C) cases by vaccination status in California.
Vaccine. 2024;43.
PubMed Abstract available

KERFUA SD, Haydon DT, Wilsden G, Ludi A, et al
Corrigendum to "Evaluation of commercial quadrivalent foot-and-mouth disease vaccines against east African virus strains reveals limited immunogenicity and duration of protection" [Vaccine 42 (1-12) (2024) 126325].
Vaccine. 2024;43.
PubMed

DELARUELLE K, Lermytte E, Bockstal M, Vuolanto P, et al
Unraveling COVID-19 vaccine hesitancy in Europeans 50 and older through a lens of preventive practices.
Vaccine. 2024;43.
PubMed Abstract available

KIM SA, Maeda M, Murata F, Fukuda H, et al
Effect of COVID-19 vaccination on the risk of developing post-COVID conditions: The VENUS study.
Vaccine. 2024;43.
PubMed Abstract available

THOBARI JA, Watts E, Carvalho N, Haposan JH, et al
Cost effectiveness analysis of rotavirus vaccination in Indonesia.
Vaccine. 2024;43.
PubMed Abstract available

CHARLAND K, Quach C, Papenburg J, Pierce L, et al
Parental decisions regarding the vaccination of children and adolescents against SARS-CoV-2 from 2020 to 2023: A descriptive longitudinal study of parents and children in Montreal, Canada.
Vaccine. 2024;43.
PubMed Abstract available

WARIRI O, Utazi CE, Okomo U, Dotse-Gborgbortsi W, et al
Multi-level determinants of timely routine childhood vaccinations in The Gambia: Findings from a nationwide analysis.
Vaccine. 2024;43.
PubMed Abstract available

October 2024

ZACHARIA MM, Ziema SA, Abanga WA, Kyeremeh RA, et al
RTS, S malaria vaccination among children aged 24-59 months in the Sunyani Municipality, Ghana; 2023.
Vaccine. 2024;42:126490.
PubMed Abstract available

KASAMATSU A, Yahata Y, Fukushima W, Sakamoto H, et al
Estimating influenza vaccine effectiveness among older adults using an integrated administrative database and the implications of potential bias: A population-based cohort study in Japan.
Vaccine. 2024;42:126488.
PubMed Abstract available

HOFSTETTER AM, Klein EJ, Strelitz B, Selvarangan R, et al
On-time childhood vaccination before and during the COVID-19 pandemic in seven communities: Findings from the New Vaccine Surveillance Network.
Vaccine. 2024;42:126455.
PubMed Abstract available

MOSCHESE V, Graziani S, Spadea A, D'Amore M, et al
Vaccinations in children of non-European origin: The Vax4globe survey.
Vaccine. 2024;42:126466.
PubMed Abstract available

SANCHEZ-MARTINEZ ZV, Alpuche-Lazcano SP, Stuible M, Akache B, et al
SARS-CoV-2 spike-based virus-like particles incorporate influenza H1/N1 antigens and induce dual immunity in mice.
Vaccine. 2024;42:126463.
PubMed Abstract available

MACINTYRE CR, Akhtar Z, Moa A
Corrigendum to "Influenza B/Yamagata - extinct, eradicated or hiding? [Vaccine 42/26 (2024) 126450]".
Vaccine. 2024 Oct 29:126486. doi: 10.1016/j.vaccine.2024.126486.
PubMed

WHITE TM, Lazarus JV, Rabin KH, Ratzan SC, et al
Emerging global patterns of COVID-19 vaccine information fatigue in 23 countries in 2023.
Vaccine. 2024;42:126475.
PubMed Abstract available

LEIS AM, Wagner A, Flannery B, Chung JR, et al
Evaluation of test-negative design estimates of influenza vaccine effectiveness in the context of multiple, co-circulating, vaccine preventable respiratory viruses.
Vaccine. 2024;42:126493.
PubMed Abstract available

EBERHARDT J, Al-Qerem W, Ling J
Comparing COVID-19 booster vaccine acceptance in the United Kingdom, Germany, Austria, and Jordan: The role of protection motivation theory, conspiracy beliefs, social media use and religiosity.
Vaccine. 2024;42:126474.
PubMed Abstract available

GAM PH, Dung NM, Aziz JMA, Makram AM, et al
Vaccine for hand, foot, and mouth disease (HFMD): A call to action.
Vaccine. 2024 Oct 27:126491. doi: 10.1016/j.vaccine.2024.126491.
PubMed

MAURE C, Khazhidinov K, Kang H, Auzenbergs M, et al
Chikungunya vaccine development, challenges, and pathway toward public health impact.
Vaccine. 2024;42:126483.
PubMed Abstract available

MCGREGOR R, Paterson A, Lavender B, Hooker C, et al
The SARS-CoV-2 neutralising antibody profile of New Zealand adults in 2023: Impact of vaccination and infection.
Vaccine. 2024;42:126482.
PubMed Abstract available

VIELOT NA, Ballard CAP, St Jean DT, Page S, et al
Documenting human papillomavirus vaccine refusal among adolescents in electronic health records: A mixed methods study.
Vaccine. 2024;42:126467.
PubMed Abstract available

LENTAKIS E, Seale H, Lazarus R, Mounier-Jack S, et al
Exploring the delivery of adult vaccination outside of primary care settings: A mixed methods scoping review.
Vaccine. 2024;42:126458.
PubMed Abstract available

HO TC, Chuang SC, Hung KC, Chang CC, et al
Exploring risk factors for Raynaud's phenomenon post COVID-19 vaccination.
Vaccine. 2024;42:126470.
PubMed Abstract available

LENTAKIS E, Seale H, Lazarus R, Mounier-Jack S, et al
Exploring the attitudes and practices of adult service users and providers towards vaccination in non-primary care settings: A mixed methods scoping review.
Vaccine. 2024;42:126472.
PubMed Abstract available

MOHD HISHAM AA, Mat Yassim AS, Suppian R, Azlan M, et al
Comparable and sustained levels of S1-RBD-IgG and S1-RBD-IgA in BNT162b2 homologous and CoronaVac-BNT162b2 heterologous booster vaccination: A 22-month prospective study in Malaysia.
Vaccine. 2024;42:126471.
PubMed Abstract available

JORDAN E, Jenkins V, Silbernagl G, Chavez MPV, et al
A multivalent RSV vaccine based on the modified vaccinia Ankara vector shows moderate protection against disease caused by RSV in older adults in a phase 3 clinical study.
Vaccine. 2024;42:126427.
PubMed Abstract available

VALENCIA-HERNANDEZ AM, Zhao G, Miranda-Hernandez S, Segura-Cerda CA, et al
A second-generation recombinant BCG strain combines protection against murine tuberculosis with an enhanced safety profile in immunocompromised hosts.
Vaccine. 2024;42:126291.
PubMed Abstract available

ROWE M, Collier AY, Barouch DH
Insights from an observational translational research program during the COVID-19 pandemic: Four years of experience.
Vaccine. 2024;42:126306.
PubMed Abstract available

PHAM-HUY A, Bowes J, Russell K, Amira A, et al
Short- and long-term outcomes of cardiac adverse events following COVID-19 immunization managed in a Canadian pediatric center.
Vaccine. 2024;42:126090.
PubMed Abstract available

KILIC G, Debisarun PA, Alaswad A, Baltissen MP, et al
Seasonal variation in BCG-induced trained immunity.
Vaccine. 2024;42:126109.
PubMed Abstract available

SHANMUGASUNDARAM D, Viswanathan R, Winter AK, Agarwal A, et al
Rubella immunity among pregnant women and the burden of congenital rubella syndrome (CRS) in India, 2022.
Vaccine. 2024;42:126077.
PubMed Abstract available

SINTAYEHU K, Shaum A, Bonger ZT, Dagnachew Zeleke E, et al
Applicability of selected Brighton Collaboration case definitions in low-resource settings: A prospective hospital-based active surveillance in Addis Ababa, Ethiopia.
Vaccine. 2024;42:126079.
PubMed Abstract available

GOLDIN S, Moen A, Moss WJ, Nuzzo J, et al
The 2020 immunization programme landscape: Piloting an assessment metric to evaluate the maturity of national immunization programmes across the life course.
Vaccine. 2024;42 Suppl 4:125541.
PubMed Abstract available

NG AJJ, Teo DCH, Dorajoo SR, Yap AJY, et al
Acute autoimmune hepatitis following COVID-19 mRNA vaccination: A population-based study using electronic health records in Singapore.
Vaccine. 2024;42:126462.
PubMed Abstract available

ESSALIM S, Tachet C, Demingo S, Bruel S, et al
Vaccination during febrile illness, what do we know? A systematic-narrative hybrid review of the literature and international recommendations.
Vaccine. 2024;42:126473.
PubMed Abstract available

DARKO DM, Seaneke SK, Karikari-Boateng E, Nkansah E, et al
Safety of mRNA COVID-19 vaccines among persons 15- years and above in Ghana: A cohort event monitoring study.
Vaccine. 2024;42:126460.
PubMed Abstract available

AB RAHMAN N, King TL, Peariasamy KM, Sivasampu S, et al
Risk of major adverse cerebro-cardiovascular events following BNT162b2, CoronaVac, and ChAdOx1 vaccination and SARS-CoV-2 infection: A self-controlled case-series study.
Vaccine. 2024;42:126465.
PubMed Abstract available

SHARFF KA, Tandy TK, Lewis PF, Johnson ES, et al
Incidence of ischemic stroke after COVID-19 bivalent booster vaccination in an integrated health system.
Vaccine. 2024;42:126440.
PubMed Abstract available

BREWER SE, Cataldi JR, Perreira C, Nederveld A, et al
"But then that's another barrier": A qualitative study of parent and provider perspectives on rural versus urban disparities in adolescent vaccination.
Vaccine. 2024;42:126456.
PubMed Abstract available

WICKLINE MM, Carpenter PA, Harris JR, Iribarren SJ, et al
Vaccine hesitancy and routine revaccination among adult HCT survivors in the United States: A convergent mixed methods analysis.
Vaccine. 2024;42:126374.
PubMed Abstract available

PAPAILIOU S, Soldatou A, Marmarinos A, Avgeris M, et al
Seroprevalence of diphtheria, tetanus and pertussis antibodies and Tdap vaccination in pregnant women in Greece - A cross- sectional study.
Vaccine. 2024;42:126435.
PubMed Abstract available

HARRACHE A, Saker K, Mokdad B, Generenaz L, et al
Anti-RBD IgG dynamics following infection or vaccination.
Vaccine. 2024;42:126464.
PubMed Abstract available

SMOK-KALWAT J, Gozdz S, Macek P, Wasinski P, et al
FTIR monitoring of the 13-valent pneumococcal conjugate vaccine for lung cancer patients: Changes in amides vibrations correlated with biochemical assays.
Vaccine. 2024;42:126459.
PubMed Abstract available

AREFAINE M, Johannessen A, Teklehaymanot T, Mihret A, et al
A prospective, multicenter study of hepatitis B birth-dose vaccine with or without hepatitis B immunoglobulin in preventing mother-to-child transmission of hepatitis B virus in Ethiopia.
Vaccine. 2024;42:126461.
PubMed Abstract available

MA SH, Chen TL, Ou WF, Chao WC, et al
The risk of postherpetic neuralgia in COVID-19 vaccination-associated herpes zoster: A retrospective cohort study using TriNetX.
Vaccine. 2024;42:126451.
PubMed Abstract available

EVIATAR T, Ziv A, Oved A, Miller-Barmak A, et al
Longitudinal safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine in children aged 4-11 years with juvenile-onset autoimmune inflammatory rheumatic diseases: A prospective multicenter study.
Vaccine. 2024;42:126426.
PubMed Abstract available

ESHRAGHISAMANI R, Facciuolo A, De Buck J
Oral paratuberculosis vaccine efficacy and mucosal immunity in cattle.
Vaccine. 2024;42:126447.
PubMed Abstract available

NAZARENO AL, Newall AT, Muscatello DJ, Hogan AB, et al
Modelling the epidemiological impact of maternal respiratory syncytial virus (RSV) vaccination in Australia.
Vaccine. 2024;42:126418.
PubMed Abstract available

BERENDSEN MLT, Bles P, de Bree LCJ, Jensen KJ, et al
Bacillus Calmette-Guerin vaccination induces a trained innate immunity phenotype in adults over 50 years of age: A randomized trial in Guinea-Bissau.
Vaccine. 2024;42:126439.
PubMed Abstract available

DUBE E, Gagnon D, Pelletier C, Comeau JL, et al
Enhancing HPV vaccine uptake in girls and boys - A qualitative analysis of Canadian school-based vaccination programs.
Vaccine. 2024;42:126425.
PubMed Abstract available

TRAVILL DI, Machalek DA, Rees H, Mbulawa Z, et al
High prevalence of human papillomavirus (HPV) in unvaccinated adolescent girls in South Africa, particularly those living with HIV.
Vaccine. 2024;42:126442.
PubMed Abstract available

TYAGI A, Bajaj SS, Nayeu EN, Stanford FC, et al
No person left behind: Understanding vaccine hesitancy in low- and middle-income countries.
Vaccine. 2024 Oct 16:126446. doi: 10.1016/j.vaccine.2024.126446.
PubMed

SANO K, Kurosawa T, Horikawa K, Kimura Y, et al
Cellular and humoral immunity and IgG subclass distribution after omicron XBB.1.5 monovalent vaccination in Japan.
Vaccine. 2024;42:126452.
PubMed Abstract available

NUZHATH T, Colwell B, Callaghan T, Hotez P, et al
Pediatric COVID-19 vaccine hesitancy among pregnant and post-partum women: A mixed-method study.
Vaccine. 2024;42:126420.
PubMed Abstract available

LI J, Li X, Liu F, Jiang S, et al
Development and characterization of HCMV recombinant subunit vaccines based on T-cell epitopes.
Vaccine. 2024;42:126454.
PubMed Abstract available

EIDEN AL, Drakeley S, Modi K, Mackie D, et al
Attitudes and beliefs of healthcare providers toward vaccination in the United States: A cross-sectional online survey.
Vaccine. 2024;42:126437.
PubMed Abstract available

PHADKE VK, Gromer DJ, Rebolledo PA, Graciaa DS, et al
Safety and immunogenicity of a ChAd155-vectored rabies vaccine compared with inactivated, purified chick embryo cell rabies vaccine in healthy adults.
Vaccine. 2024;42:126441.
PubMed Abstract available

COCKERILL R, Horney JA, Penta SC, Silver A, et al
Factors associated with COVID-19 vaccination or intent to be vaccinated across three U.S. states.
Vaccine. 2024;42:126457.
PubMed Abstract available

TOP KA, Shulha HP, Muller MP, Valiquette L, et al
Participant-reported neurological events following immunization in the Canadian National Vaccine Safety Network-COVID-19 vaccine (CANVAS-COVID) study.
Vaccine. 2024;42:126445.
PubMed Abstract available

HSIEH HC, Chen CC, Liu WC, Wu SC, et al
Intranasal booster with SARS-CoV-2 RBD protein fused to E. coli enterotoxin a subunit after primary mRNA vaccination in mice.
Vaccine. 2024;42:126448.
PubMed Abstract available

TASKIN T, Roncancio AM, Cano MA, Valente M, et al
Cancer fatalism is associated with HPV vaccine uptake among Hispanic emerging adult women in the US.
Vaccine. 2024;42:126417.
PubMed Abstract available

MASON LMK, Betancur E, Riera-Montes M, Lienert F, et al
MVA-BN vaccine effectiveness: A systematic review of real-world evidence in outbreak settings.
Vaccine. 2024;42:126409.
PubMed Abstract available

SEDAGHAT M, Karami B, Najafi F, Shadmani FK, et al
Gender differences in adverse effects following the second dose of AstraZeneca COVID-19 vaccine: a cross-sectional study among healthcare workers.
Vaccine. 2024;42:126424.
PubMed Abstract available

LITAO L, Feng C, Hongyu Z, Wenbin C, et al
Field production efficiency investigation of broilers immunized with a turkey herpesvirus vector vaccine expressing hemagglutinin from H9N2 subtype avian influenza virus.
Vaccine. 2024;42:126436.
PubMed Abstract available

SCHULTZE A, Martin I, Messina D, Bots S, et al
Corrigendum to "A comparison of four self-controlled study designs in an analysis of COVID-19 vaccines and myocarditis using five European databases" [Vaccine 42 (12) (2024) 3039-3048].
Vaccine. 2024 Oct 12:126438. doi: 10.1016/j.vaccine.2024.126438.
PubMed

BAMOUH Z, Semmate N, Mouahid M, Kerbal I, et al
Safety and efficacy of 9R live attenuated vaccine against fowl typhoid in partridge's species.
Vaccine. 2024;42:126413.
PubMed Abstract available

MOUCHERAUD C, Ochieng E, Ogutu V, Chang LC, et al
Intervention-amenable factors associated with lack of HPV vaccination in Kenya: Results from a large national phone survey.
Vaccine. 2024;42:126410.
PubMed Abstract available

WANG J, Gan Y, Yuan T, Huang Y, et al
Protection against Mycoplasma hyorhinis infection in commercial pigs via immunization with inactivated vaccines prepared with homologous or heterologous strains.
Vaccine. 2024;42:126421.
PubMed Abstract available

GERA S, Hoq M, Danchin M, Tuckerman J, et al
Association between parental vaccine hesitancy and geographical coverage for childhood vaccination: A cross-sectional study.
Vaccine. 2024;42:126422.
PubMed Abstract available

DOYON-PLOURDE P, Farley R, Krishnan R, Tunis M, et al
Direct quantitative comparison of benefits and risks of COVID-19 vaccines used in National Immunization Technical Advisory Groups Guidance during the first two years of the pandemic.
Vaccine. 2024;42:126406.
PubMed Abstract available

MYLONA E, Pereira-Dias J, Keane JA, Karkey A, et al
Phenotypic variation in the lipopolysaccharide O-antigen of Salmonella Paratyphi A and implications for vaccine development.
Vaccine. 2024;42:126404.
PubMed Abstract available

TAAFFE J, Ostrowsky JT, Mott J, Goldin S, et al
Advancing influenza vaccines: A review of next-generation candidates and their potential for global health impact.
Vaccine. 2024;42:126408.
PubMed Abstract available

MWAMBA G, Gibson EM, Toko C, Tunda C, et al
Effective integration of COVID-19 vaccination with routine immunization: A case study from Kinshasa, DRC.
Vaccine. 2024 Oct 4:126392. doi: 10.1016/j.vaccine.2024.126392.
PubMed Abstract available

PASCOE KM, Bishop S, Ci X, Ramirez M, et al
Factors that shape COVID-19 pediatric vaccine decision-making in rural agricultural communities: A qualitative study.
Vaccine. 2024;42:126389.
PubMed Abstract available

HOJO-SOUZA NS, de Castro JT, Rivelli GG, Azevedo PO, et al
SpiN-Tec: A T cell-based recombinant vaccine that is safe, immunogenic, and shows high efficacy in experimental models challenged with SARS-CoV-2 variants of concern.
Vaccine. 2024;42:126394.
PubMed Abstract available

TAHA, Eskandari S, Slesarenko VA, Haselhorst T, et al
Refinement and optimisation of Neisseria gonorrhoeae NHBA and MetQ vaccine candidates.
Vaccine. 2024;42:126416.
PubMed Abstract available

ALANSARI KDH, Buhl C, Thabit AK, Badr AF, et al
Validation of the Arabic translation of the vaccination attitudes examination (VAX) scale.
Vaccine. 2024;42:126411.
PubMed Abstract available

PERCIO J, Kobayashi CD, Silva RMA, Marinho AKBB, et al
Safety signal detected: Anaphylaxis after attenuated dengue vaccine (TAK-003) - Brazil, march 1, 2023-march 11, 2024.
Vaccine. 2024;42:126407.
PubMed Abstract available

EARP M, Meng L, Black CL, Carter RJ, et al
Using regression tree analysis to examine demographic and geographic characteristics of COVID-19 vaccination trends over time, United States, May 2021-April 2022, National Immunization Survey Adult COVID Module.
Vaccine. 2024;42:126372.
PubMed Abstract available

REN J, Gao Q, Zhou X, Chen L, et al
Identification of gene and protein signatures associated with long-term effects of COVID-19 on the immune system after patient recovery by analyzing single-cell multi-omics data using a machine learning approach.
Vaccine. 2024;42:126253.
PubMed Abstract available

BARBOSA TN, Ferreira MRA, Scholl NR, Pegoraro HG, et al
Iridaea cordata lipid extract associated with the rCP01850 protein of C. pseudotuberculosis elicited a Th1 immune response in immunized sheep.
Vaccine. 2024;42:126220.
PubMed Abstract available

SPENCER CLINTON JL, Hoornweg TE, Tan J, Peng R, et al
The EEHV1A gH/gL complex elicits humoral and cell-mediated immune responses in mice.
Vaccine. 2024;42:126227.
PubMed Abstract available

RAMIREZ MA, Loaiza RA, Martinez-Balboa Y, Bruneau N, et al
Co-administration of recombinant BCG and SARS-CoV-2 proteins leads to robust antiviral immunity.
Vaccine. 2024;42:126203.
PubMed Abstract available

IQBAL I, Shahid S, Kanwar S, Kabir F, et al
Pneumococcal carriage and changes in serotype distribution post- PCV13 introduction in children in Matiari, Pakistan.
Vaccine. 2024;42:126238.
PubMed Abstract available

GUINAZU G, Dvorkin J, Mahmud S, Baral R, et al
Evaluation of the potential impact and cost-effectiveness of respiratory syncytial virus (RSV) prevention strategies for infants in Argentina.
Vaccine. 2024;42:126234.
PubMed Abstract available

BROWN L, Bingham J, Pulliam J, Mthombothi Z, et al
Estimation of the poliovirus type 2 immunity gap in South Africa.
Vaccine. 2024;42:126062.
PubMed Abstract available

HOWARD LUDLAM A, Paynter J, Goodyear-Smith F, Petousis-Harris H, et al
Pertussis epidemiology in adults: Retrospective analysis of pertussis incidence and association with comorbidities among adult populations in Aotearoa New Zealand, using national administrative datasets.
Vaccine. 2024;42:126048.
PubMed Abstract available

LANGER S, Holzapfel S, August L, Badura A, et al
Parental knowledge and attitudes to infant immunization in the context of RSV: All about confidence?
Vaccine. 2024;42:126050.
PubMed Abstract available

RUSSELL FA, Trim L, Bryan E, Fisher MA, et al
Stability and antigenicity of Chlamydia muridarum major outer membrane protein antigen at body temperature.
Vaccine. 2024;42:126047.
PubMed Abstract available

NAHAR UJ, Wang J, Shalash AO, Lu L, et al
Self-assembled monovalent lipidated mannose ligand as a standalone nanoadjuvant.
Vaccine. 2024;42:126060.
PubMed Abstract available

WEGMAN AD, Kalimuddin S, Marques ETA, Adams LE, et al
Proceedings of the dengue endgame summit: Imagining a world with dengue control.
Vaccine. 2024;42:126071.
PubMed Abstract available

COLOMBATTI OLIVIERI MA, Cuerda MX, Moyano RD, Gravisaco MJ, et al
Superior protection against paratuberculosis by a heterologous prime-boost immunization in a murine model.
Vaccine. 2024;42:126055.
PubMed Abstract available

GARLAND SM, Bhatla N, Woo YL
IPVS STATEMENT on HPV vaccination: No longer supply constraints: Towards achieving WHO vaccine targets.
Vaccine. 2024;42:126400.
PubMed Abstract available

GUINAZU G, Dvorkin J, Mahmud S, Baral R, et al
Corrigendum to "Evaluation of the potential impact and cost-effectiveness of respiratory syncytial virus (RSV) prevention strategies for infants in Argentina" [Vaccine. Volume 42, Issue 23, 3 October 2024, 126234].
Vaccine. 2024 Oct 2:126402. doi: 10.1016/j.vaccine.2024.126402.
PubMed

MIRANDA FM, da Silva LD, Fortuna LBDP, Silva AB, et al
Long-term predominance in childhood colonization of the multidrug-resistant lineage 6C/ST386 of Streptococcus pneumoniae after universal immunization with the 10-valent pneumococcal conjugate vaccine in Brazil.
Vaccine. 2024;42:126414.
PubMed Abstract available

CHOI YJ, Song JY, Wie SH, Choi WS, et al
Real-world effectiveness of influenza vaccine over a decade during the 2011-2021 seasons-Implications of vaccine mismatch.
Vaccine. 2024;42:126381.
PubMed Abstract available

PATRICK-SMITH M, Emary K, Hodgson SH, Thomas TM, et al
Roles and responsibilities of participants, researchers, and the media in the communication of vaccine trials: Experience from the United Kingdom's first COVID-19 vaccine trial.
Vaccine. 2024;42:126391.
PubMed Abstract available

KANG S, Chung E, Hong C, Aziz AB, et al
Raising the case of hepatitis E: Report from the 2nd international HEV symposium.
Vaccine. 2024;42:126398.
PubMed Abstract available

September 2024

TEUFEL LU, Taks EJM, van Gemert J, Neacsu M, et al
Interleukin 38 reduces antigen-presentation capacity and antibody production after vaccination.
Vaccine. 2024;42:126396.
PubMed Abstract available

FLETCHER MA, Vojicic J, Daigle D, Taysi B, et al
National recommendations for adult pneumococcal vaccination in countries of the WHO regions of Americas, Africa, Eastern Mediterranean, South East Asia, and Western Pacific.
Vaccine. 2024;42:126390.
PubMed Abstract available

MOTTA M, Motta G, Stecula D
Conceptual debates in the study of canine & feline vaccine hesitancy: A response to Haeder 2023.
Vaccine. 2024 Sep 28:126397. doi: 10.1016/j.vaccine.2024.126397.
PubMed

SPASENOSKA D, Bloem P, Akaba H, Kahn AL, et al
Using human papillomavirus (HPV) vaccine in controlled temperature chain (CTC): A solution looking for a problem? Or a solution to problems that are not systematically documented?
Vaccine. 2024 Sep 28:126399. doi: 10.1016/j.vaccine.2024.126399.
PubMed

LYU X, Liu X, Hong H
Validation of the Chinese version of the vaccine conspiracy beliefs scale during COVID-19 pandemic and its correlates.
Vaccine. 2024;42:126395.
PubMed Abstract available

SOTOODEH A, Hedberg P, Granath F, Alfven T, et al
Sociodemographic determinants of COVID-19 vaccination in adolescents in Stockholm, Sweden.
Vaccine. 2024;42:126388.
PubMed Abstract available

SRITIPSUKHO P, Sinlapamongkolkul P, Satdhabudha A, Chaiyakulsil C, et al
Corrigendum to "Immunogenicity during 6 months after SARS-CoV-2 infection is significantly different depending on previous COVID-19 vaccine regimens and a booster dose received" [Vaccine 42 (22) (2024) 126025].
Vaccine. 2024 Sep 27:126403. doi: 10.1016/j.vaccine.2024.126403.
PubMed

ARCIDIACO S, Schreiber P, Poincelot L, Loukeri S, et al
Vaccines efficacy against infection with circulating feline calicivirus after one single injection: Comparison of Leucofeligen FeLV/RCP and Purevax RCPFeLV vaccines.
Vaccine. 2024;42:126393.
PubMed Abstract available

BARBIERI E, Cocchio S, Furlan P, Scamarcia A, et al
A population database analysis to estimate the varicella vaccine effectiveness in children < 14 years in a high vaccination coverage area from 2004 to 2022.
Vaccine. 2024;42:126387.
PubMed Abstract available

DECEUNINCK G, Brousseau N, Lefebvre B, Quach C, et al
Effectiveness of the ten- and thirteen-valent pneumococcal conjugate vaccines to prevent serotype 19A invasive pneumococcal disease in Quebec, Canada. A Canadian immunization research network (CIRN) study.
Vaccine. 2024;42:126379.
PubMed Abstract available

ENGLAND A, Sung J, Deulofeu M, Soler LF, et al
Variant-specific neutralising antibodies levels induced by the PHH-1 V SARS-CoV-2 vaccine (Bimervax(R)) by HIPRA.
Vaccine. 2024;42:126386.
PubMed Abstract available

DANZELLE C, Cunha P, Noleto PG, Gilbert FB, et al
Saccharomyces cerevisiae as a platform for vaccination against bovine mastitis.
Vaccine. 2024;42:126385.
PubMed Abstract available

TAN M, Zhang R, Shen T, Li A, et al
Systematic evaluation of the induction of efficient neutralizing antibodies by recombinant multicomponent subunit vaccines against monkeypox virus.
Vaccine. 2024;42:126384.
PubMed Abstract available

WEITZMAN ER
Social complexity of a fentanyl vaccine to prevent opioid overdose conference proceedings: Radcliffe institute for advanced study conference proceedings.
Vaccine. 2024 Sep 23:126324. doi: 10.1016/j.vaccine.2024.126324.
PubMed Abstract available

LAZARUS R, Harris R, Thirard R, Baos S, et al
Comparison of assays used to detect antibody response in COVID-19 vaccine trials: Results from of a UK multi-Centre randomised controlled trial to determine the immunogenicity responses of COVID-19 vaccines administered concomitantly with seasonal inf
Vaccine. 2024;42:126369.
PubMed Abstract available

AL-DAHIR S, Hassan TAL, Moss W, Khalil A, et al
The impact of coronavirus pandemic shutdowns on immunization completion in Hadeetha, Anbar, Iraq: A case-study of vaccine completion in a recovering healthcare system.
Vaccine. 2024 Sep 21:126383. doi: 10.1016/j.vaccine.2024.126383.
PubMed Abstract available

BERNADIN O, Cochin M, Driouich JS, Laprie C, et al
Preclinical evaluation in hamster model of the mRNA COVID-19 vaccine candidate AfriVac 2121 (Wuhan) produced under the WHO/MPP mRNA Technology Transfer Programme.
Vaccine. 2024;42:126378.
PubMed Abstract available

LUI L, Requia WJ, Dos Santos F, Albert CE, et al
Determining factors associated with vaccination coverage in the first year of life in Brazil (2013-2022).
Vaccine. 2024;42:126382.
PubMed Abstract available

LAEMMLE-RUFF I, Fryk JJ, Shenton P, Clothier HJ, et al
Detailed review of mortality reported following COVID-19 vaccination in Victoria, Australia: 2021-2023.
Vaccine. 2024;42:126368.
PubMed Abstract available

SHARMA H, Parekh S, Pujari P, Shewale S, et al
A randomized, active-controlled, multi-centric, phase-II clinical study to assess safety and immunogenicity of a fully liquid DTwP-HepB-IPV-Hib hexavalent vaccine (HEXASIIL(R)) in Indian toddlers.
Vaccine. 2024;42:126380.
PubMed Abstract available

WEE LE, Malek MIBA, Tan J, Chiew C, et al
Risk of death and cardiovascular events following COVID-19 vaccination or positive SARS-CoV-2 test amongst adult Singaporeans during omicron transmission.
Vaccine. 2024;42:126356.
PubMed Abstract available

GOLDIN S, Brooks D, Jorgensen P, Wijesinghe P, et al
Seasonal influenza vaccination: A global review of national policies in 194 WHO member states in 2022.
Vaccine. 2024;42:126274.
PubMed Abstract available

IMRAN M, Mills C, McDermott KW, Dean A, et al
Relative effectiveness of adjuvanted versus non-adjuvanted influenza vaccines in older adults with risk factors for influenza complications during the 2019-2020 U.S. influenza season.
Vaccine. 2024;42:126316.
PubMed Abstract available

CHOI KY, El-Hamdi N, McGregor A
T cell inducing vaccine against cytomegalovirus immediate early 1 (IE1) protein provides high level cross strain protection against congenital CMV.
Vaccine. 2024;42:126357.
PubMed Abstract available

CANDEIAS C, Almeida ST, Paulo AC, Simoes AS, et al
Streptococcus pneumoniae carriage, serotypes, genotypes, and antimicrobial resistance trends among children in Portugal, after introduction of PCV13 in National Immunization Program: A cross-sectional study.
Vaccine. 2024;42:126219.
PubMed Abstract available

ROELS S, Bruckner M, Sadoff J, Cardenas V, et al
Pre- and post-Ad26.COV2.S booster dose antibody levels predict COVID-19 disease risk.
Vaccine. 2024;42:126159.
PubMed Abstract available

SHEN AK, Gutu V, Druc A, Ebama M, et al
An evaluation of the National Influenza Vaccination Program in the Republic of Moldova, 2023-2024.
Vaccine. 2024;42:126322.
PubMed Abstract available

WITTESAELE C, Toska E, Cluver L, Weiss HA, et al
Vaccine coverage and timeliness among children of adolescent mothers: A community-based study in the eastern cape, South Africa.
Vaccine. 2024;42:126318.
PubMed Abstract available

MEANEY-DELMAN D, Carroll S, Polen K, Jatlaoui TC, et al
Planning for the future of maternal immunization: Building on lessons learned from the COVID-19 pandemic.
Vaccine. 2024;42 Suppl 3.
PubMed Abstract available

JONES-JACK N, El Kalach R, Yassanye D, Link-Gelles R, et al
Advancing public health informatics during the COVID-19 pandemic: Lessons learned from a public-private partnership with pharmacies.
Vaccine. 2024;42 Suppl 3:125667.
PubMed Abstract available

MAHAPATRA B, Singh A, Banerjee A, Sirohi S, et al
A squalene oil emulsified MPL-A and anti-CD200/CD300a antibodies adjuvanted whole-killed Leishmania vaccine provides durable immunity against L. donovani parasites.
Vaccine. 2024;42:126373.
PubMed Abstract available

WADA YA, Mazlan M, Noordin MM, Mohd-Lila MA, et al
Rabies epidemiology in Malaysia (2015-2023): A cross-sectional insights and strategies for control.
Vaccine. 2024;42:126371.
PubMed Abstract available

KRAUSE KD, D'Avanzo PA, Karr AG, Rhem C, et al
Vaccination uptake in LGBTQ adults in two US states: Findings from the QVax study.
Vaccine. 2024;42:126320.
PubMed Abstract available

HEINS MJ, Spreeuwenberg P, Caini S, Hooiveld M, et al
Measuring the impact of influenza vaccination in the Netherlands using retrospective observational primary care, hospitalisation and mortality data.
Vaccine. 2024;42:126244.
PubMed Abstract available

LAMBACH P, Silal S, Sbarra AN, Crowcroft NS, et al
Report from the World Health Organization's immunization and vaccines-related implementation research advisory committee (IVIR-AC) ad hoc meeting, 28 June - 1 July 2024.
Vaccine. 2024;42:126307.
PubMed Abstract available

SHIU EYC, Cheng SMS, Martin-Sanchez M, Au NYM, et al
Durability for 12 months of antibody response to a booster dose of monovalent BNT162b2 in adults who had initially received 2 doses of inactivated vaccine.
Vaccine. 2024;42:126317.
PubMed Abstract available

ARTETA-ACOSTA C, Villena R, Hormazabal JC, Fernandez J, et al
Whole-genome sequencing of Neisseria meningitidis collected in Chile from pediatric patients during 2016-2019 and coverage vaccine prediction.
Vaccine. 2024;42:126311.
PubMed Abstract available

VAN HEESBEEN R, Bastian AR, Omoruyi E, Rosen J, et al
Immunogenicity and safety of different dose levels of Ad26.RSV.preF/RSV preF protein vaccine in adults aged 60 years and older: A randomized, double-blind, placebo-controlled, phase 2a study.
Vaccine. 2024;42:126273.
PubMed Abstract available

KERFUA SD, Haydon DT, Wilsden G, Ludi A, et al
Evaluation of commercial quadrivalent foot-and-mouth disease vaccines against east African virus strains reveals limited immunogenicity and duration of protection.
Vaccine. 2024;42:126325.
PubMed Abstract available

CHANG JY, Chang M, Huang S, Bosco J, et al
COVID-19 vaccine uptake in a predominantly minoritized cohort hospitalized during the early pandemic in New York City.
Vaccine. 2024;42:126260.
PubMed Abstract available

PHAM M, Pichichero M
Modeling conjugate vaccine and natural induced antibody correlates of protection for pneumococcal colonization and acute otitis media infection in young children.
Vaccine. 2024;42:126295.
PubMed Abstract available

BAFFOUR AWUAH G, Tanaka LF, Eberl M, Donnachie E, et al
Analysis of health claims data on vaccination coverage in older adults in Bavaria, Germany: Influenza, pneumococcus and herpes zoster.
Vaccine. 2024;42:126354.
PubMed Abstract available

RABOBA JL, Rahajamanana VL, Rakotojoelimaria HE, Masembe YV, et al
Monovalent rotavirus vaccine effectiveness and long-term impact among children <5 years old in Antananarivo, Madagascar, 2010-2022.
Vaccine. 2024;42:126321.
PubMed Abstract available

ABARA WE, Modaressi S, Fireman B, Klein NP, et al
Effectiveness of a serogroup B meningococcal vaccine against gonorrhea: A retrospective study.
Vaccine. 2024;42:126312.
PubMed Abstract available

KING LM, Lewnard JA
Health-economic burden attributable to novel serotypes in candidate 24- and 31-valent pneumococcal conjugate vaccines.
Vaccine. 2024;42:126310.
PubMed Abstract available

GAUDOUEN H, Tattevin P, Thibault V, Menard G, et al
Determinants of influenza and COVID vaccine uptake in healthcare workers: A cross-sectional survey during the post-pandemic era in a network of academic hospitals in France.
Vaccine. 2024;42:126272.
PubMed Abstract available

REGAN AK, Sullivan SG, Arah OA
Maternal influenza vaccination and associated risk of fetal loss: A claims-based prospective cohort study.
Vaccine. 2024;42:126256.
PubMed Abstract available

WANG C, Damiano RJ, Ruebush LE, Engelen MPKJ, et al
A randomized, triple-blinded, placebo-controlled clinical trial evaluating immune responses of Typhim Vi and PPSV23 vaccines in healthy adults: The PREP study.
Vaccine. 2024;42:126292.
PubMed Abstract available

PETRI E, Biswal S, Lloyd E, Tricou V, et al
Early onset of protection of the TAK-003 dengue vaccine: Data from the DEN-301 clinical trial.
Vaccine. 2024;42:126309.
PubMed Abstract available

BLASCO A, Royuela A, Garcia-Gomez S, Gomez-Lozano N, et al
Association of SARS-CoV-2 immunoserology and vaccination status with myocardial infarction severity and outcome.
Vaccine. 2024;42:126305.
PubMed Abstract available

RAMIREZ OR, Farraye FA, Hayney MS, Caldera F, et al
Inadvertent live vaccine administration in adult patients with inflammatory bowel disease on immunosuppressive therapy.
Vaccine. 2024;42:126319.
PubMed Abstract available

WOO EJ, Miller ER, Stroud E
Syncope after live attenuated influenza vaccine: Reports to the Vaccine Adverse Event Reporting System (2003-2024).
Vaccine. 2024;42:126290.
PubMed Abstract available

GROOM HC, Biel FM, Crane B, Sun E, et al
Disparities in COVID-19 vaccination receipt by race, ethnicity, and social determinants of health among a large patient population in a network of community-based healthcare centers.
Vaccine. 2024;42:126288.
PubMed Abstract available

HOXIE I, Vasilev K, Clark JJ, Bushfield K, et al
A recombinant N2 neuraminidase-based CpG 1018(R) adjuvanted vaccine provides protection against challenge with heterologous influenza viruses in mice and hamsters.
Vaccine. 2024;42:126269.
PubMed Abstract available

HUTTON DW, Prosser LA, Rose AM, Mercon K, et al
Cost-effectiveness of vaccinating adults aged 60 years and older against respiratory syncytial virus.
Vaccine. 2024;42:126294.
PubMed Abstract available

SCHLEY K, Whichello C, Hauber B, Krucien N, et al
Preferences of US adolescents and parents for vaccination against invasive meningococcal disease.
Vaccine. 2024;42:126264.
PubMed Abstract available

POH XY, Torres-Ruesta A, Yoong T, Wong N, et al
Immunogenicity of mRNA vs. BBV152 vaccine boosters against Omicron subvariants: Final results from Phase B of the PRIBIVAC study, a randomized clinical trial.
Vaccine. 2024;42:126275.
PubMed Abstract available

CUI Y, Cibichakravarthy B, Tang X, Alameh MG, et al
Salp14 epitope-based mRNA vaccination induces early recognition of a tick bite.
Vaccine. 2024;42:126304.
PubMed Abstract available

KIM C, Dunphy C, Duggar C, Pike J, et al
Jurisdiction-level costs of the initial phase of the COVID-19 vaccination program in the United States, December 20, 2020-May 31, 2021.
Vaccine. 2024;42:126287.
PubMed Abstract available

BONNER C, Taba M, Fajardo MA, Batcup C, et al
Using health literacy principles to improve understanding of evolving evidence in health emergencies: Optimisation and evaluation of a COVID-19 vaccination risk-benefit calculator.
Vaccine. 2024;42:126296.
PubMed Abstract available

KARUNAKARAN KP, Yu H, Jiang X, Chan QWT, et al
Immunoproteomic discovery of Mycobacterium bovis antigens, including the surface lipoprotein Mpt83 as a T cell antigen useful for vaccine development.
Vaccine. 2024;42:126266.
PubMed Abstract available

LIU S, van Dijk LLA, den Hartog Y, Hoek R, et al
mRNA-based COVID-19 vaccination of lung transplant recipients with prior SARS-CoV-2 infection induces durable SARS-CoV-2-specific antibodies and T cells.
Vaccine. 2024;42:126250.
PubMed Abstract available

BOTTON J, Bertrand M, Jabagi MJ, Duranteau L, et al
Risk of heavy menstrual bleeding following COVID-19 vaccination: A nationwide case-control study.
Vaccine. 2024;42:126252.
PubMed Abstract available

HOU X, Li N, Zhang H, Liu W, et al
Hepatitis B virus infection and vaccination among people who use drugs in Xi'an, China.
Vaccine. 2024;42:126259.
PubMed Abstract available

RICHMOND P, Nolan T, McGirr A, Napier-Flood F, et al
Phase 1 trial of an investigational Tdap booster vaccine with CpG 1018 adjuvant compared with Boostrix in healthy adults and adolescents.
Vaccine. 2024;42:126251.
PubMed Abstract available

COLEMAN BL, Gutmanis I, Bondy SJ, Harrison R, et al
Canadian health care providers' and education workers' hesitance to receive original and bivalent COVID-19 vaccines.
Vaccine. 2024;42:126271.
PubMed Abstract available

August 2024

LI G, Ren T, Zhang H, Ti J, et al
Persistence of immunity in children aged 2 months and 7 months - 5 years old after primary immunization with 13-valent pneumococcal conjugate vaccine.
Vaccine. 2024;42:126209.
PubMed Abstract available

VIETRI J, Maculaitis MC, Cappelleri JC, Yu H, et al
Preferences for a Clostridioides difficile vaccine among adults in the United States.
Vaccine. 2024;42:126261.
PubMed Abstract available

KELLY M, Janardhanan J, Wagh C, Verma S, et al
Development of a Shigella conjugate vaccine targeting Shigella flexneri 6 that is immunogenic and provides protection against virulent challenge.
Vaccine. 2024;42:126263.
PubMed Abstract available

MACKAY H, Gretton JD, Chyderiotis S, Elliott S, et al
Confidence and barriers: Analysis of factors associated with timely routine childhood vaccination in Canada during the COVID-19 pandemic.
Vaccine. 2024;42:126236.
PubMed Abstract available

AIZAWA Y, Sato I, Abe Y, Sasagawa F, et al
Impact of the emergence of severe acute respiratory syndrome coronavirus 2 omicron variants on routine childhood immunization in Japan.
Vaccine. 2024;42:126137.
PubMed Abstract available

MAI W, Shen J, Ma F, Zhu J, et al
Specific humoral immune response and XBB variants re-infection risk of hemodialysis patients after Omicron BA.5 infection in China.
Vaccine. 2024;42:126108.
PubMed Abstract available

EYAWO O, Ugoji UC, Pan S, Oyibo P, et al
Predictors of the willingness to accept a free COVID-19 vaccine among households in Nigeria.
Vaccine. 2024;42:126225.
PubMed Abstract available

CHI X, Han F, Jiang Y, Cao L, et al
Characterization of a triple-type chimeric vaccine against human papillomavirus types 18, 45, and 59.
Vaccine. 2024;42:126245.
PubMed Abstract available

BRESEE JS, Lafond KE
The partnership for international vaccine initiatives: The importance and opportunity to develop influenza vaccination programs in low- and middle-income countries.
Vaccine. 2024 Aug 29:126255. doi: 10.1016/j.vaccine.2024.126255.
PubMed

NAVARRO-TORNE A, Anderson A, Panwar K, Ghys E, et al
How has post-implementation surveillance of high-coverage vaccination with HPV16/18-AS04 vaccine in England added to evidence about its cross-protective effects?
Vaccine. 2024;42:126215.
PubMed Abstract available

FOURIE KR, Jeffery A, Chand D, Choudhary P, et al
Vaccination with a Lawsonia intracellularis subunit water in oil emulsion vaccine mitigated some disease parameters but failed to affect shedding.
Vaccine. 2024;42:126254.
PubMed Abstract available

HARADA Y, Takahashi H, Fujimoto T, Horikoshi F, et al
Evaluation of a qualified MDCK cell line for virus isolation to develop cell-based influenza vaccine viruses with appropriate antigenicity.
Vaccine. 2024;42:126242.
PubMed Abstract available

DONG R, Luo Z, Shao J, Xue H, et al
Understanding hepatitis E vaccination intention among women of childbearing-age: A theory-based cross-sectional study.
Vaccine. 2024;42:126258.
PubMed Abstract available

LLABRE MM, Timpano KR, Broos HC, Leite RO, et al
Lessons from a longitudinal community-based investigation of adherence to guidelines and intent to vaccinate during the COVID-19 pandemic.
Vaccine. 2024;42:126265.
PubMed Abstract available

PETRI FAM, Malcher CS, Mechler-Dreibi ML, Panneitz AK, et al
Shedding reduction and immunity modulation in piglets with an inactivated Mycoplasma hyopneumoniae vaccine encapsulated in nanostructured SBA-15 silica.
Vaccine. 2024;42:126268.
PubMed Abstract available

PATHER S, Charpentier N, van den Ouweland F, Rizzi R, et al
A Brighton Collaboration standardized template with key considerations for a benefit-risk assessment for the Comirnaty COVID-19 mRNA vaccine.
Vaccine. 2024;42:126165.
PubMed Abstract available

KANU FA, Freeland C, Nwokoro UU, Mohammed Y, et al
Evaluation of interventions to improve timely hepatitis B birth dose vaccination among infants and maternal tetanus vaccination among pregnant women in Nigeria.
Vaccine. 2024;42:126222.
PubMed Abstract available

FERREIRA-SILVA SN, Soares MEM, Vasconcelos R, Barbieri C, et al
COVID-19 vaccine hesitancy: Meaning relations between responses in an epidemiological study and twitter messages.
Vaccine. 2024;42:126247.
PubMed Abstract available

HUANG X, Yang S, Zhao J, Yang J, et al
Generation and evaluation of Salmonella entericaserovar Choleraesuis mutant strains as a potential live-attenuated vaccine.
Vaccine. 2024;42:126262.
PubMed Abstract available

GUZMAN RUIZ L, Zollner AM, Hoxie I, Kuchler J, et al
Enhancing NA immunogenicity through novel VLP designs.
Vaccine. 2024;42:126270.
PubMed Abstract available

ADAMS K, Diallo D, Tadount F, Mouajou V, et al
Evaluation of the decision-making process underlying the initial off-label use of vaccines: A scoping review.
Vaccine. 2024;42:126246.
PubMed Abstract available

SINGH D, Damasevicius R, Kumar V, Bagnoli F, et al
Editorial: ML-driven vaccine against COVID-19: Developmental challenges and foresight.
Vaccine. 2024;42:126267.
PubMed

EVANS I, Jury S, Morrison A, Best E, et al
Onward transmission of measles virus among vaccinated cases in a large community outbreak in Auckland, New Zealand, 2019.
Vaccine. 2024;42:126257.
PubMed Abstract available

VIELOT NA, Kelly NK, Ludema C, Rosenberg M, et al
Patterns and predictors of COVID-19 vaccination among young adults at 44 US sites: Secondary analysis of a randomized, controlled, open-label trial, March - December 2021.
Vaccine. 2024;42:126237.
PubMed Abstract available

UNAGAMI K, Yoshikawa M, Egawa H, Ohfuji S, et al
Delayed peak antibody titers after the second dose of SARS-CoV-2 vaccine in solid organ transplant recipients: Prospective cohort study.
Vaccine. 2024;42:126221.
PubMed Abstract available

SHINJOH M, Yaginuma M, Yamaguchi Y, Tamura K, et al
Effectiveness of inactivated influenza vaccine in children during the 2023/24 season: The first season after relaxation of intensive COVID-19 measures.
Vaccine. 2024;42:126241.
PubMed Abstract available

ADAMS L, Prasinou AK, Hadley L, Ramsay M, et al
Estimating the potential number of cases prevented by infant/ toddler immunisation with a MenACWY vaccine.
Vaccine. 2024;42:126240.
PubMed Abstract available

OGAR CK, Gilbert HN, Bloem LT, Leopold C, et al
Patient-reported outcomes of adverse events after COVID-19 vaccination in Nigeria: A mixed methods study.
Vaccine. 2024;42:126196.
PubMed Abstract available

SKIRROW H, Lewis C, Haque H, Choudary-Salter L, et al
'Why did nobody ask us?': A mixed-methods co-produced study in the United Kingdom exploring why some children are unvaccinated or vaccinated late.
Vaccine. 2024;42:126172.
PubMed Abstract available

POURAKBARI B, Ashraf Talesh S, Mahmoudi S, Sotoudeh M, et al
Measles immunity status in Iranian infants and children and outbreak concerns: Time for reconsidering the vaccination schedule?
Vaccine. 2024;42:126243.
PubMed Abstract available

CHEN Z, Gou Q, Yuan Y, Zhang X, et al
Vaccination with a trivalent Klebsiella pneumoniae vaccine confers protection in a murine model of pneumonia.
Vaccine. 2024;42:126217.
PubMed Abstract available

ESPOSITO GL, Fassio F, Girardi D, Picasso E, et al
"REAl LIfe" observational study on the effectiveness of Evusheld prophylaxis against SARS-CoV-2 omicron variants in vaccine non-responder immunocompromised patients (REALISE).
Vaccine. 2024;42:126208.
PubMed Abstract available

SANFTENBERG L, Bader F, Rottenkolber M, Sebastiao M, et al
Associations of mental health with vaccination readiness in informal caregivers and the vaccination status of their care recipients during the Covid-19 pandemic - A cross sectional analysis.
Vaccine. 2024;42:126218.
PubMed Abstract available

CASEY RM, Najjengo MS, Lubega I, Sekiziyivu AB, et al
Adverse events following immunization (AEFI) with fractional one-fifth and one-half doses of yellow fever vaccine compared to full dose in children 9-23 months old in Uganda, 2019-2020 - Preliminary report.
Vaccine. 2024;42:126197.
PubMed Abstract available

WANDERA EA, Kurokawa N, Mutua MM, Muriithi B, et al
Long-term impact of rotavirus vaccination on all-cause and rotavirus-specific gastroenteritis and strain distribution in Central Kenya: An 11-year interrupted time-series analysis.
Vaccine. 2024;42:126210.
PubMed Abstract available

HERNANDEZ-BERNAL F, Noa-Romero E, Quintana-Guerra J, Chavez-Chong CO, et al
Efficacy and safety of Abdala COVID-19 subunit vaccine in children and adolescents: An open-label, single-arm, phase 2 trial (MENIQUE).
Vaccine. 2024;42:126223.
PubMed Abstract available

SNIDER CJ, Zaman K, Estivariz CF, Aziz AB, et al
Assessing the mucosal intestinal and systemic humoral immunity of sequential schedules of inactivated poliovirus vaccine and bivalent oral poliovirus vaccine for essential immunization in Bangladesh: An open-label, randomized controlled trial.
Vaccine. 2024;42:126216.
PubMed Abstract available

HADLEY L, Soeters HM, Cooper LV, Fernandez K, et al
Modelling control strategies for pneumococcal meningitis outbreaks in the African meningitis belt.
Vaccine. 2024;42:125983.
PubMed Abstract available

IHENETU G, Aylin P, Novov V, Skirrow H, et al
Uptake of COVID-19 vaccines and association with hospitalisation due to COVID-19 in pregnancy: Retrospective cohort study.
Vaccine. 2024 Aug 13:126214. doi: 10.1016/j.vaccine.2024.126214.
PubMed Abstract available

FINN MB, Penfound TA, Salehi S, Ogega CO, et al
Immunogenicity of a 30-valent M protein mRNA group A Streptococcus vaccine.
Vaccine. 2024;42:126205.
PubMed Abstract available

VALDES I, Suzarte E, Lazo L, Cobas K, et al
Addition of nucleotide adjuvants enhances the immunogenicity of a recombinant subunit vaccine against the Zika virus in BALB/c mice.
Vaccine. 2024 Aug 12:126213. doi: 10.1016/j.vaccine.2024.126213.
PubMed Abstract available

GLEASON A, Kumar CK, Klein E, Laxminarayan R, et al
Effect of rotavirus vaccination on the burden of rotavirus disease and associated antibiotic use in India: A dynamic agent-based simulation analysis.
Vaccine. 2024;42:126211.
PubMed Abstract available

CAMERON RL, Palmer TJ, Cuschieri K, Kavanagh K, et al
Assessing real world vaccine effectiveness: A review of Scotland's approach to monitoring human papillomavirus (HPV) vaccine impact on HPV infection and cervical disease.
Vaccine. 2024;42:126177.
PubMed Abstract available

NASIR S, Anwer F, Ishaq Z, Saeed MT, et al
VacSol-ML(ESKAPE)(:) Machine learning empowering vaccine antigen prediction for ESKAPE pathogens.
Vaccine. 2024;42:126204.
PubMed Abstract available

JOB MJ, Kim D, Acosta F, Valera S, et al
Attitudes of pregnant women in the Dominican Republic towards a future maternal Group B Streptococcus vaccine.
Vaccine. 2024;42:126169.
PubMed Abstract available

WALDEN J, Stanek JR, Young J, Griffith MM, et al
Influenza vaccine uptake among youth with sickle cell disease who are seen in clinic before and after the COVID-19 pandemic.
Vaccine. 2024;42:126212.
PubMed Abstract available

GRAF DD, Westphal L, Hallgreen CE
The life cycle of vaccines evaluated by the European Medicines Agency.
Vaccine. 2024;42:126186.
PubMed Abstract available

BAJPAI D, Bose S, Saxena N, Kulkarni B, et al
Antibody response to non-mRNA SARS-CoV-2 vaccine in kidney transplant recipients.
Vaccine. 2024 Aug 8:126206. doi: 10.1016/j.vaccine.2024.126206.
PubMed Abstract available

BLOODWORTH S, Singleton D, Perkins E, Radford A, et al
Temporal trends and factors associated with vaccination uptake in dogs and cats from 2016 to 2022 in the United Kingdom.
Vaccine. 2024;42:126185.
PubMed Abstract available

O'MAHONY E, Sherman SM, Marlow R, Bedford H, et al
UK paediatricians' attitudes towards the chicken pox vaccine: The SPOTTY study.
Vaccine. 2024;42:126199.
PubMed Abstract available

GOMEZ-ACEBO I, Barquin-Ruiz A, Llorente S, Alonso-Molero J, et al
The impact of the COVID-19 pandemic on childhood vaccination rates and the role of sociodemographic factors: A cohort study.
Vaccine. 2024;42:126207.
PubMed Abstract available

D'SOUZA S, Ghatole B, Raghuram H, Sukhija S, et al
Understanding structural inequities in Covid-19 vaccine access and uptake among disability, transgender and gender-diverse communities in India.
Vaccine. 2024 Aug 7:126174. doi: 10.1016/j.vaccine.2024.126174.
PubMed Abstract available

GAO Y, Yang X, Li X, Chen H, et al
Lot-to-lot consistency, immunogenicity and safety of a quadrivalent split virion inactivated influenza vaccine in healthy population aged 9-59 years: A randomized, double-blind, controlled, phase IV clinical trial.
Vaccine. 2024;42:126182.
PubMed Abstract available

BUTLER AM, Newland JG, Sahrmann JM, O'Neil CA, et al
Characterizing timeliness of recommended vaccinations among privately-insured children in the United States, 2009-2019.
Vaccine. 2024;42:126179.
PubMed Abstract available

GEORGE G, Strauss M, Lansdell E, Nota P, et al
Factors associated with COVID-19 vaccine uptake among south African health care workers.
Vaccine. 2024;42:126181.
PubMed Abstract available

BOKEL J, Martins-Goncalves R, Grinsztejn E, Mendes-de-Almeida DP, et al
Anti-PF4 positivity and platelet activation after Ad26.COV2.S vaccination in Brazil.
Vaccine. 2024 Aug 5:126175. doi: 10.1016/j.vaccine.2024.126175.
PubMed Abstract available

BRONSTEIN MV, Kummerfeld E, MacDonald A 3rd, Vinogradov S, et al
Identifying psychological predictors of SARS-CoV-2 vaccination: A machine learning study.
Vaccine. 2024;42:126198.
PubMed Abstract available

AUGELLO M, Wagenhauser I, Krone M, Dauby N, et al
Should SARS-CoV-2 serological testing be used in the decision to deliver a COVID-19 vaccine booster? A pro-con assessment.
Vaccine. 2024 Aug 2:126184. doi: 10.1016/j.vaccine.2024.126184.
PubMed Abstract available

MCCARRON M, Marcenac P, Yau TS, Lafond KE, et al
Healthcare personnel acceptance and recommendations for influenza vaccine in twelve low- and middle-income countries: A pooled analysis from 2018 to 2020.
Vaccine. 2024 Aug 2:125670. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

WOOLFORK MN, Haire K, Farinu O, Ruffin J, et al
A health equity science approach to assessing drivers of COVID-19 vaccination coverage disparities over the course of the COVID-19 pandemic, United States, December 2020-December 2022.
Vaccine. 2024 Aug 1:126158. doi: 10.1016/j.vaccine.2024.126158.
PubMed Abstract available

JIANG M, Zhang H, Yao X, Wang Y, et al
Immunization-related stress and stress-related responses of mucosal versus intramuscular COVID-19 vaccination among adults in China.
Vaccine. 2024 Aug 1:126150. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

July 2024

ABIL OZ, Liu S, Yeh YW, Wu Y, et al
A mucosal vaccine formulation against tuberculosis by exploiting the adjuvant activity of S100A4-A damage-associated molecular pattern molecule.
Vaccine. 2024 Jul 31:126151. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

PHIRIYASART F, Aimyong N, Jirapongsuwan A, Roseh N, et al
Corrigendum to "COVID-19 vaccine hesitancy among older adult Thai Muslim people: A case-control study" [Vaccine 2023;41(41):6048-6054].
Vaccine. 2024 Jul 31:126180. doi: 10.1016/j.vaccine.2024.126180.
PubMed

SANGWE CN, Budzi MN, Shifu IN, Ghangha JG, et al
The use of community-oriented primary care (COPC) model to generate vaccine demand: The case of a remote fishing community in Cameroon.
Vaccine. 2024 Jul 31:126173. doi: 10.1016/j.vaccine.2024.126173.
PubMed Abstract available

DE WEERDT L, Herzog SA, Van Damme P, Maertens K, et al
Timing of pertussis vaccination during pregnancy: Evidence and implementation - A systematic review.
Vaccine. 2024;42:126152.
PubMed Abstract available

GUO S, Li Z, Zheng M, Wu F, et al
Safety and 6-month immune persistence of inactivated poliovirus vaccine (Sabin strains) simultaneously administrated with other vaccines for primary and booster immunization in Jiangxi Province, China.
Vaccine. 2024;42:126183.
PubMed Abstract available

MATSUMOTO N, Sasaki A, Kadowaki T, Mitsuhashi T, et al
Kinetics of SARS-CoV-2 antibody titers after booster vaccinations during an Omicron surge in Japan.
Vaccine. 2024;42:126156.
PubMed Abstract available

BESBASSI H, Elias G, Meysman P, Jansens H, et al
Modeling antigen-specific T cell dynamics following Hepatitis B Vaccination indicates differences between conventional and regulatory T cell dynamics.
Vaccine. 2024;42:126148.
PubMed Abstract available

ASUPOTO O, Li X, Hemberg JL, Emerson A, et al
COVID-19 and influenza vaccine uptake in women with criminal-legal system involvement.
Vaccine. 2024 Jul 30:126176. doi: 10.1016/j.vaccine.2024.126176.
PubMed Abstract available

ELYASS J, Desalegn A, Trinh NTH, Orangzeb S, et al
Individual and familial factors associated with mRNA COVID-19 vaccine uptake in pregnancy: A large-scale registry-based linkage study.
Vaccine. 2024 Jul 29:126171. doi: 10.1016/j.vaccine.2024.126171.
PubMed Abstract available

GE Y, Lu Y, Allen JD, Einav T, et al
Pre-existing immunity to influenza aids ferrets in developing stronger and broader H3 vaccine-induced antibody responses.
Vaccine. 2024 Jul 29:126149. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

TAHSIN A, Bhattacharjee P, Al Saba A, Yasmin T, et al
Genetic and epigenetic analyses of IFN-gamma gene proximal promoter region underlying positive correlation between persistently high anti-SARS-CoV-2 IgG and IFN-gamma among COVID-19 vaccinated Bangladeshi adults.
Vaccine. 2024 Jul 29:126157. doi: 10.1016/j.vaccine.2024.126157.
PubMed Abstract available

GEBRETEKLE GB, Yeung MW, Ximenes R, Cernat A, et al
Cost-effectiveness of RSVpreF vaccine and nirsevimab for the prevention of respiratory syncytial virus disease in Canadian infants.
Vaccine. 2024 Jul 29:126164. doi: 10.1016/j.vaccine.2024.126164.
PubMed Abstract available

WILLIS DE, Moore R, Selig JP, Shafeek Amin N, et al
Pediatric HPV vaccination: Provider recommendations matter among hesitant parents.
Vaccine. 2024 Jul 29:126166. doi: 10.1016/j.vaccine.2024.126166.
PubMed Abstract available

MOTAGHI S, Pullenayegum E, Morgan RL, Loeb M, et al
The role of influenza Hemagglutination-Inhibition antibody as a vaccine mediator in children.
Vaccine. 2024 Jul 28:126122. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

SULEMAN A, Vicente P
COVID-19 vaccination reluctance across Europe: Lessons for the future.
Vaccine. 2024 Jul 27:126168. doi: 10.1016/j.vaccine.2024.126168.
PubMed Abstract available

REN J, Huang Z, Tian J, Li Z, et al
Evaluation of pre-school pertussis booster vaccination in Shanghai, China: A cost-effectiveness analysis.
Vaccine. 2024 Jul 27:126162. doi: 10.1016/j.vaccine.2024.126162.
PubMed Abstract available

WILLIS DE, Moore R, Purvis RS, McElfish PA, et al
Hesitant but vaccinated: Lessons learned from hesitant adopters.
Vaccine. 2024 Jul 27:126135. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

JENA D, Ghosh A, Jha A, Prasad P, et al
Impact of vaccination on SARS-CoV-2 evolution and immune escape variants.
Vaccine. 2024 Jul 26:126153. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

ATAULLAHJAN A, Piche-Renaud PP, Shahrbabak EK, Fadaleh SA, et al
Weighing the risks and benefits: Parental perspectives on COVID-19 vaccines for 5- to 11-year-old children.
Vaccine. 2024 Jul 26:126154. doi: 10.1016/j.vaccine.2024.126154.
PubMed Abstract available

WILLIAMS LR, Emary KRW, Phillips DJ, Hay J, et al
Implementation and adherence to regular asymptomatic testing in a COVID-19 vaccine trial.
Vaccine. 2024 Jul 26:126167. doi: 10.1016/j.vaccine.2024.126167.
PubMed Abstract available

BILGIN GM, Munira SL, Lokuge K, Glass K, et al
Mathematical modelling of the 100-day target for vaccine availability after the detection of a novel pathogen: A case study in Indonesia.
Vaccine. 2024 Jul 26:126163. doi: 10.1016/j.vaccine.2024.126163.
PubMed Abstract available

KHANAFER N, Oudot S, Maligeay M, Planckaert C, et al
A quick access to information on influenza burden and prevention in Lyon university hospital: A prospective QR code-based information campaign in 2022-2023.
Vaccine. 2024 Jul 26:126160. doi: 10.1016/j.vaccine.2024.126160.
PubMed Abstract available

JIMENEZ-SEPULVEDA N, Gras-Valenti P, Chico-Sanchez P, Castro-Garcia JM, et al
Effectiveness of mRNA booster doses in preventing infections and hospitalizations due to SARS-CoV-2 and its dominant variant over time in Valencian healthcare workers, Spain.
Vaccine. 2024;42:4011-4021.
PubMed Abstract available

JOHNSTON C, Scheele S, Bachmann L, Boily MC, et al
Vaccine value profile for herpes simplex virus.
Vaccine. 2024;42.
PubMed Abstract available

MARTIN LB, Tack B, Marchello CS, Sikorski MJ, et al
Vaccine value profile for invasive non-typhoidal Salmonella disease.
Vaccine. 2024;42.
PubMed Abstract available

LAWAL S, St-Jean M, Hu Y, Bakos B, et al
Assessing sociodemographic disparities in HPV vaccine uptake among grade 6 and 9 students in the Vancouver Coastal Health region.
Vaccine. 2024 Jul 25:126147. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

SILVER ER, Fink L, Baylis KR, Faust RA, et al
Challenging the 'acceptable option': Public health's advocacy for continued care in the case of pediatric vaccine refusal.
Vaccine. 2024 Jul 23:126144. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

YAMEY G, McDade KK, Anderson RM, Bartsch SM, et al
Vaccine value profile for schistosomiasis.
Vaccine. 2024 Jul 23:126020. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

WAGENHAUSER I, Almanzar G, Forg FB, Stein A, et al
Heterologous and homologous COVID-19 mRNA vaccination schemes for induction of basic immunity show similar immunogenicity regarding long-term spike-specific cellular immunity in healthcare workers.
Vaccine. 2024 Jul 20:126132. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

ZOU GQ, Li K, Yan C, Li YQ, et al
Aluminum hydroxide and immunostimulatory glycolipid adjuvant combination for enhanced COVID-19 subunit vaccine immunogenicity.
Vaccine. 2024 Jul 20:126145. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

CAO Y, Hayashi CTH, Araujo MDS, Tripathi AK, et al
Evaluation of combination vaccines targeting transmission of Plasmodium falciparum and P. vivax.
Vaccine. 2024 Jul 19:126140. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

SANADA T, Honda T, Kohara M
Modeling of anti-spike IgG and neutralizing antibody waning after anti-SARS-CoV-2 mRNA vaccination.
Vaccine. 2024 Jul 19:126146. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

CHAU M, Kaufman J, Holland P, Danchin M, et al
Co-designing an intervention to improve the childhood catch-up vaccination process for migrant parents in Australia.
Vaccine. 2024 Jul 18:S0264-410X(24)00745-X. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

BAUER BU, Herms TL, Jahnke R, Ossowski N, et al
Control of Coxiella burnetii shedding in a dairy goat herd by annual offspring vaccination.
Vaccine. 2024 Jul 18:S0264-410X(24)00787-4. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

WASSIL J, Sisti M, Fairman J, Rankin B, et al
A phase 2, randomized, blinded, dose-finding, controlled clinical trial to evaluate the safety, tolerability, and immunogenicity of a 24-valent pneumococcal conjugate vaccine (VAX-24) in healthy adults 65 years and older.
Vaccine. 2024 Jul 17:S0264-410X(24)00786-2. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

ANDERSON S, Kuter BJ, Brien K, Bauerle Bass S, et al
Perceptions of vaccine requirements among students at four Pennsylvania universities.
Vaccine. 2024 Jul 17:S0264-410X(24)00801-6. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

JIN CHOI S, Lee W, Cheol Kim S, Jo HY, et al
Longitudinal multiomic profiling and corticosteroid modulation of the immediate innate immune response to an adenovirus-vector vaccine.
Vaccine. 2024 Jul 17:S0264-410X(24)00774-6. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

SANTIBANEZ TA, Black CL, Zhou T, Srivastav A, et al
Parental hesitancy about COVID-19, influenza, HPV, and other childhood vaccines.
Vaccine. 2024 Jul 16:S0264-410X(24)00802-8. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

HU TH, Tou CY, Lee YH, Chang HH, et al
Knowledge gap of human monkeypox among high-risk individuals receiving preexposure vaccination in Taiwan.
Vaccine. 2024 Jul 16:S0264-410X(24)00753-9. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

JIN F, Zhu L, Wang Y, Qin G, et al
Corrigendum to "Randomized, blind, controlled phase III clinical trial: Assessing the immunogenicity and safety of freeze-dried human rabies vaccine (vero cell) with a 4-dose regimen (2-1-1) in a 10-60 year-old demographic" [Vaccine (2024) 26059].
Vaccine. 2024 Jul 16:S0264-410X(24)00791-6. doi: 10.1016/j.vaccine.2024.
PubMed

LIU G, Pang Y, Lv M, Lu M, et al
Effectiveness of influenza vaccination on hospitalization outcomes among older patients with diabetes.
Vaccine. 2024 Jul 16:S0264-410X(24)00806-5. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

STEENACKERS K, Hanning N, Bruckers L, Desombere I, et al
Humoral immune response against SARS-CoV-2 after adapted COVID-19 vaccine schedules in healthy adults: The IMCOVAS randomized clinical trial.
Vaccine. 2024 Jul 16:S0264-410X(24)00773-4. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

LUNA-MUSCHI A, Carmo Borges I, Dos Santos Barboza A, de Faria E, et al
Duration of vaccine protection against breakthrough infections during five COVID-19 waves among healthcare workers primarily vaccinated with CoronaVac.
Vaccine. 2024 Jul 16:S0264-410X(24)00752-7. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

TAKAHASHI Y, Tanaka H, Taniguchi C, Ogata T, et al
Efficiency of indirect protection of COVID-19 vaccination and interactions between indirect and direct protection on household transmission.
Vaccine. 2024 Jul 16:S0264-410X(24)00749-7. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

HATFIELD K, Wiegand R, Reddy S, Patel A, et al
Effectiveness of COVID-19 bivalent vaccination against SARS-CoV-2 infection among residents of US nursing homes, November 2022 - March 2023.
Vaccine. 2024 Jul 16:S0264-410X(24)00754-0. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

ALTAWALBEH SM, Wateska AR, Patricia Nowalk M, Lin CJ, et al
Corrigendum to "Cost-effectiveness of an in-development adult-formulated 21-valent pneumococcal conjugate vaccine in US adults aged 50 years or older" [Vaccine 42 (2024) 3024-3032].
Vaccine. 2024 Jul 15:S0264-410X(24)00789-8. doi: 10.1016/j.vaccine.2024.
PubMed

STEFANIZZI P, Di Lorenzo A, Capodiferro L, Moscara L, et al
Increasing vaccination coverage among healthcare workers: Active call and mandatory laws. Data from a large general hospital in Southern Italy.
Vaccine. 2024 Jul 15:S0264-410X(24)00739-4. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

FISMAN DN, Simmons AE, Tuite AR
Case-cohort design as an efficient approach to evaluating COVID-19 vaccine effectiveness, waning, heterologous immune effect and optimal dosing interval.
Vaccine. 2024 Jul 13:S0264-410X(24)00797-7. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

JAJOU R, Lieber T, van Puijenbroek EP, Mulder E, et al
GP consultations for menstrual disorders after COVID-19 vaccination - A self-controlled cohort study based on routine healthcare data from the Netherlands.
Vaccine. 2024 Jul 13:S0264-410X(24)00793-X. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

DULL PM, Achilles SL, Ahmed R, Barnabas RV, et al
Meeting report: Considerations for trial design and endpoints in licensing therapeutic HPV16/18 vaccines to prevent cervical cancer.
Vaccine. 2024 Jul 13:S0264-410X(24)00741-2. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

VERANI JR, Omondi D, Odoyo A, Odiembo H, et al
Long-term impact of 10-valent pneumococcal conjugate vaccine in Kenya: Nasopharyngeal carriage among children in a rural and an urban site six years after introduction.
Vaccine. 2024 Jul 13:S0264-410X(24)00782-5. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

MIAO Q, Nguyen W, Zhu J, Liu G, et al
A getah virus-like-particle vaccine provides complete protection from viremia and arthritis in wild-type mice.
Vaccine. 2024 Jul 13:S0264-410X(24)00799-0. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

LE BAGOUSSE-BERNARD A, Dussart C, Pin P, Tazarourte K, et al
Mass COVID-19 vaccination center: Optimizing the vaccination pathway during a 12 month timeframe.
Vaccine. 2024 Jul 12:S0264-410X(24)00742-4. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

HUANG WT, Law B, Tran H, Schonborn L, et al
Validation of the newly proposed Brighton Collaboration case definition for vaccine-induced immune thrombocytopenia and thrombosis.
Vaccine. 2024 Jul 12:S0264-410X(24)00794-1. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

DANELIAN G, Burton L, Bayley T, Sanchez-Marroquin A, et al
The impact and cost-effectiveness of pneumococcal immunisation strategies for the elderly in England.
Vaccine. 2024;42:3838-3850.
PubMed Abstract available

AGARWAL S, Harsukhbhai Chandpa H, Naskar S, Lal Meena C, et al
Dominant B cell-T cell epitopes instigated robust immune response in-silico against Scrub Typhus.
Vaccine. 2024;42:3899-3915.
PubMed Abstract available

BUCHHORN DE FREITAS S, Clair Pinto Seixas Neto A, Aparecido Panagio L, Pereira Soares M, et al
Hypothetical adhesin CAM87009.1 formulated in alum or biogenic silver nanoparticles protects mice from lethal infection by multidrug-resistant Acinetobacter baumannii.
Vaccine. 2024;42:3802-3810.
PubMed Abstract available

LI J, Gong L, Li J, Gong Z, et al
Low neutralization of SARS-CoV-2 Omicron BA.5.2.48 and XBB.1 sub-variants in response to breakthrough infection by booster.
Vaccine. 2024;42:3751-3755.
PubMed Abstract available

SARTORI AL, Buffarini R, Machado da Silva A, Amaral de Andrade Leao O, et al
Child COVID-19 vaccine uptake among participants of the 2015 Pelotas (Brazil) Birth Cohort Study.
Vaccine. 2024 Jul 11:S0264-410X(24)00746-1. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

LAMBACH P, Silal S, Sbarra AN, Koh M, et al
Corrigendum to "Report from the World Health Organization's immunization and vaccines-related implementation research advisory committee (IVIR-AC) meeting, virtual gathering, 26 February-1 March 2024" [Vaccine 42(15) (2024) 3379-3383].
Vaccine. 2024 Jul 11:S0264-410X(24)00743-6. doi: 10.1016/j.vaccine.2024.
PubMed

HOEVE CE, Huiberts AJ, de Gier B, Andeweg SP, et al
COVID-19 vaccination-induced antibody responses and waning by age and comorbidity status in a large population-based prospective cohort study.
Vaccine. 2024 Jul 11:S0264-410X(24)00783-7. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

MILLER E, Michel A, Singh P, Limaye R, et al
Countering vaccine misinformation: Designing a learning resource for healthcare workers in eight countries.
Vaccine. 2024 Jul 11:S0264-410X(24)00732-1. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

GARCIA S, Shin M, Gill M, He Z, et al
Identifying the intersection of parental HPV and COVID-19 vaccine hesitancy to inform health messaging interventions in community-based settings.
Vaccine. 2024 Jul 11:S0264-410X(24)00792-8. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

BOLIO A, Waheed DE, Mugo N, Garland SM, et al
Overview of CHIC symposia series: Summary of Africa and South Asia symposia.
Vaccine. 2024;42 Suppl 2:S9-S15.
PubMed Abstract available

NDIAYE C, Kyesi F, Masupha T, Ranyali M, et al
Integrating HPV vaccine service delivery with adolescent health programmes - Experiences and perspectives from selected countries in Africa.
Vaccine. 2024;42 Suppl 2:S45-S48.
PubMed Abstract available

SIDIBE A, Kouassi KS, Ekra D, Bloem P, et al
Accelerating and broadening multisectoral partnerships for introducing and rebuilding HPV vaccination programmes.
Vaccine. 2024;42 Suppl 2:S41-S44.
PubMed

WAHEED DE, Bolio A, Kyesi F, Miano CW, et al
Routine HPV vaccination: Reflection on delivery strategies based on countries' experiences.
Vaccine. 2024;42 Suppl 2:S37-S40.
PubMed Abstract available

KOUASSI KS, Chisupa E, Clarke A, Massenon I, et al
Pandemic-related resilience in HPV vaccination programmes - Perspectives from selected countries in Africa on what it will take to vaccinate 90 % of girls by 2030.
Vaccine. 2024;42 Suppl 2:S33-S36.
PubMed Abstract available

NJOGU R, Deb Roy A, Bagudu Z, Borda H, et al
Effective communication by health care workers to promote HPV vaccination: Lessons learned from Kenya, India, and Nigeria.
Vaccine. 2024;42 Suppl 2:S27-S32.
PubMed Abstract available

WAHEED DE, Mumba M, Alfred D, Bogale M, et al
Identifying key challenges and optimizing approaches for training of health care professionals for HPV vaccination programmes.
Vaccine. 2024;42 Suppl 2:S22-S26.
PubMed Abstract available

STANLEY M, Schuind A, Muralidharan KK, Guillaume D, et al
Evidence for an HPV one-dose schedule.
Vaccine. 2024;42 Suppl 2:S16-S21.
PubMed Abstract available

BORDA H, Bloem P, Akaba H, Guillaume D, et al
Status of HPV disease and vaccination programmes in LMICs: Introduction to special issue.
Vaccine. 2024;42 Suppl 2:S1-S8.
PubMed Abstract available

GHARPURE R, Longley AT, Takamiya M, Hidle A, et al
Typhoid conjugate vaccine perceptions and coverage among children and adults: Findings from a post-campaign coverage survey - Harare, Zimbabwe, 2019.
Vaccine. 2024 Jul 10:S0264-410X(24)00727-8. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

WEITZMAN ER, Pierce SE, Blakemore LM, Murdock A, et al
Need for strategic communications and stakeholder engagement to advance acceptability of an overdose preventing vaccine targeting fentanyl.
Vaccine. 2024 Jul 10:S0264-410X(24)00722-9. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

ZOU M, Lei C, Huang D, Liu L, et al
Application of plant-derived products as adjuvants for immune activation and vaccine development.
Vaccine. 2024 Jul 9:S0264-410X(24)00756-4. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

SANCHEZ-GONZALEZ G, Luna-Casas G, Mascarenas C, Macina D, et al
Corrigendum to "Pertussis in Mexico from 2000 to 2019: A real-world study of incidence, vaccination coverage, and vaccine effectiveness" [Vaccine 41(41) (2023) 6105-6111].
Vaccine. 2024 Jul 8:S0264-410X(24)00726-6. doi: 10.1016/j.vaccine.2024.
PubMed

JITENDER, Vikram Kumar B, Singh S, Verma G, et al
Mammalian cell expressed recombinant trimeric spike protein is a potent vaccine antigen and confers near-complete protection against SARS-CoV-2 infection in Hamster.
Vaccine. 2024 Jul 8:S0264-410X(24)00740-0. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

BANG JY, Kim YJ, Seo YJ, Hong SH, et al
Reduced cell-mediated immune response in hyperglycemic NOD mice following influenza vaccination.
Vaccine. 2024 Jul 8:S0264-410X(24)00757-6. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

KORCHINSKI I, Marquez C, McClymont E, Av-Gay G, et al
Maternal-infant transfer of SARS-CoV-2 antibodies following vaccination in pregnancy: A prospective cohort study.
Vaccine. 2024 Jul 8:S0264-410X(24)00785-0. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

WACHINGER J, Renosa MDC, Endoma V, Landicho-Guevarra J, et al
Routines, disruptions, revised decisions: A biographical analysis of vaccination trajectories among Filipino caregivers.
Vaccine. 2024 Jul 6:S0264-410X(24)00736-9. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

ARAUJO-CHAVERON L, Olivier C, Pellissier G, Bouvet E, et al
Analyzing the 7C psychological antecedents of vaccine acceptance throughout the COVID-19 pandemic among healthcare sector workers in France: A repeated cross-sectional study (CappVac-Cov).
Vaccine. 2024 Jul 6:S0264-410X(24)00744-8. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

LANIECE DELAUNAY C, Melo A, Maurel M, Mazagatos C, et al
Corrigendum to "Effectiveness of COVID-19 vaccines administered in the 2023 autumnal campaigns in Europe: results from the VEBIS primary care test-negative design study, September 2023-January 2024" [Vaccine 42(19) (2024)].
Vaccine. 2024 Jul 5:S0264-410X(24)00730-8. doi: 10.1016/j.vaccine.2024.
PubMed

NOWALK MP, Smith KJ, Raviotta JM, Wateska A, et al
Cost-effectiveness of recombinant influenza vaccine compared with standard dose influenza vaccine in adults 18-64 years of age.
Vaccine. 2024 Jul 5:S0264-410X(24)00748-5. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

MESHRAM R, Kolte B, Gacche R
Reverse vaccinology approach for identification of epitopes from E1 protein as peptide vaccine against HCV: A proof of concept.
Vaccine. 2024 Jul 5:S0264-410X(24)00747-3. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

KOUTSOUMPLI G, Stasiukonyte N, Hoogeboom BN, Daemen T, et al
An in vitro CD8 T-cell priming assay enables epitope selection for hepatitis C virus vaccines.
Vaccine. 2024 Jul 3:S0264-410X(24)00659-5. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

KAFADAR AH, Sabatini S, Jones KA, Dening T, et al
Categorising interventions to enhance vaccine uptake or reduce vaccine hesitancy in the United Kingdom: A systematic review and meta-analysis.
Vaccine. 2024 Jul 2:S0264-410X(24)00733-3. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

ZHANG D, Jiang Y, Wang M, Zhao J, et al
A novel costimulatory molecule gene-modified leukemia cell-derived exosome enhances the anti-leukemia efficacy of DC vaccine in mouse models.
Vaccine. 2024 Jul 2:S0264-410X(24)00738-2. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

HOULE SKD, Waite NM, Vernon-Wilson E, Dolovich L, et al
Uptake and outcomes of VaxCheck, an adult life-course vaccination service: A study among community pharmacists.
Vaccine. 2024 Jul 1:S0264-410X(24)00737-0. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

June 2024

GAO H, Zhang S, Chang H, Guo Y, et al
Generation of a novel attenuated IBDV vaccine strain by mutation of critical amino acids in IBDV VP5.
Vaccine. 2024 Jun 28:S0264-410X(24)00723-0. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

ROOZEN GVT, Granger A, van Binnendijk RS, den Hartog G, et al
Intradermal fractional dose vaccination as a method to vaccinate individuals with suspected allergy to mRNA COVID-19 vaccines.
Vaccine. 2024 Jun 28:S0264-410X(24)00734-5. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

BHELLA S, Wilkin AM, Hueniken K, Vijenthira A, et al
COVID-19 vaccine immunogenicity and safety surrounding fourth and subsequent vaccine doses in patients with hematologic malignancies.
Vaccine. 2024 Jun 28:S0264-410X(24)00715-1. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

PLEY C, Kampmann B
Opportunities and challenges to the development and deployment of vaccines for pregnant women in Germany.
Vaccine. 2024 Jun 28:S0264-410X(24)00735-7. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

KELLY JA, Walsh JL, Quinn K, Amirkhanian YA, et al
Factors predicting primary and booster COVID-19 vaccination in a community sample of African American men and women in the United States Midwest.
Vaccine. 2024 Jun 27:S0264-410X(24)00729-1. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

JIN F, Zhu L, Wang Y, Qin G, et al
Randomized, blind, controlled phase III clinical trial: Assessing the immunogenicity and safety of freeze-dried human rabies vaccine (vero cell) with a 4-dose regimen (2-1-1) in a 10-60 year-old demographic.
Vaccine. 2024 Jun 26:S0264-410X(24)00700-X. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

GUTIERREZ MP, Huckaby AB, Yang E, Weaver KL, et al
Antibody-mediated immunological memory correlates with long-term Lyme veterinary vaccine protection in mice.
Vaccine. 2024 Jun 26:S0264-410X(24)00725-4. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

COULIBALY D, Douba A, N'Guessan K, N'Gattia AK, et al
Intent to receive flu vaccine and influenza vaccination coverage among health professionals during 2019, 2020 and 2021 campaigns in Cote d'Ivoire.
Vaccine. 2024 Jun 25:S0264-410X(24)00717-5. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

YOO YM, Katz MA, Greenberg D, Marcenac P, et al
Knowledge, attitudes, and practices associated with influenza vaccine uptake among healthcare personnel in Israel during three influenza seasons, 2016-2019.
Vaccine. 2024 Jun 25:S0264-410X(24)00705-9. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

HUSSEIN I, Mohamud H, Hussein A, Luomala O, et al
"If the nurse tells me this is a good thing, I trust her completely" - Exploring health system enablers of MMR vaccine uptake in the Finnish Somali community: A mixed method study.
Vaccine. 2024 Jun 25:S0264-410X(24)00728-X. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

VIANNA CM, Noronha TG, Camacho LAB, Andrade RC, et al
Duration of post-vaccination immunity to yellow fever in volunteers ten years after a dose-response study - A complementary study.
Vaccine. 2024 Jun 25:S0264-410X(24)00724-2. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

CHATZILENA A, Hyams C, Challen R, Marlow R, et al
Winter 2022-23 influenza vaccine effectiveness against influenza-related hospitalised aLRTD: A test-negative, case-control study.
Vaccine. 2024 Jun 24:S0264-410X(24)00713-8. doi: 10.1016/j.vaccine.2024.
PubMed

LE GARS M, Sadoff J, Cardenas V, Heerwegh D, et al
Safety, reactogenicity, and immunogenicity of Ad26.COV2.S as homologous or heterologous COVID-19 booster vaccination: Results of a randomized, double-blind, phase 2 trial.
Vaccine. 2024 Jun 24:S0264-410X(24)00401-8. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

LIN M, Deng JZ, Scapin G, Yuan Y, et al
Quantitation and characterization of serotype 6A activation for pneumococcal conjugate vaccine by cryo-EM and SEC methods.
Vaccine. 2024 Jun 24:S0264-410X(24)00709-6. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

HELARY A, Botelho-Nevers E, Bonneton M, Khennouf L, et al
Factors, motivations and barriers associated with eagerness to volunteer in COVID-19 vaccine clinical trials in France: A mixed-method study.
Vaccine. 2024 Jun 22:S0264-410X(24)00662-5. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

FITZPATRICK T, Yamoah P, Lacuesta G, Sadarangani M, et al
Revaccination outcomes among adolescents and adults with suspected hypersensitivity reactions following COVID-19 vaccination: A Canadian immunization research network study.
Vaccine. 2024 Jun 22:S0264-410X(24)00719-9. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

RIMAL RN, Ganjoo R, Jamison A, Parida M, et al
Social norms, vaccine confidence, and interpersonal communication as predictors of vaccination intentions: Findings from slum areas in Varanasi, India.
Vaccine. 2024 Jun 21:S0264-410X(24)00666-2. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

POVEDA-URKIXO I, Mena-Bueno S, Ramirez GA, Zabalza-Barangua A, et al
Brucella melitensis Rev1Deltawzm: Placental pathogenesis studies and safety in pregnant ewes.
Vaccine. 2024;42:3710-3720.
PubMed Abstract available

MCDERMID P, Abdi I, Mustafa K, Blazek K, et al
Examining the influence of community leaders and other community actors on immunisation practices in Australia: A national cross-sectional study.
Vaccine. 2024;42:3647-3654.
PubMed Abstract available

PISCHEL L, Martini BA, Yu N, Cacesse D, et al
Vaccine effectiveness of 3rd generation mpox vaccines against mpox and disease severity: A systematic review and meta-analysis.
Vaccine. 2024 Jun 20:S0264-410X(24)00694-7. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

CHU X, Ge S, Zuo Y, Cui J, et al
Thoughts on the research of African swine fever live-attenuated vaccines.
Vaccine. 2024 Jun 20:S0264-410X(24)00693-5. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

ZHANG X, Monnat SM
Watchful, skeptics, and system distrusters: Characteristics associated with different types of COVID-19 vaccine hesitancy among U.S. working-age adults.
Vaccine. 2024 Jun 19:S0264-410X(24)00721-7. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

CARLSON CJ, Garnier R, Tiu A, Luby SP, et al
Strategic vaccine stockpiles for regional epidemics of emerging viruses: A geospatial modeling framework.
Vaccine. 2024 Jun 19:S0264-410X(24)00690-X. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

CARLOS GUILLERMO B, Tomas Alberto O, Julio I
First vaccine confidence and access index in Argentina: Comparison of results from 2019 to 2022.
Vaccine. 2024 Jun 19:S0264-410X(24)00711-4. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

AHMED T, Tauheed I, Hoque S, Sarower Bhuyan G, et al
A phase 3 non-inferiority trial of locally manufactured Meningococcal ACWY vaccine 'Ingovax ACWY' among Bangladeshi adults.
Vaccine. 2024 Jun 18:S0264-410X(24)00704-7. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

CHICHILI GR, Smulders R, Santos V, Cywin B, et al
Corrigendum to "Phase 1/2 study of a novel 24-valent pneumococcal vaccine in healthy adults aged 18 to 64 years and in older adults aged 65 to 85 years" [Vaccine 40 (2002) 4190-4198].
Vaccine. 2024 Jun 18:S0264-410X(24)00650-9. doi: 10.1016/j.vaccine.2024.
PubMed

HOPKINS KL, Lihemo G, Underwood T, Sommers T, et al
The second annual Vaccination Acceptance Research Network Conference (VARN2023): Shifting the immunization narrative to center equity and community expertise.
Vaccine. 2024 Jun 18:S0264-410X(24)00655-8. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

CHENG TM, Chen YS, Wei KC, Chang YC, et al
Assessment of the herpes zoster risk among renal transplant recipients administered the influenza vaccine.
Vaccine. 2024 Jun 18:S0264-410X(24)00716-3. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

LAEMMLE-RUFF I, Morgan HJ, Harris A, Abruzzo V, et al
Guillain-Barre syndrome temporally associated with COVID-19 vaccines - Progress over time.
Vaccine. 2024 Jun 17:S0264-410X(24)00714-X. doi: 10.1016/j.vaccine.2024.
PubMed

YAZDAN PANAH M, Vaheb S, Mokary Y, Afshari-Safavi A, et al
Comparing the consequences of COVID-19 vaccination between central nervous system (CNS) demyelinating diseases and other neurological disorders.
Vaccine. 2024 Jun 16:S0264-410X(24)00702-3. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

FERM J, Jaworski DC, Stoll I, Kleinhenz MD, et al
Genetically modified live vaccine offers protective immunity against wild-type Anaplasma marginale tick-transmission challenge.
Vaccine. 2024 Jun 15:S0264-410X(24)00710-2. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

DESLAURIERS F, Hoq M, Kaufman J, Enticott J, et al
Comparison of parent-reported motivators of non-vaccination for children 5-11 years old in Australia and Canada: Results of the iCARE study.
Vaccine. 2024 Jun 15:S0264-410X(24)00698-4. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

WALTENBURG MA, Kainulainen MH, Whitesell A, Nyakarahuka L, et al
Knowledge, attitudes, and practices and long-term immune response after rVSVDeltaG-ZEBOV-GP Ebola vaccination in healthcare workers in high-risk districts in Uganda.
Vaccine. 2024 Jun 15:S0264-410X(24)00658-3. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

GUL C, Gul A, Karakavuk T, Erkunt Alak S, et al
A novel DNA vaccine encoding the SRS13 protein administered by electroporation confers protection against chronic toxoplasmosis.
Vaccine. 2024 Jun 15:S0264-410X(24)00706-0. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

JIANG X, Wang J, Li C, Yeoh EK, et al
Relationship between parental acceptance of the COVID-19 vaccine and attitudes towards measles vaccination for children: A cross-sectional study.
Vaccine. 2024 Jun 15:S0264-410X(24)00708-4. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

REY-ARES L, Ta A, Freigofaite D, Warren S, et al
Cost-effectiveness analysis of the pediatric 20-valent pneumococcal conjugate vaccine compared with lower-valent alternatives in Argentina.
Vaccine. 2024 Jun 14:S0264-410X(24)00670-4. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

TING DK, Rosychuk RJ, Hau JP, Righolt CH, et al
Leveraging a clinical emergency department dataset to estimate two-dose COVID-19 vaccine effectiveness and duration of protection in Canada.
Vaccine. 2024 Jun 14:S0264-410X(24)00699-6. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

SONG T, Cao F, Huang X, Wu S, et al
Augmenting vaccine efficacy: Tailored immune strategy with alum-stabilized Pickering emulsion.
Vaccine. 2024 Jun 13:S0264-410X(24)00649-2. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

WHITE MC, Osazuwa-Peters OL, Abouelella DK, Barnes JM, et al
Trends and factors associated with receipt of human papillomavirus (HPV) vaccine in private, public, and alternative settings in the United States.
Vaccine. 2024 Jun 13:S0264-410X(24)00663-7. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

DAVEY SA, Hampson C, Christodoulaki ME, Gaffiero D, et al
Investigating the predictors of COVID-19 vaccine decision-making among parents of children aged 5-11 in the UK.
Vaccine. 2024 Jun 13:S0264-410X(24)00646-7. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

HASSO-AGOPSOWICZ M, Sparrow E, Cameron AM, Sati H, et al
The role of vaccines in reducing antimicrobial resistance: A review of potential impact of vaccines on AMR and insights across 16 vaccines and pathogens.
Vaccine. 2024 Jun 13:S0264-410X(24)00676-5. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

CARDOSO N, Eschbaumer M, Capozzo AV
An IgG1 single-dilution avidity ELISA predicts cross-protection against heterologous foot-and-mouth disease virus challenge after vaccination.
Vaccine. 2024 Jun 13:S0264-410X(24)00707-2. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

EMILIE HARTVIG RASMUSSEN C, Odgaard Vedel J, Moller Jensen A, Da Silva Borges I, et al
Implementation of the vaccination program in Guinea-Bissau: Coverage and missed opportunities for BCG at birth.
Vaccine. 2024 Jun 12:S0264-410X(24)00697-2. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

QUIROGA R, Gastellu S, Fernandez B, Ottaviani R, et al
The impact of COVID-19 childhood and adolescent vaccination on mortality in Argentina.
Vaccine. 2024 Jun 12:S0264-410X(24)00665-0. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

CARDENAS V, Le Gars M, Truyers C, Ruiz-Guinazu J, et al
Safety and immunogenicity of Ad26.COV2.S in adults: A randomised, double-blind, placebo-controlled Phase 2a dose-finding study.
Vaccine. 2024;42:3536-3546.
PubMed Abstract available

SHERMAN AC, van Haren SD, Borberg E, Swank Z, et al
Heterologous SARS-CoV-2 booster vaccine for individuals with hematological malignancies after a primary SARS-CoV-2 mRNA vaccine series.
Vaccine. 2024 Jun 10:S0264-410X(24)00695-9. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

MANANDHAR P, Katz J, Lama TP, Khatry SK, et al
COVID-19 vaccine hesitancy, trust, and communication in Sarlahi District, Nepal.
Vaccine. 2024 Jun 10:S0264-410X(24)00661-3. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

HOFFMAN E, Kahan T, Auerbach E, Brody H, et al
Peer education as a strategy to promote vaccine acceptance: A randomized controlled trial within New York community healthcare practices.
Vaccine. 2024 Jun 10:S0264-410X(24)00654-6. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

OTSUKI T, Akada S, Anami A, Kosaka K, et al
Efficacy and safety of bivalent RSVpreF maternal vaccination to prevent RSV illness in Japanese infants: Subset analysis from the pivotal randomized phase 3 MATISSE trial.
Vaccine. 2024 Jun 8:S0264-410X(24)00668-6. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

BRADY K, Lee A, Bassler J, Young Pierce J, et al
Human papillomavirus vaccine beliefs and intentions Post-COVID-19 vaccine release among mothers in Alabama.
Vaccine. 2024 Jun 8:S0264-410X(24)00673-X. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

BADLIS S, Yu H, Klusaritz H, S L Tan A, et al
Engaging Trusted Messengers to Increase COVID-19 Pediatric Vaccine Uptake in Philadelphia: Lessons from the VaxUpPhillyFamilies program.
Vaccine. 2024 Jun 8:S0264-410X(24)00664-9. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

SRITIPSUKHO P, Sinlapamongkolkul P, Satdhabudha A, Chaiyakulsil C, et al
Immunogenicity during 6 months after SARS-CoV-2 infection is significantly different depending on previous COVID-19 vaccine regimens and a booster dose received.
Vaccine. 2024 Jun 7:S0264-410X(24)00652-2. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

R MUGALI R, Ip H, Zikusooka A, Vong L, et al
Striving for equitable vaccination coverage: Leveraging rapid coverage and community assessments during the COVID-19 pandemic to reach missed populations in Cambodia.
Vaccine. 2024 Jun 7:S0264-410X(24)00642-X. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

JAYAWARDANA S, Esquivel M, Oreskovic T, Mossialos E, et al
Gender differences in COVID-19 preventative measures and vaccination rates in the United States: A longitudinal survey analysis.
Vaccine. 2024 Jun 7:S0264-410X(24)00671-6. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

DE POUVOURVILLE G, Guyot E, Farge G, Belhassen M, et al
Human Papillomavirus (HPV) vaccination coverage among French adolescents: A claims data study.
Vaccine. 2024 Jun 7:S0264-410X(24)00667-4. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

VILLENA R, Izquierdo G, Wilhelm J, Garcia C, et al
Dynamics of multisystem inflammatory syndrome in children associated to COVID-19 in Chile: Epidemiologic trends during pandemic, before and after children vaccination.
Vaccine. 2024 Jun 7:S0264-410X(24)00640-6. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

YOUNES S, Nicolai E, Younes N, Pieri M, et al
Comparable antibody levels in heterologous and homologous mRNA COVID-19 vaccination, with superior neutralizing and IgA antibody responses in mRNA homologous boosting.
Vaccine. 2024 Jun 5:S0264-410X(24)00669-8. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

KANG DW, June Choe Y, Lee JY, Suk IA, et al
Cost-effectiveness analysis of the 20-valent pneumococcal conjugate vaccine for the pediatric population in South Korea.
Vaccine. 2024 Jun 5:S0264-410X(24)00616-9. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

LANIECE DELAUNAY C, Melo A, Maurel M, Mazagatos C, et al
Effectiveness of COVID-19 vaccines administered in the 2023 autumnal campaigns in Europe: Results from the VEBIS primary care test-negative design study, September 2023-January 2024.
Vaccine. 2024 Jun 4:S0264-410X(24)00644-3. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

KAWASUJI H, Morinaga Y, Tani H, Yamada H, et al
Low pre-infection levels of neutralizing antibody in breakthrough infections after bivalent BA.4-5 vaccine and practical application of dried blood spots.
Vaccine. 2024 Jun 4:S0264-410X(24)00656-X. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

GOBIN S, Sahakyan G, Kusi Appiah M, Manukyan A, et al
Costs of in- and outpatient respiratory disease and the seasonal influenza vaccination program in Armenia - 2020-2021.
Vaccine. 2024 Jun 4:S0264-410X(24)00623-6. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

FENG J, Du Y, Chen L, Su W, et al
A quadrivalent recombinant influenza Hemagglutinin vaccine induced strong protective immune responses in animal models.
Vaccine. 2024 Jun 3:S0264-410X(24)00624-8. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

FABIANI M, Mateo-Urdiales A, Sacco C, Fotakis EA, et al
Effectiveness against severe COVID-19 of a seasonal booster dose of bivalent (original/Omicron BA.4-5) mRNA vaccines in persons aged >/=60 years: Estimates over calendar time and by time since administration during prevalent circulation of different O
Vaccine. 2024 Jun 3:S0264-410X(24)00653-4. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

QUIAMBAO BP, Payumo RA, Roa C, Borja-Tabora CF, et al
A phase 2b, Randomized, double blinded comparison of the safety and efficacy of the monoclonal antibody mixture SYN023 and human rabies immune globulin in patients exposed to rabies.
Vaccine. 2024 Jun 3:S0264-410X(24)00643-1. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

BEJKO D, Ernst C, Vergison A, Stranges S, et al
High vaccine effectiveness against severe COVID-19 outcomes and population preventable fraction during the Omicron era in Luxembourg: A nationwide retrospective risk factor analysis.
Vaccine. 2024 Jun 1:S0264-410X(24)00636-4. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

May 2024

KUPEK E
Avoidable COVID-19-related deaths and hospitalizations in Brazil, 2020-2023.
Vaccine. 2024;42:3437-3444.
PubMed Abstract available

WOLFSCHMIDT-FIETKAU A, Goertz RS, Goertzen S, Schmid K, et al
Immunity against vaccine-preventable diseases among pregnant employees in Germany. A situation analysis before the introduction of the Measles Protection Act.
Vaccine. 2024 May 31:S0264-410X(24)00604-2. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

HE Q, Chen Y, Li Y, Cheng X, et al
Single immunization of non-adjuvanted recombinant TTFC-mi3 nanoparticle vaccine elicited a rapid and potent protective immunity against tetanus.
Vaccine. 2024 May 31:S0264-410X(24)00583-8. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

EDOKA I, Silal S, Jamieson L, Meyer-Rath G, et al
A cost-effectiveness analysis of South Africa's COVID-19 vaccination programme.
Vaccine. 2024 May 31:S0264-410X(24)00595-4. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

COMER D, Warner NZ, Noone C
Human PapillomaVirus vaccination in gay and bi men: Predictors, dynamic norms, and connectedness to the LGBT+ community.
Vaccine. 2024 May 31:S0264-410X(24)00639-X. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

MANSFIELD LN, Kahn BZ, Kokitkar S, Kritikos KI, et al
HPV vaccine standing orders and communication in primary care: A qualitative study.
Vaccine. 2024 May 29:S0264-410X(24)00554-1. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

NAKASE T, Brownwright T, Okunromade O, Egwuenu A, et al
The impact of sub-national heterogeneities in demography and epidemiology on the introduction of rubella vaccination programs in Nigeria.
Vaccine. 2024 May 28:S0264-410X(24)00589-9. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

LUO H, Ma Y, Bi J, Li Z, et al
Experimental and molecular dynamics simulation studies on the physical properties of three HBc-VLP derivatives as nanoparticle protein vaccine candidates.
Vaccine. 2024 May 28:S0264-410X(24)00599-1. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

BATOOL R, Yousafzai MT, Mir F, Muhammad S, et al
Longevity of serologic responses following a single dose of typhoid conjugate vaccine among children living with HIV in Pakistan: A prospective cohort study.
Vaccine. 2024 May 28:S0264-410X(24)00625-X. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

BEGUM T, Efstathiou N, Bailey C, Guo P, et al
Cultural and social attitudes towards COVID-19 vaccination and factors associated with vaccine acceptance in adults across the globe: A systematic review.
Vaccine. 2024 May 27:S0264-410X(24)00600-5. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

EOM J, Kim Y, Kim D, Lee E, et al
Cost-benefit analysis of human adenovirus vaccine development in a Korean military setting.
Vaccine. 2024 May 27:S0264-410X(24)00622-4. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

MENA-BUENO S, Garrido V, Romero F, Zabalza-Barangua A, et al
Rev1Deltawzm vaccine candidate is safe in young and adult sheep and protects against Brucella ovis infection in rams.
Vaccine. 2024 May 27:S0264-410X(24)00605-4. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

LUSTIG Y, Barda N, Weiss-Ottolenghi Y, Indenbaum V, et al
Humoral response superiority of the monovalent XBB.1.5 over the bivalent BA.1 and BA.5 mRNA COVID-19 vaccines.
Vaccine. 2024 May 27:S0264-410X(24)00635-2. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

VASHIST K, Yankey D, Elam-Evans LD, Mu Y, et al
Changes in vaccine hesitancy among parents of children aged 6 months - 17 Years, National Immunization Surveys, 2019-2022.
Vaccine. 2024 May 27:S0264-410X(24)00596-6. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

RENDUCHINTALA K, Arevalo M, Fonseca G, Haver MK, et al
Vaccination uptake among post-treatment cancer survivors: A multi-vaccine scoping review.
Vaccine. 2024 May 27:S0264-410X(24)00602-9. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

TREHARNE A, Patel Murthy B, Zell ER, Jones-Jack N, et al
Impact of the COVID-19 pandemic on routine childhood vaccination in 9 U.S. jurisdictions.
Vaccine. 2024 May 25:S0264-410X(24)00603-0. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

DOHERTY K, Bonnett L, Agbla SC, Beveridge NER, et al
The effectiveness of revaccination with pneumococcal polysaccharide vaccine for preventing pneumococcal disease in older adults in England: A population-based cohort study.
Vaccine. 2024 May 24:S0264-410X(24)00618-2. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

OKOLI GN, Neilson CJ, Grossman Moon A, Kimmel Supron H, et al
Exploration of individual socioeconomic and health-related characteristics associated with human papillomavirus vaccination initiation and vaccination series completion among adult females: A comprehensive systematic evidence review with meta-analysis
Vaccine. 2024 May 24:S0264-410X(24)00601-7. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

LYNETTE EJEZIE C, Cuccaro P, Savas LS, Shegog R, et al
Regional differences in provider recommendation of HPV vaccines among 13-to-17 year old adolescents from 2019 to 2021.
Vaccine. 2024 May 24:S0264-410X(24)00581-4. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

WU JY, Zhang W, Pu J, Liu Y, et al
A randomized, double-blind, placebo-controlled phase I clinical trial of rotavirus inactivated vaccine (Vero cell) in a healthy adult population aged 18-49 years to assess safety and preliminary observation of immunogenicity.
Vaccine. 2024 May 24:S0264-410X(24)00559-0. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

BAK J, Hasan Q, Kissa J, Mere MO, et al
Deployment of COVID-19 vaccine in the WHO Eastern Mediterranean Region 2021-23: How do we switch to a life course approach?
Vaccine. 2024 May 24:S0264-410X(24)00560-7. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

MARANTOS T, Kyriazopoulou E, Angelakis E, Kitsos D, et al
Immunogenicity of a seasonal influenza and a pneumococcal polysaccharide vaccine in multiple sclerosis patients under disease modifying therapies: A single-center prospective study.
Vaccine. 2024 May 24:S0264-410X(24)00617-0. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

TSAMPALIEROS A, Zemek R, Barrowman N, Langlois MA, et al
Hybrid immunity after BNT162b2 Covid-19 vaccine administration in children aged 5 to 11 years.
Vaccine. 2024 May 23:S0264-410X(24)00588-7. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

BENEDICT KPOZEHOUEN E, Raina Macintyre C, Tan TC
Coverage of influenza, pneumococcal and zoster vaccination and determinants of influenza and pneumococcal vaccination among adults with cardiovascular diseases in community.
Vaccine. 2024 May 23:S0264-410X(24)00619-4. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

EIBERG MF, Rezahosseini O, Bukan KB, Charlotte Arp B, et al
Changes in vaccination uptake against pneumococcal disease, influenza, and coronavirus disease 2019 (COVID-19) before and after a Head and Neck cancer diagnosis.
Vaccine. 2024 May 23:S0264-410X(24)00566-8. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

KANDASAMY R, Gurung M, Shrestha S, Gautam MC, et al
Decline in pneumococcal vaccine serotype carriage, multiple-serotype carriage, and carriage density in Nepalese children after PCV10 introduction: A pre-post comparison study.
Vaccine. 2024 May 23:S0264-410X(24)00564-4. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

YEGANEH N, Yin S, Moir O, Danza P, et al
Effectiveness of JYNNEOS vaccine against symptomatic mpox disease in adult men in Los Angeles County, August 29, 2022 to January 1, 2023.
Vaccine. 2024 May 23:S0264-410X(24)00594-2. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

CARNALLA M, Stern D, Arantxa Colchero M, Rangel-Moreno K, et al
Who is getting COVID-19 boosters? A latent class analysis in a nationally representative sample of Mexican adults 60 years and over.
Vaccine. 2024;42:3273-3276.
PubMed Abstract available

RAMOS-DUARTE VA, Orlowski A, Jaquenod de Giusti C, Corigliano MG, et al
Safe plant Hsp90 adjuvants elicit an effective immune response against SARS-CoV2-derived RBD antigen.
Vaccine. 2024;42:3355-3364.
PubMed Abstract available

PROSPER P, Rodriguez Puertas R, Guerin DMA, Branda MM, et al
Computational method for designing vaccines applied to virus-like particles (VLPs) as epitope carriers.
Vaccine. 2024 May 22:S0264-410X(24)00584-X. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

ZHOU H, Zhao W, Ma R, Zheng Y, et al
Mixed methods examination of risk perception on vaccination intentions: The perspective of doctor-patient communication.
Vaccine. 2024 May 22:S0264-410X(24)00565-6. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

ZHANG WX, Zhang Y, Du J, Shi W, et al
Effectiveness of momentary intervention on influenza vaccination among the elderly in China: From willingness to action.
Vaccine. 2024 May 22:S0264-410X(24)00591-7. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

PAN X, Guo X, Shi J
Design of a novel multiepitope vaccine with CTLA-4 extracellular domain against Mycoplasma pneumoniae: A vaccine-immunoinformatics approach.
Vaccine. 2024 May 21:S0264-410X(24)00568-1. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

CHIHANA R, Jin Kee J, Moodie Z, Huang Y, et al
Factors associated with reactogenicity to an investigational HIV vaccine regimen in HIV vaccine trials network 702.
Vaccine. 2024 May 21:S0264-410X(24)00598-X. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

VAN DER PLAS JL, Haijema BJ, Leenhouts K, Paul Zoeteweij J, et al
Safety, reactogenicity and immunogenicity of an intranasal seasonal influenza vaccine adjuvanted with gram-positive matrix (GEM) particles (FluGEM): A randomized, double-blind, controlled, ascending dose study in healthy adults and elderly.
Vaccine. 2024 May 20:S0264-410X(24)00370-0. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

MACHIDA M, Fukushima S, Saitoh A, Inoue S, et al
Uptake among four indicated vaccines by adults aged 65 years and older in Japan, 2023.
Vaccine. 2024 May 20:S0264-410X(24)00592-9. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

KARIMI-SHAHRBABAK E, Di Chiara C, Farrar DS, Abu Fadaleh SM, et al
COVID-19 vaccine acceptance and uptake among caregivers of children aged 5-11?years in Ontario, Canada: A cross-sectional survey.
Vaccine. 2024 May 20:S0264-410X(24)00553-X. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

GARG R, Liu Q, Van Kessel J, Asavajaru A, et al
Efficacy of a stable broadly protective subunit vaccine platform against SARS-CoV-2 variants of concern.
Vaccine. 2024 May 19:S0264-410X(24)00586-3. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

TSUJII A, Takahashi K, Harada H, Kawashima S, et al
Evaluation of the protective effect of the intranasal vaccines adjuvanted with bacterium-like particles against intestinal infection.
Vaccine. 2024 May 18:S0264-410X(24)00582-6. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

ANN COSTA CLEMENS S, Weckx L, Milan EP, Smolenov I, et al
Interchangeability of different COVID-19 vaccine platforms as booster doses: A phase 3 study mimicking real-world practice.
Vaccine. 2024 May 17:S0264-410X(24)00555-3. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

YANG T, Tong F, Tang L, Li P, et al
Repeated vaccination does not appear to significantly weaken the protective effect of influenza vaccine in the elderly: A test-negative case-control study in China.
Vaccine. 2024 May 17:S0264-410X(24)00593-0. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

KIM S, Choi JK, Suh J, Park SH, et al
The epidemiologic and economic impact of varicella and herpes zoster vaccination in South Korea: A mathematical modelling study.
Vaccine. 2024 May 17:S0264-410X(24)00562-0. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

GRIFFIN I, Berry I, Navarra T, Priyamvada L, et al
Serologic responses to the MVA-based JYNNEOS mpox vaccine in a cohort of participants from the District of Columbia (D.C.).
Vaccine. 2024 May 17:S0264-410X(24)00563-2. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

GARCIA-VICENTE EJ, Rey-Casero I, Martin M, Perez A, et al
Oral supplementation with postbiotics modulates the immune response produced by myxomatosis vaccination in wild rabbits.
Vaccine. 2024 May 16:S0264-410X(24)00585-1. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

URAGUCHI K, Matsumoto N, Mitsuhashi T, Takao S, et al
Pediatric otitis media in Japan: A nationwide longitudinal study of the pre- and post-pneumococcal conjugate vaccine eras born in 2001 and 2010.
Vaccine. 2024 May 16:S0264-410X(24)00567-X. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

NG'OMBE H, Bosomprah S, Phiri B, Muchimba M, et al
Comparative analysis of cholera serum vibriocidal antibodies from Convalescent and vaccinated adults in Zambia.
Vaccine. 2024 May 16:S0264-410X(24)00587-5. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

URQUIDI C, Sepulveda-Penaloza A, Valenzuela MT, Ponce A, et al
Vaccine effectiveness in reducing COVID-19-related hospitalization after a risk-age-based mass vaccination program in a Chilean municipality: A comparison of observational study designs.
Vaccine. 2024 May 14:S0264-410X(24)00538-3. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

MIRANDA-LOPEZ A, Gonzalez-Ortega O, Govea-Alonso DO, Betancourt-Mendiola L, et al
Rational design and production of a chimeric antigen targeting Zika virus that induces neutralizing antibodies in mice.
Vaccine. 2024 May 14:S0264-410X(24)00518-8. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

MUANGNOICHAROEN S, Wiangcharoen R, Lawpoolsri S, Nanthapisal S, et al
Heterologous Ad26.COV2.S booster after primary BBIBP-CorV vaccination against SARS-CoV-2 infection: 1-year follow-up of a phase 1/2 open-label trial.
Vaccine. 2024 May 13:S0264-410X(24)00556-5. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

KARIM S, Rehana Siddiqui A, Karim N, Pradhan NA, et al
Role of rotavirus vaccine in reducing diarrheal episodes in infants visiting private primary health care clinics in Karachi, Pakistan: A mixed-methods study.
Vaccine. 2024 May 13:S0264-410X(24)00558-9. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

EJNAR HANSEN M, David Pickering S
The role of religion and COVID-19 vaccine uptake in England.
Vaccine. 2024;42:3215-3219.
PubMed Abstract available

MUTTUCUMARU R, Lau CL, Leeb A, Mills DJ, et al
Post-marketing surveillance of 10,392 herpes zoster vaccines doses in Australia.
Vaccine. 2024;42:3166-3171.
PubMed Abstract available

LIU F, Li Z, Wang H, Cao Y, et al
Effectiveness of the varicella vaccine in the real world, a matched case-control study.
Vaccine. 2024 May 10:S0264-410X(24)00552-8. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

DINH THIEM V, Van Anh PT, Van Men C, Hung DT, et al
A SARS-CoV-2 recombinant spike protein vaccine (S-268019-b) for COVID-19 prevention during the Omicron-dominant period: A phase 3, randomised, placebo-controlled clinical trial.
Vaccine. 2024 May 10:S0264-410X(24)00523-1. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

MALTEZOU HC, Gamaletsou MN, Giannouchos TV, Koukou DM, et al
Effectiveness of COVID-19 booster vaccination, morbidity and absenteeism among healthcare personnel during the 2022-2023 season dominated by Omicron BA.5 and BA.2 subvariants.
Vaccine. 2024 May 9:S0264-410X(24)00522-X. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

SHANI M, Hermesh I, Feldhamer I, Reges O, et al
The association between BNT162b2 vaccinations and incidence of immune-mediated comorbidities.
Vaccine. 2024 May 9:S0264-410X(24)00536-X. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

LEE KY, Song KH, Lee KH, Baek JY, et al
Persistent differences in the immunogenicity of the two COVID-19 primary vaccines series, modulated by booster mRNA vaccination and breakthrough infection.
Vaccine. 2024 May 9:S0264-410X(24)00539-5. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

KIM DH, Lee SH, Kim J, Lee J, et al
Efficacy of live and inactivated recombinant Newcastle disease virus vaccines expressing clade 2.3.4.4b H5 hemagglutinin against H5N1 highly pathogenic avian influenza in SPF chickens, Broilers, and domestic ducks.
Vaccine. 2024 May 8:S0264-410X(24)00527-9. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

LAURA SORIANO PEREZ M, Montironi I, Alejandro Funes J, Margineda C, et al
Nanogel-Mediated antigen delivery: Biocompatibility, immunogenicity, and potential for tailored vaccine design across species.
Vaccine. 2024 May 7:S0264-410X(24)00525-5. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

BASKOL ELIK D, Yildirim C, Akyol Seyhan D, Aytac Erdem H, et al
Evaluation of antibody responses in healthcare workers before & after meningococcal vaccine and determination of meningococcal carriage rates.
Vaccine. 2024 May 7:S0264-410X(24)00540-1. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

TIPPINS A, Acevedo JC, Palomeque FS, Coy KC, et al
Strategies to strengthen COVID-19 vaccine uptake and improve vaccine equity in U.S. Territories and Freely Associated States during the first six months of vaccine rollout.
Vaccine. 2024 May 7:S0264-410X(24)00541-3. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

DIONNE M, Etienne D, Witteman HO, Sauvageau C, et al
Impact of interventions to improve HPV vaccination acceptance and uptake in school-based programs: Findings of a pilot project in Quebec.
Vaccine. 2024 May 6:S0264-410X(24)00528-0. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

CAO A, Ueta M, Uchibori M, Murakami M, et al
Trust in governments, public health institutions, and other information sources as determinants of COVID-19 vaccine uptake behavior in Japan.
Vaccine. 2024 May 6:S0264-410X(24)00520-6. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

SONG H, Waheed Abdullah S, Yin S, Dong H, et al
Virus-like particle-based multipathogen vaccine of FMD and SVA elicits balanced and broad protective efficacy in mice and pigs.
Vaccine. 2024 May 6:S0264-410X(24)00530-9. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

SOE P, Wong H, Naus M, Muller MP, et al
mRNA COVID-19 vaccine safety among older adults from the Canadian National Vaccine Safety Network.
Vaccine. 2024 May 6:S0264-410X(24)00535-8. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

JEARANAIWITAYAKUL T, Sunintaboon P, Kittiayuwat A, Limthongkul J, et al
Intranasal immunization with the bivalent SARS-CoV-2 vaccine effectively protects mice from nasal infection and completely inhibits disease development.
Vaccine. 2024 May 6:S0264-410X(24)00519-X. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

KOLAKOWSKA A, Marshall E, Krastinova E, Cros A, et al
Insufficient vaccine coverage and vaccine hesitancy in people living with HIV: A prospective study in outpatient clinics in the Paris region.
Vaccine. 2024 May 6:S0264-410X(24)00516-4. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

KIM J, Chang J
Cross-protective efficacy and safety of an adenovirus-based universal influenza vaccine expressing nucleoprotein, hemagglutinin, and the ectodomain of matrix protein 2.
Vaccine. 2024 May 6:S0264-410X(24)00481-X. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

LI H, Li Q, Hao Z, Zhang L, et al
A recombinant IL-1beta vaccine attenuates bleomycin-induced pulmonary fibrosis in mice.
Vaccine. 2024 May 6:S0264-410X(24)00531-0. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

CROWE CL, Dreyfus J, Lanes S, Chung H, et al
Variation in incidence rates of outcomes relevant to vaccine safety monitoring in a US commercially insured population by case identification algorithm.
Vaccine. 2024 May 6:S0264-410X(24)00534-6. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

MAJE BELLO A, Chaimongkolnukul K, Poomputsa K, Mekvichitsaeng P, et al
Immunogenicity and immunodominant linear B-cell epitopes of a new DNA-based tetravalent vaccine against four major enteroviruses causing hand, foot, and mouth disease.
Vaccine. 2024 May 4:S0264-410X(24)00526-7. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

ANDREJKO KL, Gierke R, Rowlands JV, Rosen JB, et al
Effectiveness of 13-valent pneumococcal conjugate vaccine for prevention of invasive pneumococcal disease among children in the United States between 2010 and 2019: An indirect cohort study.
Vaccine. 2024 May 3:S0264-410X(24)00499-7. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

ADINUGROHO I, Stafford T, Bentall RP
The correlation between conspiracy mentality and vaccine intentions is moderated by social events: Evidence from longitudinal data during COVID-19 pandemic in the UK.
Vaccine. 2024 May 3:S0264-410X(24)00510-3. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

CHRISTOU-ERGOS M, Bleicher K, Leask J
Factors associated with vaccination intention and uptake over time in a sample of older Australians.
Vaccine. 2024 May 3:S0264-410X(24)00508-5. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

ESPARZA J
Introduction of the smallpox vaccine in Napoleonic France, as recorded in contemporary medals.
Vaccine. 2024 May 3:S0264-410X(24)00503-6. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

SHI XC, Gruber JF, Ondari M, Lloyd PC, et al
Assessment of potential adverse events following the 2022-2023 seasonal influenza vaccines among U.S. adults aged 65 years and older.
Vaccine. 2024 May 3:S0264-410X(24)00478-X. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

MAUREL M, Mazagatos C, Goerlitz L, Oroszi B, et al
Exploring the effect of clinical case definitions on influenza vaccine effectiveness estimation at primary care level: Results from the end-of-season 2022-23 VEBIS multicentre study in Europe.
Vaccine. 2024 May 3:S0264-410X(24)00497-3. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

SEFAT KMSR, Kumar M, Kehl S, Kulkarni R, et al
An intranasal nanoparticle vaccine elicits protective immunity against Mycobacterium tuberculosis.
Vaccine. 2024 May 3:S0264-410X(24)00482-1. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

BENEDICT KPOZEHOUEN E, Macintyre CR, Tan TC
Determinants of uptake of influenza, zoster and pneumococcal vaccines in patients with cardiovascular diseases.
Vaccine. 2024 May 3:S0264-410X(24)00445-6. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

BAGLIVO F, De Angelis L, Magri M, De Nicola I, et al
The impact of COVID-19 vaccination campaign on pediatric vaccine uptake based on parents' attitudes towards mandatory and recommended vaccination in Southern Italy.
Vaccine. 2024 May 3:S0264-410X(24)00513-9. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

MERTENS JE, Rigby CA, Bardelli M, Quinkert D, et al
Evaluation of the precision of the Plasmodium knowlesi growth inhibition assay for Plasmodium vivax Duffy-binding protein-based malaria vaccine development.
Vaccine. 2024 May 3:S0264-410X(24)00514-0. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

MARINTHE G, Brown G, Cristea M, Kutlaca M, et al
Predicting vaccination hesitancy: The role of basic needs satisfaction and institutional trust.
Vaccine. 2024 May 3:S0264-410X(24)00507-3. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

HU H, Ma F, Gong L, Wang Y, et al
Immunogenicity and safety of a recombinant Omicron BA.4/5-Delta COVID-19 vaccine ZF2202-A in Chinese adults.
Vaccine. 2024 May 3:S0264-410X(24)00495-X. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

LAMBACH P, Silal S, Sbarra AN, Koh M, et al
Report from the World Health Organization's immunization and vaccines-related implementation research advisory committee (IVIR-AC) meeting, virtual gathering, 26 February-1 March 2024.
Vaccine. 2024 May 3:S0264-410X(24)00494-8. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

ANGAITKAR P, Ram Janghel R, Prasad Sahu T
An MCDM approach for Reverse vaccinology model to predict bacterial protective antigens.
Vaccine. 2024 May 3:S0264-410X(24)00517-6. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

DHALARIA P, Kumar P, Verma A, Priyadarshini P, et al
Exploring landscape of measles vaccination coverage: A step towards measles elimination goal in India.
Vaccine. 2024 May 3:S0264-410X(24)00511-5. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

EHRLICH KB, Lyle SM, Corallo KL, Lavner JA, et al
Changes in depressive symptoms and antibody production following influenza vaccination in adolescents and adults.
Vaccine. 2024 May 2:S0264-410X(24)00505-X. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

MASTROLEO I
Use of experimental vaccines is ethically permissible during public health emergencies.
Vaccine. 2024 May 1:S0264-410X(24)00504-8. doi: 10.1016/j.vaccine.2024.
PubMed

April 2024

LV M, Du J, Xie MZ, Zhou Y, et al
Protective effect of PCV13 against all-cause hospitalized pneumonia in children in Beijing, China: real-world evidence.
Vaccine. 2024;42:3091-3098.
PubMed Abstract available

WANG Z, Wang M, Wang F, Luo Y, et al
Dendritic cell targeting peptide plus Salmonella FliCd flagellin fused outer membrane protein H (OmpH) demonstrated increased efficacy against infections caused by different Pasteurella multocida serogroups in mouse models.
Vaccine. 2024;42:3075-3083.
PubMed Abstract available

MAGALI P, Sophie M, Arnaud B, Pol L, et al
Retrospective study on the health and economic burden of hospitalized patients due to pneumonia and invasive pneumococcal infections in Belgium settings.
Vaccine. 2024;42:3018-3023.
PubMed Abstract available

GRANT LR, Hanquet G, Sepulveda-Pachon IT, Theilacker C, et al
Effects of PCV10 and PCV13 on pneumococcal serotype 6C disease, carriage, and antimicrobial resistance.
Vaccine. 2024;42:2983-2993.
PubMed Abstract available

JI W, Zhou H, Li J, Britto CD, et al
Distributions of candidate vaccine Targets, virulence Factors, and resistance features of invasive group B Streptococcus using Whole-Genome Sequencing: A Multicenter, population-based surveillance study.
Vaccine. 2024 Apr 30:S0264-410X(24)00498-5. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

FLEARY SA, Shahn Z, Teasdale CA
Effects of parental childhood cultural health environment on children's influenza and COVID-19 vaccination status.
Vaccine. 2024 Apr 29:S0264-410X(24)00515-2. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

NIESSEN FA, Bruijning-Verhagen PCJL, Bonten MJM, Knol MJ, et al
Vaccine effectiveness against COVID-19 related hospital admission in the Netherlands by medical risk condition: A test-negative case-control study.
Vaccine. 2024 Apr 29:S0264-410X(24)00432-8. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

GUDOORU K, Nguyen K, Le K, Sarabu V, et al
Collective good and individual choice: Perceptions on COVID-19 vaccine mandate among COVID-19 vaccinated individuals.
Vaccine. 2024 Apr 27:S0264-410X(24)00479-1. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

DORJEE K, Namdon T, Topgyal S, Gyatso U, et al
Association between Covishield vaccine and menstrual disturbance. Findings from a cross-sectional study among participants of Zero TB cohort in India.
Vaccine. 2024 Apr 27:S0264-410X(24)00500-0. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

PIASECKI AM, Hall DM, Zajac J, Miller SA, et al
A programmatic update on COVID-19 vaccination in rural communities in the United States.
Vaccine. 2024 Apr 25:S0264-410X(24)00469-9. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

LUO G, Zeng Y, Sheng R, Zhang Z, et al
Wa-VP4* as a candidate rotavirus vaccine induced homologous and heterologous virus neutralizing antibody responses in mice, pigs, and cynomolgus monkeys.
Vaccine. 2024 Apr 25:S0264-410X(24)00483-3. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

XIE Z, Stallings-Smith S, Patel S, Case S, et al
COVID-19 booster vaccine uptake and reduced risks for long-COVID: A cross-sectional study of a U.S. adult population.
Vaccine. 2024 Apr 25:S0264-410X(24)00509-7. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

LYTRAS T, Athanasiadou M, Demetriou A, Stylianou D, et al
Authors' reply: Excess mortality in Cyprus during the COVID-19 vaccination campaign.
Vaccine. 2024 Apr 25:S0264-410X(24)00506-1. doi: 10.1016/j.vaccine.2024.
PubMed

FUJITA DM, da Silva Nali LH, da Costa RR, de Andrade Junior HF, et al
Low vaccine coverage and varicella outbreaks in Brazil - 2019-2022.
Vaccine. 2024 Apr 24:S0264-410X(24)00435-3. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

SELLIES AJ, Knol MJ, de Melker HE, Bruijning-Verhagen PCJL, et al
Non-specific effects of the inactivated influenza vaccine. A test-negative study: The inactivated influenza vaccine and SARS-CoV-2 infections.
Vaccine. 2024 Apr 23:S0264-410X(24)00468-7. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

SWITALSKI J, Miazga W, Wnuk K, Tatara T, et al
Analyzing the dynamics of meningococcal vaccinations initiatives by local government units in Poland (2017-2021) - Scope, challenges and recommendations.
Vaccine. 2024 Apr 22:S0264-410X(24)00472-9. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

SONG S, Madewell ZJ, Liu M, Miao Y, et al
A systematic review and meta-analysis on the effectiveness of bivalent mRNA booster vaccines against Omicron variants.
Vaccine. 2024 Apr 22:S0264-410X(24)00476-6. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

MUSA S, Merdrignac L, Skocibusic S, Nedic R, et al
BBIBP-CorV vaccine effectiveness against COVID-19 in patients aged 60 years and older during the Delta-dominant period in the Federation of Bosnia and Herzegovina, a test-negative case-control study.
Vaccine. 2024 Apr 20:S0264-410X(24)00471-7. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

WANG Y, Xu F, Yuan C, Zhang Y, et al
Comparison of immune effects of porcine circovirus type 2d (PCV2d) capsid protein expressed by Escherichia coli and baculovirus-insect cells.
Vaccine. 2024;42:2848-2857.
PubMed Abstract available

MOHANTY S, Done N, Liu Q, Song Y, et al
Incidence of pneumococcal disease in children
Vaccine. 2024;42:2758-2769.
PubMed Abstract available

LIEVRE G, Sicsic J, Galmiche S, Charmet T, et al
Are the 7C psychological antecedents associated with COVID-19 vaccine behaviours beyond intentions? A cross-sectional study on at-least-one-dose and up-to-date vaccination status, and uptake speed among adults in France.
Vaccine. 2024 Apr 19:S0264-410X(24)00438-9. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

INGRAO F, Ngabirano E, Rauw F, Dauphin G, et al
Immunogenicity and protective efficacy of a multivalent herpesvirus vectored vaccine against H9N2 low pathogenic avian influenza in chicken.
Vaccine. 2024 Apr 18:S0264-410X(24)00452-3. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

WON H, Kim JA, Jeong NY, Choi NK, et al
Safety of concomitant administration of 23-valent polysaccharide pneumococcal vaccine and influenza vaccine among the elderly.
Vaccine. 2024 Apr 18:S0264-410X(24)00400-6. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

RICKE IJ, Spaulding AB, Rajtar NN, Benton EM, et al
Predictors of willingness to receive updated 2023-2024 COVID-19 booster vaccines among a convenience sample in Minnesota.
Vaccine. 2024 Apr 18:S0264-410X(24)00480-8. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

ORANGZEB S, Desalegn A, Trinh NTH, Zhao J, et al
COVID-19 vaccine uptake among children and adolescents in Norway: A comprehensive registry-based cohort study of over 800,000 individuals.
Vaccine. 2024 Apr 18:S0264-410X(24)00464-X. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

GAJEWSKA M, Lewtak K, Gorynski P, Piotrowicz M, et al
Effect of the PCV 10 vaccination on community-acquired pneumonia hospitalisations after four years of its introduction into the Polish National Immunisation Programme: Follow-up study.
Vaccine. 2024 Apr 18:S0264-410X(24)00433-X. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

TRINITE B, Durr E, Pons-Grifols A, O'Donnell G, et al
VLPs generated by the fusion of RSV-F or hMPV-F glycoprotein to HIV-Gag show improved immunogenicity and neutralizing response in mice.
Vaccine. 2024 Apr 18:S0264-410X(24)00473-0. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

BEITARI S, Yi S, Sharma S, Yung R, et al
Exploring COVID-19 vaccine uptake and hesitancy among vulnerable populations in inner city Vancouver, Canada: Insights into characteristics and clinical outcomes.
Vaccine. 2024 Apr 17:S0264-410X(24)00477-8. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

MUTSAERTS EAML, van Cranenbroek B, Madhi SA, Simonetti E, et al
Impact of nutritional status on vaccine-induced immunity in children living in South Africa: Investigating the B-cell repertoire and metabolic hormones.
Vaccine. 2024 Apr 17:S0264-410X(24)00448-1. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

MATUR RV, Thuluva S, Gunneri S, Yerroju V, et al
Immunogenicity and safety of a 14-valent pneumococcal polysaccharide conjugate vaccine (PNEUBEVAX 14) administered to 6-8 weeks old healthy Indian Infants: A single blind, randomized, active-controlled, Phase-III study.
Vaccine. 2024 Apr 17:S0264-410X(24)00362-1. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

VAN DER POL S, Zeevat F, Postma MJ, Boersma C, et al
Cost-effectiveness of high-dose influenza vaccination in the Netherlands: Incorporating the impact on both respiratory and cardiovascular hospitalizations.
Vaccine. 2024 Apr 17:S0264-410X(24)00465-1. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

JI Y, Sui X, Miao W, Wang C, et al
Erratum to "Immunogenicity of an adenovirus-vectored bivalent vaccine against wild type SARS-CoV-2 and Omicron variants in a murine model" [Vaccine 42(6) (2024) 1292-1299].
Vaccine. 2024 Apr 16:S0264-410X(24)00386-4. doi: 10.1016/j.vaccine.2024.
PubMed

PEREIRA ET, Iasulaitis S, Greco BC
Analysis of causal relations between vaccine hesitancy for COVID-19 vaccines and ideological orientations in Brazil.
Vaccine. 2024 Apr 16:S0264-410X(24)00436-5. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

GEE J, Shimabukuro TT, Su JR, Shay D, et al
Overview of U.S. COVID-19 vaccine safety surveillance systems.
Vaccine. 2024 Apr 16:S0264-410X(24)00224-X. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

LEE N, Hong Y, Kirkpatrick CE, Hu S, et al
COVID-19 vaccination communication: Effects of vaccine conspiracy beliefs and message framing among black and white participants.
Vaccine. 2024 Apr 16:S0264-410X(24)00402-X. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

DEAL A, Crawshaw AF, Salloum M, Hayward SE, et al
Understanding the views of adult migrants around catch-up vaccination for missed routine immunisations to define strategies to improve coverage: A UK in-depth interview study.
Vaccine. 2024 Apr 16:S0264-410X(24)00406-7. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

SHEFFER R, Bucris E, Amitai Z, Indenbaum V, et al
Measles outbreak associated with a preschool setting among partially vaccinated children in the Tel Aviv District, Israel, October 2023.
Vaccine. 2024 Apr 15:S0264-410X(24)00427-4. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

MELNIKOW J, Padovani A, Zhang J, Miller M, et al
Patient concerns and physician strategies for addressing COVID-19 vaccine hesitancy.
Vaccine. 2024 Apr 15:S0264-410X(24)00437-7. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

WONG IOL, Wong C, Mak N, Dai A, et al
Assessment of the impact of the vaccine pass policy on COVID-19 vaccine hesitancy and uptake among Chinese adults in Hong Kong.
Vaccine. 2024 Apr 15:S0264-410X(24)00449-3. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

DAVIS BM, Blake I, Panicker G, Meites E, et al
Immunogenicity of quadrivalent human papillomavirus vaccine among Alaska Native children aged 9-14 years at 5 years after vaccination.
Vaccine. 2024 Apr 15:S0264-410X(24)00447-X. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

YAGI A, Ueda Y, Kimura T
HPV Vaccine Issues in Japan: A review of our attempts to promote the HPV vaccine and to provide effective evaluation of the problem through social-medical and behavioral-economic perspectives.
Vaccine. 2024 Apr 13:S0264-410X(24)00407-9. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

SUKIK L, Chemaitelly H, Ayoub HH, Coyle P, et al
Effectiveness of two and three doses of COVID-19 mRNA vaccines against infection, symptoms, and severity in the pre-omicron era: A time-dependent gradient.
Vaccine. 2024 Apr 13:S0264-410X(24)00440-7. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

BAKER J, Aliabadi N, Munjal I, Jiang Q, et al
Equivalent immunogenicity across three RSVpreF vaccine lots in healthy adults 18-49 years of age: Results of a randomized phase 3 study.
Vaccine. 2024 Apr 13:S0264-410X(24)00387-6. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

NASKAR S, Harsukhbhai Chandpa H, Agarwal S, Meena J, et al
Super epitope dengue vaccine instigated serotype independent immune protection in-silico.
Vaccine. 2024 Apr 13:S0264-410X(24)00423-7. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

YONEKAWA M, Watanabe T, Kogawara O, Yoshii C, et al
Phase 3 immunogenicity and safety study of a tick-borne encephalitis vaccine in healthy Japanese participants 1 year of age and older.
Vaccine. 2024 Apr 12:S0264-410X(24)00388-8. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

LEE JS, Choi H, Shin SH, Hwang MJ, et al
Characterization of Brighton Collaboration criteria for myocarditis and pericarditis following COVID-19 vaccine in Korean adolescents.
Vaccine. 2024 Apr 11:S0264-410X(24)00446-8. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

NOLAN MB, Chrenka E, Walker P, Steiner A, et al
COVID-19 vaccine uptake among non-US-born populations in the United States, 2020-2022.
Vaccine. 2024 Apr 11:S0264-410X(24)00443-2. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

KAINTH MK, Sembajwe GN, Ahn H, Qian M, et al
Despite mandated primary series, health care personnel still hesitant about COVID-19 vaccine and immunizing children.
Vaccine. 2024 Apr 11:S0264-410X(24)00442-0. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

AHERN S, Browne J, Murphy A, Teljeur C, et al
An economic evaluation and incremental analysis of the cost effectiveness of three universal childhood varicella vaccination strategies for Ireland.
Vaccine. 2024 Apr 11:S0264-410X(24)00441-9. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

OWUSU-EDUSEI K, Favre-Bulle A, Tsoumani E, Mutschler T, et al
Evaluating the health and economic outcomes of a PCV15 vaccination program for adults aged 65 years-and-above in Switzerland.
Vaccine. 2024 Apr 11:S0264-410X(24)00431-6. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

PITTS PJ, Poland GA
Addressing vaccine hesitancy: Learning from the successes and failures of the COVID-19 pandemic.
Vaccine. 2024 Apr 10:S0264-410X(24)00396-7. doi: 10.1016/j.vaccine.2024.
PubMed

HUSETH-ZOSEL AL, Fuller H, Hicks A, Carson PJ, et al
Reliance on sources of immunization information and vaccine uptake among older adults in a rural state: The mediating role of trust.
Vaccine. 2024 Apr 10:S0264-410X(24)00444-4. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

BLAKE JM, Thompson J, HogenEsch H, Ekenstedt KJ, et al
Heritability and genome-wide association study of vaccine-induced immune response in Beagles: A pilot study.
Vaccine. 2024 Apr 10:S0264-410X(24)00398-0. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

THAI H, Audet EC, Koestner R
Motivation for COVID-19 Vaccination: Applying a Self-Determination Theory Perspective to a Global Health Crisis.
Vaccine. 2024 Apr 9:S0264-410X(24)00439-0. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

AKMATOVA R, Ebama MS, Temirbekov S, Alymkulova V, et al
A comparative analysis of knowledge, attitude, and practice (KAP) towards influenza and influenza vaccination among healthcare workers in Kyrgyzstan prior to and during the COVID-19 pandemic.
Vaccine. 2024 Apr 9:S0264-410X(24)00420-1. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

EL BUSHRA HE, Haroun AAA, Dauod Altaf M, Gardiwal H, et al
Early use of oral cholera vaccines as a prime control measure during outbreaks: Necessary but not sufficient.
Vaccine. 2024 Apr 8:S0264-410X(24)00332-3. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

KONERU A, Wells K, Amanda Carnes C, Drumhiller K, et al
A survey of state and local practices encouraging pediatric COVID-19 vaccination of children ages 6 months through 11 years.
Vaccine. 2024 Apr 8:S0264-410X(24)00369-4. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

WONODI C, Crowcroft N, Bose AS, Oteri J, et al
Country ownership as a guiding principle for IA2030: A case study of the measles and rubella elimination programs in Nepal and Nigeria.
Vaccine. 2024;42 Suppl 1:S107-S117.
PubMed Abstract available

PATEL MK, Scobie HM, Serhan F, Dahl B, et al
A global comprehensive vaccine-preventable disease surveillance strategy for the immunization Agenda 2030.
Vaccine. 2024;42 Suppl 1.
PubMed Abstract available

CERNUSCHI T, Malvolti S, Hall S, Debruyne L, et al
The quest for more effective vaccine markets - Opportunities, challenges, and what has changed with the SARS-CoV-2 pandemic.
Vaccine. 2024;42 Suppl 1:S64-S72.
PubMed Abstract available

ARCHER H, McCoy SI, Sears D, Kwan A, et al
Indirect vaccine effectiveness in an outbreak of Alpha B.1.1.7 variant in a California state Prison, May 2021.
Vaccine. 2024 Apr 6:S0264-410X(24)00368-2. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

CUMMINGS JF, Polhemus ME, Kester KE, Ockenhouse CF, et al
A phase IIa, randomized, double-blind, safety, immunogenicity and efficacy trial of Plasmodium falciparum vaccine antigens merozoite surface protein 1 and RTS,S formulated with AS02 adjuvant in healthy, malaria-naive adults.
Vaccine. 2024 Apr 6:S0264-410X(24)00389-X. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

CHONG CY, Kam KQ, Zhang J, Bertoletti A, et al
Immunogenicity and safety of Sinovac-CoronaVac booster vaccinations in 12-17- year-olds with clinically significant reactions from Pfizer-BNT162b2 vaccination.
Vaccine. 2024 Apr 6:S0264-410X(24)00425-0. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

BINTE HOSSAIN F, Muscatello D, Jayasinghe S, Jonnagaddala J, et al
Uptake of pneumococcal vaccines in older Australian adults before and after universal public funding of PCV13.
Vaccine. 2024 Apr 6:S0264-410X(24)00426-2. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

CHARD AN, Machingaidze C, Loayza S, Gharpure R, et al
Estimating averted illnesses from influenza vaccination for children and pregnant women - El Salvador, Panama, and Peru, 2011-2018.
Vaccine. 2024 Apr 6:S0264-410X(24)00419-5. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

SCHULTZE A, Martin I, Messina D, Bots S, et al
A comparison of four self-controlled study designs in an analysis of COVID-19 vaccines and myocarditis using five European databases.
Vaccine. 2024 Apr 5:S0264-410X(24)00330-X. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

STEFANIZZI P, Moscara L, Palmieri C, Martinelli A, et al
Safety profile of recombinant adjuvanted anti-herpes zoster vaccine (RZV) in high-risk groups: Data from active surveillance program. Puglia (Italy), 2021-23.
Vaccine. 2024 Apr 5:S0264-410X(24)00311-6. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

NYBRU GLEDITSCH R, Skogset Ofitserova T, Aubrey White R, Karoline Raberg Kjollesdal M, et al
Vaccine coverage among children born to immigrant parents in Norway, 2000-2020.
Vaccine. 2024 Apr 5:S0264-410X(24)00395-5. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

NAKANO T, Hasegawa M, Endo M, Matsuda K, et al
Immunogenicity and safety of adsorbed diphtheria-purified pertussis-tetanus-inactivated polio (Sabin strain)-Haemophilus type b conjugate combined vaccine (DPT-IPV-Hib) in healthy Japanese Infants >/= 2 and < 43 months of Age: A phase III, multicenter
Vaccine. 2024 Apr 5:S0264-410X(24)00394-3. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

BAUM HE, Thirard R, Halliday A, Baos S, et al
Detection of SARS-CoV-2-specific mucosal antibodies in saliva following concomitant COVID-19 and influenza vaccination in the ComFluCOV trial.
Vaccine. 2024 Apr 4:S0264-410X(24)00367-0. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

ALTAWALBEH SM, Wateska AR, Nowalk MP, Lin CJ, et al
Cost-effectiveness of an in-development adult-formulated 21-valent pneumococcal conjugate vaccine in US adults aged 50 years or older.
Vaccine. 2024 Apr 4:S0264-410X(24)00404-3. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

HEISLER-MACKINNON JA, Queen T, Yi Kong W, Kennedy KL, et al
Identifying effective vaccine champions: Findings from a national survey of primary care professionals.
Vaccine. 2024 Apr 3:S0264-410X(24)00403-1. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

NURDIN A, Movieta Nency Y, Maddeppungeng M, Sekartini R, et al
Immunogenicity and safety of SARS-CoV-2 recombinant protein subunit vaccine (IndoVac) adjuvanted with alum and CpG 1018 in Indonesian adults: A phase 3, randomized, active-controlled, multicenter trial.
Vaccine. 2024 Apr 3:S0264-410X(24)00399-2. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

TEMBO G, Mayuni M, Kamng'ona R, Chimgoneko L, et al
Poor association between 13-valent pneumococcal conjugate vaccine-induced serum and mucosal antibody responses with experimental Streptococcus pneumoniae serotype 6B colonisation.
Vaccine. 2024 Apr 2:S0264-410X(24)00360-8. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

WU CY, Kao SE, Tseng YC, Hou JT, et al
Pilot-scale production of a highly efficacious and stable monoglycosylated influenza split virus vaccine.
Vaccine. 2024;42:2220-2228.
PubMed Abstract available

LIU J, Qi Q, Liu Y, Ni P, et al
A paired measles-rubella catch-up campaign in Sichuan China to stop an outbreak and strengthen local immunization programs.
Vaccine. 2024;42:2155-2160.
PubMed Abstract available

SU L, Zhou X, Peng W, Luo J, et al
Investigation on the correlation factors of positive Streptococcus pneumoniae antibody and IgG antibody level of Streptococcus pneumoniae in the elderly over 60 years old in Shenzhen.
Vaccine. 2024;42:2448-2454.
PubMed Abstract available

HUBER A, Kovacs E, Horvath A, Sahin-Toth J, et al
Prevalence, serogroup distribution and risk factors of Neisseria meningitidis carriage in high school and university students in Hungary.
Vaccine. 2024;42:2271-2277.
PubMed Abstract available

KIMBUGWE G, Vatrinet R, Mwanga JA, Kakuru R, et al
Perceptions, attitudes, and willingness of healthcare and frontline workers to participate in an Ebola vaccine trial in Uganda.
Vaccine. 2024 Apr 1:S0264-410X(24)00358-X. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

March 2024

GONG JD, Barnboym E, O'Mara M, Gurevich N, et al
Self-reported determinants of COVID-19 vaccine acceptance among persons with and without autoimmune disease.
Vaccine. 2024 Mar 30:S0264-410X(24)00373-6. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

MALTEZOU HC, Kontogianni S, Michailidou E, Vergadi E, et al
Effectiveness of COVID-19 vaccination against school absenteeism in children and adolescents hospitalized with COVID-19.
Vaccine. 2024 Mar 30:S0264-410X(24)00397-9. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

PADENIYA TN, Hui BB, Wood JG, Regan DG, et al
Review of mathematical models of Neisseria gonorrhoeae vaccine impact: Implications for vaccine development.
Vaccine. 2024 Mar 30:S0264-410X(24)00380-3. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

HUF SW, Grailey K, Crespo RF, Woldmann L, et al
Testing the impact of differing behavioural science informed text message content in COVID-19 vaccination invitations on vaccine uptake: A randomised clinical trial.
Vaccine. 2024 Mar 28:S0264-410X(24)00365-7. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

FUKUDA Y, Suzuki T, Iwata KI, Haruta K, et al
Nanopore sequencing in distinguishing between wild-type and vaccine strains of Varicella-Zoster virus.
Vaccine. 2024 Mar 27:S0264-410X(24)00333-5. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

BRUUN N, Laursen MF, Carmelo R, Christensen E, et al
Novel nucleotide-packaging vaccine delivers antigen and poly(I:C) to dendritic cells and generate a potent antibody response in vivo.
Vaccine. 2024 Mar 26:S0264-410X(24)00364-5. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

PARISI A, Nunez O, Lopez-Perea N, Masa-Calles J, et al
Reduced pertussis disease severity in infants following the introduction of pertussis vaccination of pregnant women in Spain, 2015-2019.
Vaccine. 2024 Mar 25:S0264-410X(24)00315-3. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

WEYANT C, Hooda Y, Munira SJ, Lo NC, et al
Cost-effectiveness and public health impact of typhoid conjugate vaccine introduction strategies in Bangladesh.
Vaccine. 2024 Mar 25:S0264-410X(24)00322-0. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

DALEY MF, Reifler LM, Shoup JA, Glanz JM, et al
Influenza vaccination accuracy among adults: Self-report compared with electronic health record data.
Vaccine. 2024 Mar 25:S0264-410X(24)00339-6. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

BIEGUS J, Szenborn L, Zymlinski R, Zakliczynski M, et al
The early safety profile of simultaneous vaccination against influenza and Respiratory Syncytial Virus (RSV) in patients with high-risk heart failure.
Vaccine. 2024 Mar 25:S0264-410X(24)00366-9. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

VOLKMANN AM, Goldin S, McMurren B, Gapare C, et al
Leveraging seasonal influenza health worker vaccination programmes for COVID-19 vaccine Introduction: A global qualitative analysis.
Vaccine. 2024 Mar 25:S0264-410X(23)01490-1. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

DAHL BA, Tritter B, Butryn D, Dahlke M, et al
Global VAX: A U.S. contribution to global COVID-19 vaccination efforts, 2021-2023.
Vaccine. 2024 Mar 23:S0264-410X(24)00359-1. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

PONNE S, Kumar R, Vanmathi SM, Brilhante RSN, et al
Reverse engineering protection: A comprehensive survey of reverse vaccinology-based vaccines targeting viral pathogens.
Vaccine. 2024 Mar 23:S0264-410X(24)00265-2. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

MORGAN G, Casalino S, Chowdhary S, Frangione E, et al
COVID-19 vaccine reactogenicity among participants enrolled in the GENCOV study.
Vaccine. 2024 Mar 22:S0264-410X(24)00317-7. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

STUREBORG R, Nichols J, Dhingra B, Yang J, et al
Development and validation of VaxConcerns: A taxonomy of vaccine concerns and misinformation with Crowdsource-Viability.
Vaccine. 2024 Mar 22:S0264-410X(24)00255-X. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

CONDIE J, Northstone K, Major-Smith D, Halstead I, et al
Exploring associations between the Big Five personality traits and cognitive ability with COVID-19 vaccination hesitancy and uptake among mothers and offspring in a UK prospective cohort study.
Vaccine. 2024 Mar 22:S0264-410X(24)00305-0. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

COMES JDG, Doets K, Zegers T, Kessler M, et al
Evaluation of bird-adapted self-amplifying mRNA vaccine formulations in chickens.
Vaccine. 2024 Mar 22:S0264-410X(24)00319-0. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

PRICE O, Dietze P, Maher L, Dore GJ, et al
High COVID-19 vaccine uptake following initial hesitancy among people in Australia who inject drugs.
Vaccine. 2024 Mar 21:S0264-410X(24)00337-2. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

HIRTH J, Ostovar-Kermani T, Gutierrez JA, Thompson EL, et al
Effect of age at initiation of the human papillomavirus vaccine on the association between race/ethnicity and completion of the vaccine series.
Vaccine. 2024 Mar 21:S0264-410X(24)00336-0. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

ZHANG Y, Wang Y, Li G, Zhao X, et al
A randomized, blind, parallel controlled phase I clinical trial to evaluate the safety and preliminary immunogenicity of 23-valent pneumococcal polysaccharide vaccine in healthy people aged 2 years and older.
Vaccine. 2024 Mar 21:S0264-410X(24)00331-1. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

KLUWER B, Gleditsch R, Rydland KM, Mamelund SE, et al
Higher educational attainment associated with higher confidence in influenza vaccination in Norway.
Vaccine. 2024 Mar 21:S0264-410X(24)00338-4. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

ZHAO Z, Meng Q, Sun TZ, Zhu B, et al
Mannose modified targeted immersion vaccine delivery system improves protective immunity against Infectious spleen and kidney necrosis virus in mandarin fish (Siniperca chuatsi).
Vaccine. 2024 Mar 21:S0264-410X(24)00335-9. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

MOFFETT KW, Seserman K, Margolis KA, Kranzler EC, et al
Differences in social media use by COVID-19 vaccination status.
Vaccine. 2024 Mar 20:S0264-410X(24)00318-9. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

SASI A, Dandotiya J, Kaushal J, Ganguly S, et al
Humoral and cellular immunity to SARS-CoV-2 following vaccination with non-mRNA vaccines in adolescent/young adults with cancer: A prospective cohort study.
Vaccine. 2024 Mar 20:S0264-410X(24)00329-3. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

BROOKS SP, Sidhu K, Cooper E, Michelle Driedger S, et al
The influence of health service interactions and local policies on vaccination decision-making in immigrant women: A multi-site Canadian qualitative study.
Vaccine. 2024 Mar 20:S0264-410X(24)00299-8. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

CRISTINA MARTINI RODRIGUES C, Caroline Ribeiro Sales A, Marli Christovam Sartori A, de Souza Azevedo A, et al
Yellow fever neutralizing antibody seroprevalence proportion and titers in previously vaccinated adults with chronic kidney disease.
Vaccine. 2024 Mar 20:S0264-410X(24)00316-5. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

ARTIGAS-JERONIMO S, Villar M, Estrada-Pena A, Alberdi P, et al
Subolesin knockdown in tick cells provides insights into vaccine protective mechanisms.
Vaccine. 2024 Mar 19:S0264-410X(24)00278-0. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

CHENG Y, Shen R, Liu F, Li Y, et al
Humoral and cellular immune responses induced by serogroup W135 meningococcal conjugate and polysaccharide vaccines.
Vaccine. 2024 Mar 19:S0264-410X(24)00326-8. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

KRASILNIKOV I, Isaev A, Djonovic M, Ivanov A, et al
Transformative vaccination: A pentavalent shield against COVID-19 and influenza with betulin-based adjuvant for enhanced immunity.
Vaccine. 2024 Mar 19:S0264-410X(23)01421-4. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

GEHRT L, Englund H, Laake I, Nieminen H, et al
Is vaccination against measles, mumps, and rubella associated with reduced rates of antibiotic treatments among children below the age of 2 years? Nationwide register-based study from Denmark, Finland, Norway, and Sweden.
Vaccine. 2024 Mar 19:S0264-410X(24)00313-X. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

ANWARI P, Burnett E, Chavers TP, Samsor A, et al
Post-marketing surveillance of intussusception after Rotarix administration in Afghanistan, 2018-2022.
Vaccine. 2024;42:2059-2064.
PubMed Abstract available

LLOYD PC, Lufkin B, Moll K, Ogilvie RP, et al
Incidence rates of thrombosis with thrombocytopenia syndrome (TTS) among adults in United States commercial and Medicare claims databases, 2017-2020.
Vaccine. 2024;42:2004-2010.
PubMed Abstract available

SOVIK WLM, Madsen AMR, Aaby P, Nielsen S, et al
The association between BCG scars and self-reported chronic diseases: A cross-sectional observational study within an RCT of Danish health care workers.
Vaccine. 2024;42:1966-1972.
PubMed Abstract available

KWON KW, Choi HG, Choi HH, Choi E, et al
Immunogenicity and protective efficacy of RipA, a peptidoglycan hydrolase, against Mycobacterium tuberculosis Beijing outbreak strains.
Vaccine. 2024;42:1941-1952.
PubMed Abstract available

HILL-BATORSKI L, Bowen R, Bielefeldt-Ohmann H, Moser MJ, et al
Mucosal immunization with dual influenza/COVID-19 single-replication virus vector protects hamsters from SARS-CoV-2 challenge.
Vaccine. 2024 Mar 19:S0264-410X(24)00327-X. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

SANCHEZ-MARTINEZ ZV, Alpuche-Lazcano SP, Stuible M, Durocher Y, et al
CHO cells for virus-like particle and subunit vaccine manufacturing.
Vaccine. 2024 Mar 18:S0264-410X(24)00321-9. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

WU J, Jiang L, Shao Q, Liu J, et al
Comparison of the safety and efficacy of the wild-type and lpxL/lpxM mutant inactivated vaccine against the avian pathogenic Escherichia coli O1, O2, and O78 challenge.
Vaccine. 2024 Mar 18:S0264-410X(24)00325-6. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

MEDENI V, Altiner OT, Medeni I
Measles vaccination coverage and immunization status of nurses: An interventional study in Turkiye.
Vaccine. 2024 Mar 18:S0264-410X(24)00324-4. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

DANGOR Z, Benson N, Berkley JA, Bielicki J, et al
Vaccine value profile for Klebsiella pneumoniae.
Vaccine. 2024 Mar 18:S0264-410X(24)00248-2. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

OPMEER L, Gazzoli I, Ballmann M, Willemsen M, et al
High throughput AS LNA qPCR method for the detection of a specific mutation in poliovirus vaccine strains.
Vaccine. 2024 Mar 18:S0264-410X(24)00130-0. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

CAMPAGNA R, Dominelli F, Zingaropoli MA, Ciurluini F, et al
COVID-19 vaccination in cancer patients: Immune responses one year after the third dose.
Vaccine. 2024 Mar 17:S0264-410X(24)00304-9. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

FIERRO C, Weidenthaler H, Vidojkovic S, Schmidt D, et al
Safety and immunogenicity of a novel trivalent recombinant MVA-based equine encephalitis virus vaccine: A Phase 1 clinical trial.
Vaccine. 2024 Mar 16:S0264-410X(24)00296-2. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

HARTMEIER PR, Ostrowski SM, Busch EE, Empey KM, et al
Lymphatic distribution considerations for subunit vaccine design and development.
Vaccine. 2024 Mar 16:S0264-410X(24)00320-7. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

FIX J, Christopher Mast T, Smith K, Baker N, et al
Benefit-risk assessment for the Novavax COVID-19 vaccine (NVX-CoV2373).
Vaccine. 2024 Mar 16:S0264-410X(24)00323-2. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

COTTON SA, Subramanian A, Hughes TD, Huang Y, et al
The effect of SARS-COV-2 variant on non-respiratory features and mortality among vaccinated and non-fully vaccinated patients.
Vaccine. 2024 Mar 14:S0264-410X(24)00195-6. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

JUNEAU C, Fall E, Bros J, Le Duc-Banaszuk AS, et al
Do boys have the same intentions to get the HPV vaccine as girls? Knowledge, attitudes, and intentions in France.
Vaccine. 2024 Mar 14:S0264-410X(24)00256-1. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

CAMERON DB, Grage L, Van Wyck R, Edwards A, et al
Identifying trusted local sources and predicting behavior change pathways according to COVID-19 vaccination status: Results of a 2022 statewide survey of Alaskan adults.
Vaccine. 2024 Mar 14:S0264-410X(24)00314-1. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

MACKENZIE GA, Hossain I, Salaudeen R, Badji H, et al
Impact of pneumococcal conjugate vaccination on pneumococcal nasopharyngeal carriage in the Gambia: Population-based cross-sectional surveys.
Vaccine. 2024 Mar 14:S0264-410X(24)00225-1. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

EL SALIBI N, Abdulrahim S, El Haddad M, Abi Zeid B, et al
Predicting intention to vaccinate against COVID-19 in older Syrian refugees in Lebanon: Findings from a multi-wave study.
Vaccine. 2024 Mar 13:S0264-410X(24)00213-5. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

MCCOSKER LK, Ware RS, Seale H, Hooshmand D, et al
The effect of a financial incentive on COVID-19 vaccination uptake, and predictors of uptake, in people experiencing homelessness: A randomized controlled trial.
Vaccine. 2024 Mar 13:S0264-410X(24)00307-4. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

SAKAUE T, Sugawara T, Mukasa K, Nohara M, et al
Varicella outbreak at nursery school under routine immunization in Japan in 2017 and 2018 and vaccine effectiveness.
Vaccine. 2024 Mar 12:S0264-410X(24)00250-0. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

CHEUNG DH, Chen S, Fang Y, Sun F, et al
Influences of mpox disease perceptions, sources and contents of information exposure on mpox vaccine uptake among gay, bisexual, and other men who have sex with men in Hong Kong, China.
Vaccine. 2024 Mar 12:S0264-410X(24)00259-7. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

SHERMAN SM, Allerton-Price C, Lingley-Heath N, Lai J, et al
UK healthcare professionals' attitudes towards the introduction of varicella vaccine into the routine childhood vaccination schedule and their preferences for administration.
Vaccine. 2024 Mar 12:S0264-410X(24)00274-3. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

RUSS S, Myers C, Licherdell E, Bowden A, et al
Sociodemographic and Occupational Characteristics Associated with Early and Continued COVID-19 Vaccine Uptake Among Healthcare Personnel: Monroe County, NY.
Vaccine. 2024 Mar 12:S0264-410X(24)00306-2. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

MERDRIGNAC L, Ait El Belghiti F, Pandolfi E, Acosta L, et al
Effectiveness of one and two doses of acellular pertussis vaccines against laboratory-confirmed pertussis requiring hospitalisation in infants: Results of the PERTINENT sentinel surveillance system in six EU/EEA countries, December 2015 - December 201
Vaccine. 2024 Mar 11:S0264-410X(24)00272-X. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

SHIJIA YAN A, Jay Sehgal N
Partisan divide and Racial/Ethnic disparities in COVID-19 vaccine hesitancy among Parents/Guardians and vaccine uptake among children in the U.S.
Vaccine. 2024 Mar 11:S0264-410X(24)00309-8. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

SENPUKU K, Kataoka-Nakamura C, Kunishima Y, Hirai T, et al
An inactivated whole-virion vaccine for Enterovirus D68 adjuvanted with CpG ODN or AddaVax elicits potent protective immunity in mice.
Vaccine. 2024 Mar 11:S0264-410X(24)00303-7. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

MORO PL, Carlock G, Fifadara N, Habenicht T, et al
Safety monitoring of bivalent mRNA COVID-19 vaccine among pregnant persons in the vaccine adverse event reporting System - United States, September 1, 2022 - March 31, 2023.
Vaccine. 2024 Mar 9:S0264-410X(24)00262-7. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

HARRELL JE, Roy CJ, Gunn JS, McLachlan JB, et al
Current vaccine strategies and novel approaches to combatting Francisella infection.
Vaccine. 2024 Mar 8:S0264-410X(24)00264-0. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

SU YW, Qiu YZ, Wang YH, Xu Y, et al
Safety and immunogenicity of heterologous boosting with a bivalent SARS-CoV-2 mRNA vaccine (XBB.1.5/BQ.1) in Chinese participants aged 18 years or more: A randomised, double-blinded, active-controlled phase 1 trial.
Vaccine. 2024 Mar 8:S0264-410X(24)00277-9. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

LUISI M, Geana MV, Pei J
Pandemic antecedents - Exploring predictivity and relationships between COVID-19 vaccine uptake and influenza, shingles, and HPV vaccination.
Vaccine. 2024 Mar 8:S0264-410X(24)00275-5. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

BROUSSEAU N, Angers-Goulet ME, Bastien R, Ye L, et al
Vaccination during pregnancy and modulation of IgG response to pertussis vaccines in infants: The impact of different vaccine formulations.
Vaccine. 2024 Mar 8:S0264-410X(24)00300-1. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

ST-LOUIS P, Martin C, Khatri V, Bourgault S, et al
Intranasal delivery of a self-adjuvanted nanovaccine composed of the curli filaments and the highly conserved M2e epitope confers protection against influenza a virus in mice.
Vaccine. 2024 Mar 8:S0264-410X(24)00222-6. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

GHASEMIFAR S, Chabak O, Piri-Gharaghie T, Doosti A, et al
PIRES2-EGFP/CTB-UreI vaccination activated a mixed Th1/Th2/Th17 immune system defense towards Helicobacter pylori infection in the BALB/c mice model.
Vaccine. 2024 Mar 7:S0264-410X(24)00209-3. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

Expression of Concern: "Cross-protection against H7N9 influenza strains using a live-attenuated H7N3 virus vaccine" [Vaccine [33/1], 1 January 2015, Pages 108-116].
Vaccine. 2024;42:1851.
PubMed

Expression of Concern: "Human COBRA 2 vaccine contains two major epitopes that are responsible for eliciting neutralizing antibody responses against heterologous clades of viruses" [Vaccine Volume 38, Issue 4, 22 January 2020, Pages 830-839].
Vaccine. 2024;42:1850.
PubMed

DE WAELE A, Hendrickx G, Valckx S, Dominguez A, et al
The Vaccine Training Barometer: Assessing healthcare providers' confidence to answer vaccine-related questions and their training needs.
Vaccine. 2024 Mar 7:S0264-410X(24)00254-8. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

SIREK G, Ulysse S, Jacques Toussaint M, Nosamiefan C, et al
A community-engaged approach to translate a Vaccine Hesitancy Scale into Haitian Creole.
Vaccine. 2024 Mar 7:S0264-410X(24)00257-3. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

GILBERT PB, Fong Y, Hejazi NS, Kenny A, et al
Four statistical frameworks for assessing an immune correlate of protection (surrogate endpoint) from a randomized, controlled, vaccine efficacy trial.
Vaccine. 2024 Mar 7:S0264-410X(24)00247-0. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

MALDONADO I, Rodriguez Nino N, Valencia CF, Ortiz D, et al
Evaluation of the safety profile of the quadrivalent vaccine against human papillomavirus in the risk of developing autoimmune, neurological, and hematological diseases in adolescent women in Colombia.
Vaccine. 2024 Mar 7:S0264-410X(24)00263-9. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

ZIBOLENOVA J, Malobicka E, Ulbrichtova R, Novak M, et al
Probability of exposure to the wild measles virus in adult population - Estimation from seroepidemiology and historical data.
Vaccine. 2024;42:1648-1655.
PubMed Abstract available

HYAMS C, Lahuerta M, Theilacker C, King J, et al
Surveillance of pneumococcal serotypes in adults hospitalised with acute lower respiratory tract infection in Bristol, UK.
Vaccine. 2024;42:1599-1607.
PubMed Abstract available

MENG L, Harris L, Shaw L, Lymon H, et al
Social and demographic factors associated with receipt of a COVID-19 vaccine initial booster dose and with interval between primary series completion and initial booster dose uptake among persons aged >/= 12 years, United States, August 2021-October 2
Vaccine. 2024 Mar 6:S0264-410X(24)00271-8. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

KARRAS J, Harrison M, Steffens M, Abdi I, et al
"COVID is a huge jigsaw puzzle that I am trying to make sense of myself": Exploring the perceptions towards the COVID-19 vaccine communication strategy in Australia amongst unvaccinated Australian adults.
Vaccine. 2024 Mar 6:S0264-410X(24)00276-7. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

WONG WHS, Leung DL, Yip KM, So HK, et al
Effectiveness of inactivated COVID-19 vaccine CoronaVac in children aged less than 3 years old during Omicron wave in Hong Kong.
Vaccine. 2024 Mar 6:S0264-410X(24)00226-3. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

RAETHKE M, van Hunsel F, Luxi N, Lieber T, et al
Frequency and timing of adverse reactions to COVID-19 vaccines; A multi-country cohort event monitoring study.
Vaccine. 2024 Mar 6:S0264-410X(24)00273-1. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

CHEN D, Cowling BJ, Ainslie KEC, Lin Y, et al
Association of COVID-19 vaccination with duration of hospitalization in older adults in Hong Kong.
Vaccine. 2024 Mar 5:S0264-410X(24)00252-4. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

MARQUES RF, Gimenez AM, Caballero O, Simpson A, et al
Non-clinical toxicity and immunogenicity evaluation of a Plasmodium vivax malaria vaccine using Poly-ICLC (Hiltonol(R)) as adjuvant.
Vaccine. 2024 Mar 5:S0264-410X(24)00229-9. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

BEAVIS AC, Dienger-Stambaugh K, Briggs K, Chen Z, et al
A J Paramyxovirus-vectored HIV vaccine induces humoral and cellular responses in mice.
Vaccine. 2024 Mar 4:S0264-410X(24)00227-5. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

DUAN X, Zhang L, Ding L, Zhang C, et al
Effectiveness of enterovirus A71 vaccine against pediatric HFMD and disease profile of post-vaccination infection.
Vaccine. 2024 Mar 2:S0264-410X(24)00172-5. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

ZAMAN K, Schuind AE, Adjei S, Antony K, et al
Safety and immunogenicity of Innovax bivalent human papillomavirus vaccine in girls 9-14 years of age: Interim analysis from a phase 3 clinical trial.
Vaccine. 2024 Mar 1:S0264-410X(24)00251-2. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

YASHAR-GERSHMAN SG, Rosenberg AT, Sawhney M, Fernanda Machicao M, et al
Developing a novel screening tool to address pediatric COVID-19 vaccine hesitancy at point of care.
Vaccine. 2024 Mar 1:S0264-410X(24)00228-7. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

February 2024

YADEGARYNIA D, Keyvanfar A, Keyvani H, Tehrani S, et al
Immunogenicity and safety of a quadrivalent recombinant influenza vaccine manufactured in Iran (FluGuard) in volunteers aged 18-60 years: A double-blind, non-inferiority, randomized controlled trial.
Vaccine. 2024 Feb 29:S0264-410X(24)00249-4. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

KOHLI M, Maschio M, Lee A, Igarashi A, et al
Projections of the incidence of COVID-19 in Japan and the potential impact of a Fall 2023 COVID-19 vaccine.
Vaccine. 2024 Feb 29:S0264-410X(24)00117-8. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

CHATHAM-STEPHENS K, Carter RJ, Duggar C, Woodworth KR, et al
An overview of the COVID-19 pediatric vaccine program - The U.S. experience vaccinating children ages 6 months through 17 years.
Vaccine. 2024 Feb 29:S0264-410X(24)00166-X. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

LEVIN MJ, Ginde AA, Schmid DS, Lang N, et al
Effect of high dose vitamin D supplementation on subsequent immune responses to administration of the live herpes zoster vaccine to long-term care residents.
Vaccine. 2024 Feb 28:S0264-410X(24)00214-7. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

MARINDA E, Mathentamo Q, Coulson N, Parker S, et al
Impact evaluation of a youth led intervention to increase COVID-19 vaccine uptake in Kwazulu-Natal, South Africa.
Vaccine. 2024 Feb 28:S0264-410X(24)00211-1. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

OMAR ALI S, Dessart C, Parikh R
Co-administration of the adjuvanted recombinant zoster vaccine with other adult vaccines: An overview.
Vaccine. 2024 Feb 28:S0264-410X(24)00194-4. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

GUO J, Chen X, Guo Y, Liu M, et al
Real-world effectiveness of seasonal influenza vaccination and age as effect modifier: A systematic review, meta-analysis and meta-regression of test-negative design studies.
Vaccine. 2024 Feb 28:S0264-410X(24)00218-4. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

ZHOU W, Guo X, Lu J, Lu X, et al
Parental willingness to accept and pay human papillomavirus vaccine for boys aged 9-14 in a metropolis area of China: Evidence for developing a vaccination strategy.
Vaccine. 2024 Feb 28:S0264-410X(24)00253-6. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

JACKSON S, Kabir Z, Comiskey C
Retrospective cohort study exploring the impact of universal Tuberculosis (TB) vaccination cessation on the epidemiology of paediatric TB in Ireland, 2011-2021.
Vaccine. 2024 Feb 28:S0264-410X(24)00220-2. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

JABBAR F, Kadhim KA, Alhilfi RA, Chitheer A, et al
Intensification of integrated immunization services to recover routine vaccination coverage and bring COVID-19 vaccine to the population of Iraq in 2022.
Vaccine. 2024 Feb 27:S0264-410X(24)00197-X. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

TANAKA M, Okubo R, Hoshi SL, Kondo M, et al
Cost-effectiveness analysis of pertussis booster vaccination for adolescents in Japan.
Vaccine. 2024 Feb 27:S0264-410X(24)00199-3. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

GIDENGIL C, Scherer AM, Parker AM, Gedlinske A, et al
Lyme disease vaccine attitudes and intentions among parents of children aged 5-18 years in the United States.
Vaccine. 2024 Feb 27:S0264-410X(24)00105-1. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

YANG XY, Liu T, Jiang SC, Zhang ZW, et al
Antibodies against SARS-CoV-2 non-structural protein 3 cross-react with human muscle cells and neuroglial cells.
Vaccine. 2024;42:1259-1267.
PubMed Abstract available

MUNDO ORTIZ A, Nasri B
Socio-demographic determinants of COVID-19 vaccine uptake in Ontario: Exploring differences across the Health Region model.
Vaccine. 2024 Feb 26:S0264-410X(24)00204-4. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

KEGELE LIGNANI L, de Vasconcellos Carvalhaes de Oliveira R, Matos Dos Santos E, Antonio Bastos Camacho L, et al
Neutralizing antibody titers against D8 genotype and persistence of measles humoral and cell-mediated immunity eight years after the first dose of measles, mumps, and rubella vaccine in Brazilian children.
Vaccine. 2024 Feb 26:S0264-410X(24)00219-6. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

TOLENTINO JUNIOR DS, Vasconcelos Marques MS, de Oliveira RC
Rabies vaccination of the Maxakali indigenous population.
Vaccine. 2024 Feb 26:S0264-410X(23)01542-6. doi: 10.1016/j.vaccine.2023.
PubMed

KRISTINSDOTTIR I, Haraldsson A, Thors V
Influenza vaccination in pregnant women in Iceland 2010-2020 and the burden of influenza in pregnant women and their infants.
Vaccine. 2024 Feb 26:S0264-410X(24)00205-6. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

NEWALL AT, Nazareno AL, Muscatello DJ, Boettiger D, et al
The association between influenza vaccination uptake and influenza and pneumonia-associated deaths in the United States.
Vaccine. 2024 Feb 24:S0264-410X(24)00113-0. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

BIJUKCHHE SM, Gurung M, Pokhrel B, Shakya M, et al
Immune responses to typhoid conjugate vaccine in a two dose schedule among Nepalese children <2 years of age.
Vaccine. 2024 Feb 22:S0264-410X(24)00156-7. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

MURPHY C, Kwan MYW, Chan ELY, Wong JSC, et al
Influenza vaccine effectiveness against hospitalizations associated with influenza A(H3N2) in Hong Kong children aged 9 months to 17 years, June-November 2023.
Vaccine. 2024 Feb 22:S0264-410X(24)00215-9. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

SHETTY AN, Morgan HJ, Phuong LK, Mallard J, et al
Audiovestibular adverse events following COVID-19 vaccinations.
Vaccine. 2024 Feb 22:S0264-410X(24)00210-X. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

KOCHHAR S, Assis DN, Mack C, Izurieta HS, et al
Autoimmune hepatitis: Brighton Collaboration case definition and guidelines for data collection, analysis, and presentation of immunisation safety data.
Vaccine. 2024 Feb 16:S0264-410X(24)00021-5. doi: 10.1016/j.vaccine.2024.
PubMed Abstract available

DREYFUS J, Munnangi S, Bengtsson C, Correia B, et al
Background incidence rates of health outcomes in populations at risk for Lyme disease using US administrative claims data.
Vaccine. 2024;42:1094-1107.
PubMed Abstract available

PREVOT-MONSACRE P, Hamaide-Defrocourt F, Guyonvarch O, Masse S, et al
What is the relevancy of a surveillance of mumps without a systematic laboratory confirmation in highly immunized populations? Epidemiology of suspected and biologically confirmed mumps cases seen in general practice in France between 2014 and 2020.
Vaccine. 2024;42:1065-1070.
PubMed Abstract available

November 2023

ZURCHER SJ, Signorell A, Lechot-Huser A, Aebi C, et al
Childhood vaccination coverage and regional differences in Swiss birth cohorts 2012-2021: Are we on track?
Vaccine. 2023;41:7226-7233.
PubMed Abstract available

FLANDES X, Hansen CA, Palani S, Abbas K, et al
Vaccine value profile for Chikungunya.
Vaccine. 2023 Nov 7:S0264-410X(23)00915-5. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

HOTEZ PJ, Bottazzi ME, Kaye PM, Lee BY, et al
Neglected tropical disease vaccines: hookworm, leishmaniasis, and schistosomiasis.
Vaccine. 2023;41 Suppl 2.
PubMed

UGHASORO MD, Nnakenyi I, Echendu N, Akpeh JO, et al
Neutralizing anti-polio antibody titre in newborn babies in post-polio eradication period in Nigeria.
Vaccine. 2023;41:6820-6823.
PubMed Abstract available

DO LAH, Le NTN, Mahmud S, Mulholland K, et al
Impact and cost-effectiveness of strategies to prevent respiratory syncytial virus (RSV) disease in Vietnam: A modelling study.
Vaccine. 2023;41:6782-6790.
PubMed Abstract available

October 2023

CORSTEN C, Vang ZM, Gold I, Goldenberg MJ, et al
Understanding COVID-19 vaccine hesitancy in Canada.
Vaccine. 2023 Oct 27:S0264-410X(23)01260-4. doi: 10.1016/j.vaccine.2023.
PubMed Abstract available

LI J, Shi LW, Li K, Huang LR, et al
Comparison of the safety and persistence of immunogenicity of bivalent HPV16/18 vaccine in healthy 9-14-year-old and 18-26-year-old Chinese females: A randomized, double-blind, non-inferiority clinical trial.
Vaccine. 2023;41:7212-9.
PubMed Abstract available

MULLER T, Wallace RM, Freuling CM
Rabies importation in dogs and reduction of waiting period - The fear for scientifically justified changes.
Vaccine. 2023 Oct 20:S0264-410X(23)01043-5. doi: 10.1016/j.vaccine.2023.
PubMed

Thank you for your interest in scientific medicine.

AMEDEO Vaccines is free of charge.